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ABSTRACT OF THE DISSERTATION
SYNTHESIS OF MULTISUBSTITUTED HALO-OLEFINS VIA PD-CATALYZED
CROSS-COUPLING REACTIONS. APPLICATIONS IN NUCLEOSIDE CHEMISTRY
by
Daniela Andrei
Florida International University, 2006
Miami, Florida
Professor Stanislaw Wnuk, Major Professor
The enzyme S-adenosyl-L-homocysteine (AdoHey) hydrolase effects hydrolytic
cleavage of AdoHcy to adenosine (Ado) and L-homocysteine (Hcy). The cellular levels
of AdoHcy and Hcy are critical because AdoHcy is a potent feedback inhibitor of crucial
transmethylation enzymes. Also, elevated plasma levels of Hcy in humans have been
shown to be a risk factor in coronary artery disease.
On the basis of the previous finding that AdoHcy hydrolase is able to add the
enzyme-sequestered water molecule across the 5',6'-double bond of (halo or
dihalohomovinyl)-adenosines causing covalent binding inhibition, we designed and
synthesized AdoHcy analogues with the 5',6'-olefin motif incorporated in place of the
carbon-5' and sulfur atoms. From the available synthetic methods we chose two
independent approaches: the first approach was based on the construction of a new C5'-
C6' double bond via metathesis reactions, and the second approach was based on the
formation of a new C6'-C7' single bond via Pd-catalyzed cross-couplings.
Cross-metathesis of the suitably protected 5'-deoxy-5'-methyleneadenosine with racemic
2-amino-5-hexenoate in the presence of Hoveyda-Grubb's catalyst followed by standard
v
deprotection afforded the desired analogue as 5'E isomer of the inseparable mixture of
9'RIS diastereomers. Metathesis of chiral homoallylglycine [(2S)-amino-5-hexenoate]
produced AdoHcy analogue with established stereochemistry E at C5'atom and S at C9'
atom. The 5'-bromovinyl analogue was synthesized using the bromination-
dehydrobromination strategy with pyridinium tribromide and DBU.
Since literature reports on the Pd-catalyzed monoalkylation of dihaloalkenes
(Csp 2-Csp3 coupling) were scarce, we were prompted to undertake model studies on Pd-
catalyzed coupling between vinyl dihalides and alkyl organometallics. The 1-fluoro-1-
haloalkenes were found to undergo Negishi couplings with alkylzinc bromides to give
multisubstituted fluoroalkenes. The alkylation was trans-selective affording pure Z-
fluoroalkenes. The highest yields were obtained with PdCl 2(dppb) catalyst, but the best
stereochemical outcome was obtained with less reactive Pd(PPh3)4 . Couplings of 1,1-
dichloro-and 1,1-dibromoalkenes with organozinc reagents resulted in the formation of
monocoupled 1-halovinyl product.
vi
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1. INTRODUCTION
1.1. S-Adenosyl-L-homocysteine hydrolase
1.1.1 Biological functions of S-adenosyl-L-homocysteine hydrolase
The normal cellular role of S-Adenosyl-L-homocysteine hydrolase (AdoHcy
hydrolase) is regulating S-Adenosyl-L-methionine (AdoMet) dependent biological
methylation reactions (Scheme 1).1 AdoMet is involved in the methylation of many
biomolecules, from small molecular weight neurotransmitters (e.g., histamine) to
macromolecules (e.g., proteins, nucleic acids) and the various methyltransferases which
catalyze these reactions have themselves been targets for drug design.' 3 AdoMet is also
decarboxylated by AdoMet decarboxylase to dcAdoMet. S-Adenosyl-L-homocysteine
(AdoHcy) is the byproduct of these methylation reactions and functions as a feedback
inhibitor of these methyltransferases. Alteration of the cellular AdoMet/AdoHcy ratio
results in serious perturbation of biological methylation of viral RNA.4 AdoHcy
hydrolase provides the only known mechanism for AdoHcy catabolism in eukaryotes,
catalyzing its hydrolysis to adenosine (Ado) and L-homocysteine (Hcy). Although the in
vitro reaction favors the synthetic direction, subsequent metabolic conversions of
adenosine and homocysteine within the cell assure the reaction will run in the hydrolytic
direction.5
The cellular enzyme S-Adenosyl-L-homocysteine hydrolase effects hydrolytic
cleavage of AdoHcy to give Ado and Hcy (Scheme 1).4'6 AdoHcy hydrolase plays a
significant role in controlling the intracellular level of Hcy that is a cystathionine
synthetase- catalyzed precursor to cysteine and methionine. The metabolism of AdoHcy
by this enzyme is the only known source of Hcy in mammalian cells. 7 The elevated
1
plasma Hcy levels in humans have been demonstrated to be a risk factor for coronary
artery disease in clinical studies.8 Inhibitors of AdoHcy hydrolase have the potential to
reduce the risk of developing coronary heart disease by lowering the cellular level of
Hcy. Although, supplementation with B-vitamins and folic acid has been shown to be
effective in lowering plasma Hcy level in homocysteinemia patients with residual activity
of cystathionine synthetase'8b,9 inhibitors of AdoHcy hydrolase have also the potential to
regulate plasma level of Hcy.
nXti RXCH3
Methyl-
transferases
4
AdoMst AdoHcy Adenosine
Docarboxylase HydrolasedcAdoMet AdoMet AdoHcy yrs +
Homocysteine
AdoMet Pro4uct
MTA Synthetase Inhibition
Potyamines ATP + Met
NH NH 2  NH 2
CH3 N (;NH2 NH2N'
HOOC,,- NO N H CS N ON H N CN
H H 2  HO 2C SH
NH 2
HO OH HO OH HO OH
S-Adenosyl-L-methionine S-Adenosyl-L-homocysteine Adenosine L-Homocysteine
[AdoMet] [AdoHcy] [Ado] [Hcy]
Scheme 1. The Role of AdoHcy hydrolase in regulating AdoMet dependent
biological methylation.
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Study of the distribution of AdoHcy hydrolase in various mammalian tissues
revealed that the enzyme activity was highest in the liver, kidney and pancreas;
intermediate in the spleen and low in brain and heart.4 The liver of the mouse contains
around twelve times more AdoHcy hydrolase than the kidney, which in turn has five
times more AdoHcy than the brain. A one molar equivalent of copper is bound per
subunit of mouse liver enzyme.' 0 In copper-deficient mice there was a 45% decrease in
the hepatic level of AdoHcy. 1 The binding of copper by enzyme means that there is a
role for its involvement in copper metabolism.
AdoHcy hydrolase has attracted attention as a target for drug design6,12 13 because
inhibitors of this enzyme are known to exhibit antiviral'3" 4", antiparasitic6 ,
antiarthritic and immunosuppressive effects18 . Inhibition of the cellular AdoHcy
hydrolase results in an intracellular build-up of AdoHcy, giving rise to an increase in the
intracellular AdoHcy/AdoMet ratios and the subsequent inhibition of fundamental
AdoMet dependent methylation reactions. The relationships established are particularly
well recognized for the antiviral effect of AdoHcy. De Clercq and Cools found a linear
relationship between the log ICso values (concentration which inhibits vaccinia virus
replication by 50%) and their log Ki values (inhibition potency of AdoHcy hydrolase) for
a series of AdoHcy hydrolase inhibitors.'3
AdoHcy hydrolase inhibitors are potent as well as broad-spectrum antiviral agents,
inhibiting the replication of a variety of (-) RNA viruses and double-stranded RNA
viruses.13a This type of inhibitors are not particularly active against (+) RNA viruses or
DNA viruses, except for vaccinia and African swine fever viruses.13a,1 9 Their wide range
of activity is in contrast to almost all clinically used nucleoside antiviral drugs, which are
3
usually specific toward a particular species or strain of virus. 6a Broad-spectrum antiviral
drugs offer many advantages over narrow-spectrum agents; it is often difficult in clinical
diagnoses to identify a viral pathogen in a short time. For instance in acute infections,
viral chemotherapy must start as soon as the patient presents clinical symptoms. Thus, the
development of broad-spectrum antiviral drugs is highly desired.
1.1.2. Mechanism of S-adenosyl-L-homocysteine hydrolase action
The mechanism by which AdoHcy hydrolase catalyzes the conversion of AdoHcy
to Ado and Hcy (Figure 1) was established by Palmer and Abeles. 2 0 The first step in the
enzymatic reaction involves oxidation of the 3'-hydroxyl group of AdoHcy by the
enzyme-bound NAD+ (E.NAD+) to form E.NADH and 3'-keto-AdoHcy (oxidative
activity of the enzyme). The 3'-keto group increases the acidity of the C-4' proton,
allowing for abstraction of this proton by a base in the active site of the enzyme.
Subsequently, P-elimination of Hcy results in the formation of the intermediate 3'-keto-
4',5'-didehydro-5'-deoxyAdo, (KDDA). Michael type addition of water (hydrolytic
activity of the enzyme) to the 5' position of KDDA affords 3'-ketoAdo, which is then
reduced by the enzyme bound NADH, resulting in the formation of Ado and regenerating
the NAD+ form of the enzyme. Palmer and Abeles also found that 4',5'-didehydro-5'-
deoxyadenosine, DDA is an alternative substrate of the enzyme and its oxidation at C3'
gave enone KDDA directly. Isotopes studies21 ,22 and also general kinetic studies23a
reinforced this mechanism. 20
Porter and Boyd showed that neither the apoenzyme nor the reduced form of
AdoHcy hydrolase (E.NADH) was catalytically active.23b The mechanism suggests that
breakage of the C5'-S bond (elimination of the Hcy from 3'-keto-AdoHcy) and the
4
formation of C5'-O bond (addition of water to the KDDA) were dependent on the
oxidative activity of the enzyme. Parry and Askonas studied the stereochemistry2 2 of this
reaction and found a syn geometry of the addition of Hcy to KDDA. Thus, the overall
reaction catalyzed by AdoHcy hydrolase occurs with retention of configuration at C5'. It
also follows that the elimination step is catalyzed by an enzyme which also exhibits a syn
geometry.
A A A
RS O E.NAD, RS 
- R-SH O
H E.NADH H + R-SH
HO OH O OH 0 OH
H20 KDDA
-H 2 0
E.NAD+
A A A
HO O E.NADH HO
H E.NAD+ H k ?
HO OH O OH HO OH
DDA
R = ~O2CCHCH 2CH2 E.NAD(H)+ = enzyme-bound NAD(H)+
NH3
Figure 1. The mechanism for S-adenosyl-L-homocysteine hydrolase.
It has been assumed for long time that the Palmer and Abeles mechanism20 is
operated in a sequential fashion and that oxidation of the hydroxyl function at C3' to
form the 3' keto-AdoHcy (oxidative activity) is a prerequisite for conjugated addition of
water (hydrolytic activity) across the double bond of the activated enone KDDA.24
5
However, Borchardt and his coworkers have demonstrated that these two catalytic
activities of AdoHcy hydrolase can be considered independent of each other.25 Borchardt
et al. defined type I-mechanism-based inhibitors of AdoHcy hydrolase as inhibitors that
serve as substrates for "oxidative" activities of the enzyme. These inhibitors are oxidized
to the 3'-keto derivatives and they convert the enzyme from its active form (NAD*) to its
inactive form (NADH) (cofactor depletion mechanism). A striking feature of all these
first-generation AdoHcy hydrolase inhibitors is the similarity in their broad-spectrum
antiviral activity, indicating a common mechanism of action. The type II-mechanism-
based inhibitors of AdoHcy hydrolase were defined as inhibitors which use the
"oxidative" and/or the "hydrolytic" activity of the enzyme to produce electrophiles on the
active site, which in turn react with the protein nucleophiles to modify the enzyme
(covalent inactivation mechanism).6b ,12a,24,26 These second-generation AdoHcy hydrolase
inhibitors have added to the body of evidence indicating that inhibition of this enzyme
results in the inhibition of viral replication. Finally, type III inhibitors are those that use
neither the "oxidative" nor the "hydrolytic" activity, but they are reversibly bound to the
enzyme. 12a,26
The X-ray crystal structure of a substrate-bound NADH form of human AdoHcy
hydrolase has been determined.27 In this crucial experiment the pure NAD-form of the
enzyme was inactivated with 9-(2,3-dihydroxycyclopent-4-en-1-yl)adenine [DHCeA], to
give crystal of the 3'-ketoDHCeA/NADH form of human AdoHcy suitable for X-ray
crystallographic analysis. The sequestered water molecules at the active site were found
to be hydrogen bounded to His55, Aspi31 and His301. The water molecule seems to
have a dual role in the catalytic mechanism. It is not only the sole candidate for the
6
catalytic base responsible for the H4' abstraction initiating Hey elimination but it may
also add to the intermediate enone in the formation of 3'-ketoAdo. 6 ,2 7 A crystal
structure of AdoHcy hydrolase from rat liver in the substrate-free NAD+ form shows an
open catalytic site in the absence of substrate. 8 This identified Glu55 as a proton
acceptor from the 3'-OH during the abstraction of the H3' by NAD+ and His54 or
Asp 130 as general acid-base catalyst. The Cys 194 was proposed to modulate the
oxidation state of the bound NAD+. However, these two crystal structures do not define
clearly the binding site for the homocysteine moiety of AdoHcy at the active site of the
enzyme.
1.1.3. Hydrolytic activity of AdoHcy hydrolase with halovinyl adenine
analogues
Various adenosine analogs and adenine carboxylic nucleosides have been shown
to be potent inhibitors of AdoHey hydrolase (Figure 2).6a, 12, 13a,2,30 Many of these
compounds are type I mechanism-based inhibitors of AdoHcy hydrolase,6a,l2 b which
inactivate the enzyme by reducing the enzyme-bound NAD+ to NADH. In the process of
inactivation, the inhibitor is oxidized stoichiometrically to the corresponding 3'-keto
nucleoside.6a, 12b
McCarthy and co-workers synthesized vinyl fluoride analogs of 4',5'-didehydro-5'-
deoxyadenosine as potential mechanism-based inhibitors.3' Of the vinyl fluorides
synthesized, (Z)-4',5'-didehydro-5'-deoxy-5'-fluoroadenosine (ZDDFA, 1, Figure 2) was
shown to be the most potent inhibitor of AdoHcy hydrolase.3 In addition to being a
potent inhibitor, ZDDFA was of interest mechanistically because it was first reported as a
7
type II mechanism-based inhibitor (reduce the E.NAD' to E.NADH and release fluoride
ion quantitatively).
NH 2  NH 2
N N N N
X N N O N N
HN
OH OH OH OH
IX=F(ZDDFA) 3
2X=C1
Figure 2. Selected inhibitors of AdoHcy hydrolase.
Borchardt and his coworkers have demonstrated that vinyl fluoride 1 is not a type II
inhibitor but rather a "pro-inhibitor" that is converted by the hydrolase into adenosine 5'-
aldehyde 3 (and its epimer) which inactivates the enzyme by the type I mechanism. The
"hydrolytic" activity of AdoHcy hydrolase removes the fluoride anion from 1 by
addition-elimination process. It was proved that the "hydrolytic" activity of the enzyme
was independent of its "oxidative" activity. 1,25 The Ado-5'-aldehyde 3 was
independently synthesized and shown to be equally potent inhibitor of AdoHcy
hydrolase.3 2 The 5'-chloromethylene analog 2 was found to be a time-dependent
inactivator of the AdoHcy with potency comparable to that of its 5'-fluoromethylene
analogue 1.33,34
8
1.1.4. Hydrolytic activity of AdoHcy hydrolase with halohomovinyl adenine
Analogues
The AdoHey hydrolase is also capable of adding water across the isolated 5',6'-
double bond of the 6'-halo(vinyl)homoAdo derivative 435,36 (Figure 3). The synthesis of
homovinyl halides 436,37'38 was based on the vinyl sulfones and organotin chemistry
developed by Wnuk and others. The 6'-halo(vinyl) homoAdo analogues 4 were found to
be concentration and time dependent inactivators of AdoHcy hydrolase. The inhibition
potencies were correlated with anticancer and antiviral activities of 4 and it was found to
be in the order of I > Br> Cl > F (and E > Z).36
NH 2  NH 2  NH 2
N N N N NN
OH OH OH OH OH OH
X=F,CI,Br,I X=F,I
4 5 6
Figure 3. The 6'-halo(vinyl)homoadenosine and related aristeromycin analogues.
Surprisingly, AdoHcy hydrolase possesses the catalytic power to effect addition of water
to the isolated double bond of 4. Scheme 2 shows the mechanism by which the fluorine
derivative, (E)-51',6'-didehydro-6'-deoxy-6'-fluoro-homoadenosine (EDDFHA) 4 is
processed by AdoHcy hydrolase. The reaction was shown to proceed by three pathways:
pathway a, water attack at the 6'-position of EDDFHA and elimination of fluoride ion
results in the formation of homoadenosine 6'-carbox-aldehyde (HACA), which degrades
chemically to form Ade; pathway b, water attack at the 5' position of EDDFHA results in
9
the formation of 6'-deoxy-6'-fluoro-5'-hydroxyhomoadenosine (DFHHA) and pathway
c, oxidation of EDDFHA results in the formation of the NADH form of the enzyme
(inactive form) and 3'-keto-EDDFHA, which could react with water at either the C5' or
C6' positions. The partition ratios among the three pathways were determined to be
k3 :k 6 ':k5' = 1:29:79, with one lethal event (enzyme inactivation) occurring every 108
nonlethal turnovers. 36b
To eliminate ribosyl ring cleavage during inhibition of AdoHcy hydrolase by 4, the 6'-
halo (vinyl) homoaristeromycin derivatives 5 (Figure 3) were prepared in which the
furanosyl ring oxygen was replaced by a methylene unit. 39 This type of modification was
expected to provide analogues that could not suffer cyclopentanyl ring cleavage by P-
elimination (H5' and the ring oxygen 04') as observed for homoadenosine 6'-aldehyde
(HACA, Scheme 2). Inactivation of AdoHcy hydrolase by 5 (X = F) involved addition of
water at the vinyl C5' or C6' (with elimination of fluoride) and oxidation of C3'. The
partition ratio among three pathways were found to be: k3 ':k 6 :k 5> = 1: 1.7: 0.6.
The 4',5'-didehydro-5'-deoxy-5'-fluoroaristeromycin 6 was also synthesized
(Figure 3) and it was found not to be a substrate for the hydrolytic activity of the enzyme
since incubation of AdoHcy hydrolase with 6 did not result in the release of fluoride
ion.40a However, independently synthesized aristeromycin 5'-aldehyde as well as 6 were
found to be potent type I inhibitors.40 It is possible that enzyme-mediated protonation of
the ribosyl ring oxygen of 1 (as well 4) enhances the electrophilicity of the C5', making
the 5' position more susceptible to attack by the enzyme-bound water.
10
0
o Ad0 OH
H H + Ade
HO OH
c HACAHO H
F F0
e Ade o Ado
H H
HO OH NA~ND H HOro OH
EDDFHA
F OH F OH 0
H o Ade H a Ade o OH
H H H
HO OH 0 OH 0 OH
DFHHA
Scheme 2. Mechanism of inactivation of AdoHey hydrolase by EDDFHA
To probe "pure" hydrolytic activity of the AdoHey hydrolase, analogues of vinyl
halides 1 and 4 without an oxidizable function (hydroxyl group) at C3'have been
targeted.41 The 3'-deoxy modification gave halovinyl analogue 7 and halohomovinyl
analogue 10 with greater differences in stereoelectronic effects and lack of a hydrogen-
bond acceptor at C3' (Figure 4). In other series, the 3'-hydroxyl group was replaced with
fluoro 8 or chloro 9 substituents to give a closer stereoelectronic analogue to the natural
substrates, but still preventing the oxidative activity at C3'. The 3'-modified analogues 7-
10 were found to be weak inhibitors of AdoHcy in a sharp contrast to the 3'-hydroxy
analogues 1 and 4. They were not substrates for the "hydrolytic" activity of the enzyme 41'
Thus, it is secure to conclude, that the 3'-hydroxyl group is essential for effective
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inhibitors/substrate binding to AdoHey hydrolase, and such binding is required for
execution of the "hydrolytic" activity of the enzyme.
NH 2  NH 2  NH 2
N X NC
F N N N N N
R OH OH HO OH
7R=H 10R=I,Br,F 11X=H
8R=F 12X=C19R=CI
Figure 4. The selected vinyl and homovinyl analogues of Ado and homoAdo.
Recently, 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine 113° and 6'-chloro-
6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine 1230 were also synthesized and tested
as new mechanism-based inhibitors of AdoHcy hydrolase (Figure 4). Nucleoside (E)-11
was identified as a type I inhibitor of the enzyme, whereas inactivation of the enzyme by
nucleoside (Z)-3 and (E)-12 was accompanied by the formation of a covalent labeling of
AdoHcy hydrolase.
The geminal and vicinal (dihalo)homovinyl analogues 13-15 were also designed
as potential new substrates for the hydrolytic activity of AdoHcy hydrolase. (Figure 5).42
These types of analogues were found to be the first examples of type II (covalent)
inhibitors that are activated by the "hydrolytic" activity of the enzyme without prior
oxidation at C3'.
12
NH 2  NH 2
{N N N
Br Br
XS N N Br -' O N N
OH OH OH OH
13X=F 15
14X=Br
Figure 5. The dihalo-vinylhomoadenosine analogues.
Inactivation of the enzyme with [bromo(fluoro)]homovinyl analogue 13 was
shown to be concentration and time-dependent and resulted in covalent linkage between
the enzyme and the inhibitor with concomitant release of halide ions (F~ and Br~) 43. The
enzyme-mediated addition of water to 13 at C6' of the 5',6'-double bond (followed by
elimination of bromide ion) generates an electrophilic acyl fluoride 16 (Figure 6).
Nucleophilic attack by a proximal Arg 196-NH 2 group forms a covalent adduct 17 (lethal
event). The enzyme maintains its original NAD+/NADH content indicating no oxidation
at C3'. In second non-lethal event depurination and hydrolysis of 16 (with elimination of
fluoride ion) produced hexose-derived 6-carboxylic acid.4 3
0 0
Br A EnzeH 2O Br F A Arg-196 F A
FF OArgNH
HO OH HO OH HO OH
13 16 17
Figure 6. Possible mechanism by which 6'-bromo-6'-fluoro(homovinyl)adenosine
inactivates AdoHcy hydrolase.
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1.2. The Alkene-metathesis reaction
1.2.1 Introduction into the alkene - metathesis reaction
Olefin metathesis reaction is a unique carbon skeleton redistribution in which
unsaturated carbon-carbon bonds are rearranged in the presence of metal carbine
complexes.44 With the advent of efficient catalyst, this reaction has emerged as a
powerful tool for the formation of carbon-carbon bonds in organic chemistry. 45 In fact,
with the exception of palladium-catalyzed cross-coupling reactions, no other group of
reactions has had such a profound impact on the formation of carbon-carbon bonds in the
last quarter of a century. 46 The number of applications of this reaction has dramatically
increased in the past few years. Of particular significance, this type of reaction utilizes no
additional reagents beyond a catalytic amount of metal carbine and the only other product
from the reaction is, in most cases, a volatile olefin, such as ethylene. 45 The history of
alkene metathesis is a fascinating one, beginning with its unexpected discovery nearly 50
years ago through the design and application of the latest initiators available today.
44b'47
There are several classes of olefin metathesis reactions (Scheme 3). In the
cross-metathesis reaction (CM) a mixtures of products are obtained unless a volatile
byproduct (ethylene) is produced that can be removed from the reaction mixture. Ring
closing metathesis (RCM) is favored for the production of unstrained rings and is driven
both entropically and by the elimination of a volatile alkene. Ring opening metathesis
(ROM) is only favored at very high olefin concentration, or more commonly with
strained olefins. The same general features will hold true for the polymerization
reactions.
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2 Cross metathesis R2 + H2C=C2
R CM or XMET
R Ring Closing MetathesisRCM
n 
+
Ring Opening Metathesis
ROM
-Ring Opening metathesis
Polymerization- ROMP
- Acyclic Diene Metathesis
Polymerization- ADMET
- mH 2C=CH2
Scheme 3. Types of olefin metathesis reactions
The elucidation of the mechanistic pathway was, itself, the culmination of nearly
two decades of extensive research by numerous groups, and the subject of lively debate
in the literature during that time. The generally accepted mechanism of alkene metathesis
was originally proposed by Herisson and Chauvin 4 8 in 1971 with key experimental
evidence for its validity subsequently being provided by the Casey 49, Katz50 and Grubbs
groups , and invokes metal carbine intermediates as key propagating species in the
catalytic cycle. Chauvin proposed that olefin metathesis involves interconversion of an
olefin and a metal alkylidene. This process is believed to occur via a metal-cyclobutane
intermediate by alternating [2 + 2] cycloadditions and cycloreversions (Scheme 4). The
basic catalytic cycle for metathesis is depicted in scheme 5.
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R
R R
[M] [M] [M R
R2 R1 R2 R1 R2R
Scheme 4. Mechanism of olefin metathesis.
R
[M] [M]
R, R2
[M] R
C2 H4  R1
Scheme 5. Basic catalytic cycle for metathesis.
The success of the alkene-metathesis reaction and the many stunning and
ingenious situations in which it has been applied are largely due to the advent of today's
readily available catalyst systems that display high activity and excellent functional-
group tolerance.4 6 Some of typical metathesis catalyst which are commercially available
are shown in Figure 7.
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The molybdenum-based catalyst (Schrock catalyst) was introduced by the
Schrock group and represented the first real groundbreaking advance in catalyst design
since the tungsten carbenes initially used by Katz. 3 Schrock catalyst displays excellent
metathesis activity with a variety of alkene substrates and it is particularly useful for the
formation of sterically crowded systems. The only drawback of this catalyst is its
pronounced sensitivity to oxygen, moisture and certain polar or protic functional groups
owing to the electrophilicity of the high-oxidation-state transition-metal center.54
Grubbs and co-workers subsequently introduced ruthenium-based carbene
complexes.55 The ruthenium reacts preferentially with carbon-carbon double bonds over
most other functional groups which makes these ruthenium-catalysts unusually stable
towards alcohols, amides, aldehydes and carboxylic acids. 56 Because of this aspect, it is
possible to increase the functional group tolerance of an olefin metathesis catalyst by
focusing on a transition metal, such as ruthenium. 56
The first and second generation Grubbs catalyst exhibit much greater functional-
group tolerance than the Schrock catalyst. The Hoveyda-Grubbs catalyst shows
efficiencies similar to those of Grubbs catalyst second generation but with a different
substrate specificity. The exchange of the PCy 3 ligand with the isopropyl ether leads to
different reactivities. For instance, in contrast to Grubbs second generation catalyst,
which proved to be an excellent catalyst for yne-ene CM, analogous reaction with
Hoveyda-Grubbs second generation catalyst yielded only traces of the desired products.
Polymerisation of the alkyne component was not observed. Substantial differences in
terms of reactivity were found also in RCM reactions. The recyclable catalyst is unique in
catalyzing RCM, ROMP and CM reactions with highly electron-deficient substrates.57
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K
Me 2HC CHMe 2
CF 3  NMej M
F3C Ol MO Me
-Ph0
Me
F3C MCF3
Schrock catalyst
PCy 3  HN N
CItRu=C C Ru:
Cl PCy3 PCy3
Grubbs first generation catalyst Grubbs second generation catalyst
PCy3  N N
CI H CI H
Cly u:C Cl Ru:C
Hoveyda-Grubbs first generation catalyst Hoveyda-Grubbs second generation catalyst
Figure 7. Commonly used metathesis catalysts.
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1.2.2. Metathesis reaction in nucleoside chemistry
The intense search for clinically useful nucleoside derivatives has resulted in a
wealth of new approaches to their synthesis. In this context, the olefin metathesis
reaction4 5'47 '58' 59 has emerged over the past decade as a powerful reaction that has
fundamentally changed the outlook on nucleoside chemistry.
Historically, the first synthesis of nucleoside analogues using metathesis was
achieved in 1996 by Crimmins and King60 utilizing chiral (S)-4-benzyl-2-oxazolidinones
through a strategy combining three key transformations: (1) an asymmetric aldol addition
to establish the relative and absolute configuration of the pseudosugar, (2) a ring-closing
metathesis (RCM) to construct the carboxylic ring and (3) a Trost-type palladium(0)
substitution to introduce the heterocyclic base (Scheme 6). The cyclisation by RCM of
diene 22, was achieved in the presence of Grubbs first generation catalyst giving
enantiomerically pure cyclopentenol 23 in 97% yield.
Kuang et al.61 have prepared the carbocyclic analogue of ribavirin 26 in a similar
approach, starting from the anti-aldol 24, which then underwent a ring-closing metathesis
in the presence of Grubbs first generation catalyst to yield 25 in 96% (Scheme 7). Further
treatment of 25 with LiBH 4/MeOH/THF at 00C followed by reaction with mCPBA gave
the corresponding non-racemic epoxy diol. After protecting the hydroxyl groups, the
resulting epoxide was reacted with triazole in the presence of NaH to give the desired
ring-opening product as the major isomer. Then treatment with ammonia followed by
hydrogenolytic deprotection provided carbocyclic ribavarin 26 in a moderate yield.
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u 1. n-BuLi, THF, -78°C, O" O 0
.2W. OCH2=CH(CH2)2C(O)OPiv N__H N o N 0
2. TiC14 (-)-sparteine,
21 CH 2C 2 , R-CH=CH-CHO 22
121 T1'22
Ph
Ph
PCy3  OH O HO Base
Cllr,,, 1 ,H o
Cu ~ ~~C N O-
CIPy3-
CH2C12
97% 23 Ph
Scheme 6. First synthesis of nucleoside using RCM
O
N NH2
HO O O HO 0 H N 'NHHO N
Grubbs ls"generation
N O catalyst N O
I CH2 CI2 , 96% 
OH OH
24 25 26
Ph Ph
Scheme 7. Synthesis of carbocyclic analogue of ribavirin using RCM.
Among the nucleoside analogues prepared by metathesis approach, synthesis of
neplanocins and aristeromycins analogues represent a major part of existing literature.
Neplanocin A, 27, {(-)-9-[trans-2',trans-3'-dihydroxy-4'-(hydroxymethyl)-cyclopent-4'-
enyl]adenine}, (Figure 8), has a wide range of biological activities and it is a strong
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inhibitor of AdoHey hydrolase.62 Analogs of L-neplanocins63 32 have been synthesized
starting from methyl a-D-galactopyranoside 28 as depicted in scheme 8.
NH 2  NH 2  NH 2
N *N N NN KN
HO N N HO N N HO N
OHOH OHOH OHOH
Neplanocin A Aristeromycin 3-deaza-aristeromycin
27 32 33
Figure 8. Neplanocin A and Aristeromycin
oeI
HO BnO BnO Grubbs catalyst
0 1_0_Ph 3PCH3Br 2"d generation
HO\ OH BnO' n-BuLi,THF BnO benzene, reflux, 90%
OH OBn OBn OBn OBn
28 29 30
OBn Base
OBn OH
OBnOBn OH OH
31 32
Scheme 8. Synthesis of L-neplanocins analogues
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After benzylation and demethylation on the anomeric position of 28, reaction with
methyltriphenyl phosphonium bromide and subsequent oxidation gave optically pure L-
tagatose [L-lyxo-hexulose] as a single isomer. Oxidation of L-tagatose produced the keto-
derivative 29. A second Wittig reaction on 29 afforded the (+) diene 30 in 77% yield. The
1,6-hepta diene 30, which bears the three asymmetric centers of the final molecule,
underwent RCM in the presence of Grubbs catalyst in refluxing benzene to give the
cyclopentene derivative 31 in 90% yield. After removal of the benzyl group using sodium
metal in liquid ammonia, the heterocycles were introduced under Tsuji-Trost allylic
amination. Also, a synthesis of D-neplanocin has been realized by Jin6 4 through a similar
approach, using a RCM, starting from protected D-ribose.
The naturally occurring carbocyclic nucleoside, aristeromycin 32, (Figure 8) is
also known to be an inhibitor of AdoHey hydrolase. Borchardt and his co-workers
reported the synthesis of modified analogues of this compound65' 66 using a non-
metathesis approach. Of the carbocyclic purine nucleosides tested, the most potent
inhibitor of AdoHcy hydrolase were the carbocyclic adenosine (aristeromycin) itself and
3-deaza-carbocyclic adenosine 3367 (Figure 9) both of which totally inhibited the enzyme
at concentrations of 0.2 pM.
In most of cases, the aristeromycin analogues 40 have been synthesized involving
the key cyclopentenone intermediate 39 (Scheme 9).The cyclopentenone intermediate is
in fact a versatile starting point for the preparation of many other carbocyclic
nucleosides. 6
8 69
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CH2 =CHMgBr /c H H Nam Ph3 PMeBr, NaL
O 0 THF, -78 0C O O CH 2C12, H20 O o DMSO O O
81% >- 00C 85% 88%
34 35 36 37
HO Base
Grubbs 1iS generation /" OH MnO2 O
catalyst, CHC13  CH2 C 2  OH
90 RT 0 y O OH OH90% 80
38 89% 39 40
Aristeromycins
Scheme 9. Synthesis of the aristeromycin analogues.
Synthesis of the arysteromycin analogues started with the protected D-ribose 34
being treated with vinylmagnesium bromide to give triol 35. Oxidative cleavage of triol
35 with sodium metaperiodate gave the lactol 36 in 85% yield. Wittig reaction of 36 with
triphenylphosphonium methylidene afforded the diene 37. Ring closing-metathesis of
diene 37 using Ru-Grubbs catalyst gave the allylic alcohol 38 (90%) which was
converted to the D-cyclopentanone 39 in 89% yield. In the following steps the
cyclopentanone intermediate 39 is used in the synthesis of arysteromycins 40.69
Agrofoglio and his co-workers58b reported a method for the synthesis of E-
unsaturated acyclic nucleosides via a combination of palladium-catalyzed allylic
alkylation and ruthenium-based cross-metathesis (CM). This approach provides an
efficient and reliable route to new nucleoside analogues such as 43 (Scheme 10). Thus,
the cross-metathesis (CM) of protected allylic diol 41 with allylic pyrimidine derivatives
42 was achieved by using Grubbs 2nd generation catalyst. The tolerance of the ruthenium
metathesis catalyst towards basic tertiary amines is less understood as most examples
reported in literature use a deactivated nitrogen (amide, carbamate).58b'70
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X x
p Y N Grubbs 2 nd generation N
O catalyst, CH 2 Ci 2
N 4 p - N -_O
41 42 l O43
X = OH; NHBz
Y = H, CH 3, I
Scheme 10. Synthesis of acyclic nucleosides via cross-metathesis reaction
Less than a decade has elapsed since Crimmins60 reported the first use of
metathesis reaction for nucleoside. From the work published by this time, it is apparent
that metathesis has played and will most likely continue to play, a major role in the
synthesis of new nucleosides.
1.3. Palladium-catalyzed cross-coupling reactions
1.3.1 Introduction to Pd-catalyzed cross-coupling reaction
The palladium-catalyzed cross-coupling of an organometal (R' M) with an organic
electrophile (R2X) has emerged over the past thirty years as one of the most general and
selective methods for carbon-carbon bond formation (eq.1)71. Currently, it appears to be
generally superior to related methods involving the use of Ni, Cu of Fe catalysts in its
scope and stereo-, regio- and chemoselectivities. 7 The RI group of R'M can be aryl,
alkenyl, alkynyl, allyl, benzyl, alkyl, cyano, propargyl, enoxy; while the R2 group of R2X
can be aryl, alkenyl, alkynyl, allyl, benzyl, propargyl, alkyl or acyl.
R'M + R2X PdLn(cat) R1 - R2 + MX
Eq.1. Pd-catalyzed cross-coupling of an organometal (R'M) with an organic electrophile
(R 2X).
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The Pd-catalyzed cross-coupling can be performed with organometals containing any of
these metals including Zn, Al, Zr, B, Sn, Li, Mg, In, Si, Cu, Mn (Table 1).
Taking the mechanism for organopalladium chemistry into account, several points
should be addressed. Reactions involved in formation of organopalladium intermediates
are done in the presence of phosphine ligands. These ligands coordinate at palladium and
play an important role in the reaction by influencing the reactivity. One point is the
relative weakness of the C-Pd bond and the instability of alkylpalladium species in which
there is 8 -hydrogen. The transition metal-catalyzed coupling reactions occur in a
sequence of: (a) oxidative-addition; (b) transmetallation (alkylation)/isomerization and
(c) reductive- elimination. These three steps provide a powerful catalytic method for the
new carbon-carbon bond formation (Figure 9). Transmetallation is the most characteristic
of the cross-coupling reactions because this process combines the quality of the transition
metal and the main group metal reagent. However, this step is also the one that is the
least understood because of its highly dependence on the nature of organometallic
reagents and the conditions of the reaction.
Table 1. Transition metal-catalyzed cross-coupling reactions
Name Reaction R'M R2X
Kumada-Corriu R'-MgX or R'-Li aryl, alkenyl
Suzuki-Miyaura R -BR' 2  aryl, alkenyl, alkyl
Negishi R -ZnX, R -AIX, R -ZrX aryl, alkenyl, alkynyl, acyl
Hiyama R -SiX 3  triflates, alkenyl, aryl
Stille R-Sn(alkyl) 3  aryl, alkynyl, acyl
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The coupling reaction begins with oxidative-addition of an electrophilic component to Pd
catalyst. The Pd catalyst such as Pd(PPh3)4 , Pd 2(dba)3 , PdC12(dppb), with or without an
extra ligand are used. The reaction rates and yields vary with the choice of Pd(0) or Pd(II)
used. The stoichiometric ratio between palladium and ligand is aslo very important.
Excess of phosphine retards the oxidative-addition step that is often the rate-determining
step.
R R2 
R1  X=halide
reductive-elimination step c step a oxidative-addition
R
[M \] « f3-hydride
R step b X H elimination (undesired)
R2
. M H RM_
m-X m-R2  X
transmetallation
and isomerization
[M] = Pd, Cu, Ni, Fe, Rh... ; m = Li, Mg, Zn, B, Al, Si, Cu, Sn, Zr...
Figure 9. A general catalytic cycle for Pd-catalyzed cross-coupling reactions.
The most studies of the coupling reactions have been focused on forming of the CSp2-
CSp2 and Csp-CSp2 bonds. There has been considerably less progress in developing effective
cross-couplings involving Csp3 centers with the exception of couplings between CSp2 as
electrophiles and Csp3 as nucleophiles. 73 Moreover, the monocross-coupling reactions of
1,1-dihalovinyl electrophiles with Csp2 or Csp nucleophiles are less common 74 and
monocouplings between 1,1-dihalovinyl electrophiles and Csp3 nucleophiles are
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scarced.7' 7 ' 7 6 Couplings of two sp3 centers of unactivated alkyls do not show much
success due to the slow oxidative-addition of alkyl halides and the p6-hydride elimination
from organopalladium (II) intermediates. The final steps in Pd-mediated reactions are the
elimination of Pd to form a carbon-carbon bond. Organopalladium species with two
organic substituents show tendency to decompose with recombination of the organic
groups by reductive elimination.
1.3.2 Negishi coupling reaction
In 1972, after the discovery of Ni-catalyzed coupling of alkenyl and aryl halides with
Grignard reagents, it became apparent that in order to improve the functional group
tolerance of the process, the organometallic coupling partners should contain less
electropositive metals than lithium and magnesium. In 1976, E. Negishi and his
coworkers reported the first stereospecific Ni-catalyzed alkenyl-alkenyl and alkenyl-aryl
cross-coupling of alkenylalanes (organoaluminums) with alkenyl- and aryl halides.7 ' 78
Extensive research by Negishi showed that the best results (reaction rate, yield,
stereoselectivity) are obtained when organozincs are coupled in the presence of Pd(O)-
catalysts. 7980'81 The Pd- or Ni-catalyzed stereoselective cross-coupling of organozines
and aryl, alkenyl, or alkynyl halides is known as the Negishi cross-coupling reaction
(eq. 2).
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NiLn or PdLn
catalytic
R'-X + R2-Zn-X R]- R2
solvent/ L (ligand) coupled product
R1= aryl, alkenyl, R2= aryl, alkenyl, allyl, L = PPh 3, dppe, dppp
alkynyl, acyl benzyl, homoallyl, dppb, dppf,
homopropargyl BINAP, DPEPhos
X = CI,Br, I, OTf, OAc X = Cl, Br, I
Equation 2. Negishi cross-coupling reaction
The general features of the Negishi cross-coupling reaction are:
- both Ni and Pd-phosphine complexes work well as catalysts. However, Pd-catalyst tend
to give somewhat higher yields and better stereoselectivity, and their functional group
tolerance is better;
- the active catalysts are relatively unstable Ni(O) and Pd(O)-complexes but these can be
generated in situ from more stable Ni(II) and Pd(II)-complexes with a reducing agent
(e.g. 2 equiv. of DIBAL-H or n-BuLi);
- in the absence of the transition metal catalyst, the organozinc reagents do not react with
the alkenyl halides to any appreciable extent;
- the most widely used ligand is PPh3, but other achiral and chiral phosphine ligands have
been successfully used;
- the various organozinc reagents can be prepared by either direct reaction of the organic
halide with zinc metal or activated zinc metal or by transmetallation of the corresponding
organolithium of Grignard reagent with a zinc halide (ZnX2)8 2 ,8 3 ; also many of
organozinc reagents are commercially available;
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* the use of organozinc reagents allows for a much greater functional group tolerance in
both coupling partners than in the Kumada cross-coupling where organolithiums and
Grignard reagent are utilized as coupling partners.
- other advantages of the use of organozincs include: high reactivity, high regio- and
stereoselectivity, wide scope and applicability, few side reactions and almost no toxicity;
- the reaction is mostly used for coupling of two C (sp 2) carbons but C(sp 2) - C(sp) as
well C(sp2)- C(sp 3) are also well known;
* besides organozincs, compounds of Al and Zr can also be utilized;
" if the organoaluminium or organozirconium derivatives are not sufficiently reactive,
they can be transmetallated by the addition of zinc salts, and this protocol is reffered to as
the double metal catalysis;8 4
- of all the various organometals (Al, Zr, B, Sn, Cu, Zn), organozincs are usually the most
reactive in Pd-catalyzed cross-coupling reactions and do not require the use of additives
(e.g. bases as in Suzuki coupling) to increase the reactivity. 85
Some of the limitations of the Negishi cross-coupling reaction are: - propargylzincs
do not couple well but homopropargylzincs do; - secondary and tertiary alkylzincs may
undergo isomerization, but cross-couplings of primary alkyl- and benzylzincs give good
results; - due to the high reactivity of organozincs, CO insertion usually does not happen
unlike in the case of less reactive organotins (Stille cross-coupling).
The mechanism of the Negishi reaction follows the same pathway as the general
catalytic cycle for the Pd-catalyzed cross-coupling reactions described above in section
1.3.1.
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The Negishi cross-coupling reaction has been widely utilized in organic synthesis.
For instance, the Negishi reaction was used during the final stages of the total sythesis of
Caerulomycin C for the preparation of the bipyridyl system by T. Sammakia et a186
(Scheme 11). The highly substituted 6-bromopyridine was coupled, in the presence of the
Pd2(dba)3/PPh 3 catalyst system, with 2- lithiopyridine, which was transmetallated by
ZnC12 in situ to the corresponding organozinc reagent. Interestingly, the analogous Stille
cross-coupling using 2-tributylstannyl pyridine was far less efficient and gave a low yield
of the desired product.
OMe OMe
Me OMe MeO MeOw
N Li O steps H
Br 0 N N
Br N ZnC12, Pd2(dba) 3  r N N(i-Pr)2  -N N'OHN(i-Pr)2 PPh 3, THF, r.t. 80%
Caerulomycin C
Scheme 11. Synthetic application of Negishi coupling.
1.3.3 Negishi cross-couplings involving Csp2- Csp3 centers.
Alkyl halides and related electrophiles are much less reactive toward Pd than unsaturated
organic electrophiles including those containing aryl, alkenyl, alkynyl, acyl as well as
allyl, benzyl, and propargyl groups. The lower reactivity of alkyl halides toward Pd has
been explained in terms of the lack of a proximal 7r bond. A difference in reactivity of at
least a 100-fold between alkenyl and alkyl iodides has been observed. 87 Until recently,
the use of alkyl electrophiles lacking proximal 7r bonds had been considered very
difficult, and therefore the task of Pd-catalyzed alkylation had been achieved by using
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alkylmetals. Mainly, for this reason, Pd-catalyzed alkylation of alkenyl derivatives has
been accomplished via the alkyl-alkenyl coupling. However, alkyl halides are not inert
towards Pd. For example, the use of highly nucleophilic Pd-complexes containing bulky
trialkylphosphines, such as PCyp3 (Cyp = cyclopentyl) and PCy3 (Cy = cyclohexyl), has
permitted the alkenyl-alkyl coupling between alkenylzinc derivatives and alkyl iodides,
bromides, and tosylates.88 Fu et al.89 also developed the first ligandless palladium based
method for Negishi cross-coupling of alkyl electrophiles: Pd(acac) 2
(bis[acetylacetonato]Pd(II)) catalyzed reactions of functionalized alkyl halides/tosylates
with organozirconium reagents (Scheme 12). In view of the attractiveness of ligandless
catalyst (cost, simplicity, easy purification), this method added a significant new
dimension to the development of effective processes for coupling alkyl electrophiles.
R 2.5% Pd(acac)2 R
HH X Cp2ClZr,,,>-R1 H R
H H 2 equiv. 2.0 equiv. LiBr H
X= halogen 1:1 NMP; THF, 55 0C
Scheme 12. Negishi cross-couplings of alkyl electrophiles under "ligandless"
conditions.
Despite recent promising developments such as those mentioned above, the Pd-
catalyzed alkylation of alkenyl derivatives is still achieved mostly by alkyl-alkenyl
coupling protocol. In this regard, alkylzincs are generally superior to the other
alkylmetals that have been examined to date, although alkylborons90  and
alkylmagnesiums9 1 are satisfactory in many cases. It is important to mention that in the
Pd-catalyzed alkylation with alkylzincs or in general with organozincs, the precise
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composition of alkylzines, which significantly depends on the methods of their
generation, affects the course of the subsequent cross-coupling process. One important
determining factor is the alkyl/Zn ratio. In a synthesis of (-)-discodermolide, it was
proved to be necessary to add 3 equiv. of t-BuLi to an alkyl iodide premixed with ZnC 2
(Scheme 13).92
A large number of natural products and related compounds have been synthesized by
using the Pd-catalyzed alkenylation of alkylzinc derivatives. 87'90-96
S1t-BuLi (3 equiv.) -PM
I Et2O, -78°C OM
O O OTBS 2. Pd(PPh3 )4 , 12h, rt 0 O OTBS
PMP PMP
+ ZnC12  I OPMB
steps
(-)-discodermolide
Scheme 13. The Pd-catalyzed alkyl-alkenyl coupling with an alkylzinc in a total
synthesis of (-)-Discodermolide
Dai and Fu7 3b have also described the Negishi cross-coupling of aryl and vinyl
chlorides with alkylzincs (Scheme 14). Among aryl halides, chlorides are arguable the
most useful class of substrates for coupling reactions, due to their lower cost and the
wider diversity of available compounds. 97 The commercially available, air-stable catalyst
Pd(P(t-Bu)3)2 can effect the Negishi cross-coupling of a wide range of aryl and vinyl
chlorides with alkylzinc reagents in a single protocol. Besides primary alkylzinc reagents,
branched alkylzincs were also used in this protocol. The Negishi couplings of branched
32
alkylzines gave desired coupling products and also isomerization products, due to the
isomerization of alkyl group, mostly secondary to primary.
2% Pd(P(t-Bu) 3)2
R-Cl + CIZn-alkyl R - alkyl
R = aryl; vinyl 1.5 equiv. THF/NMP, 1 00
0 C
Scheme 14. Negishi cross-couplings of aryl and vinyl chlorides with alkylzines
1.3.4. Negishi cross-couplings with dihalovinyl derivatives
Although the development of the monosubstitution reaction of the dihalo-alkenes with
aryl, 98 alkeny, 74ab and alkynyl metals 74e and related nucleophiles has been reasonably
successful, the Pd- or Ni-catalyzed monoalkylation has not been, 99 except in one isolated
example published in 1987 by Minato et al..76a In fact, this was the first successful regio-
and stereoselective monoalkylation and -arylation of 1,1-dichloro- 1 -alkenes by
organozinc or Grignard reagents in the presence of PdCl2(dppb) as a catalyst, (dppb =
diphenylphosphine butane) which produced 1-substituted (Z)-chloro-alkenes (Scheme
15).76a In the only example of trans-selective monoalkylation reported in this paper, n-
BuZnCl led to the desired monobutylated product, trans 2- chloro- 1 -phenyl- 1 -hexene 45
while the use of n-BuMgBr did not afford the desired product. The Pd-catalyzed second
alkylation of the monobutylated intermediate with n-HexMgBr led to the formation of the
trisubstituted alkene 46 in 77% yield (Scheme 15). Most probably, the first-stage
alkylation was strongly aided by the fact that the starting material was PP-
dichlorostyrene, since attempts to achieve analogous trans-selective monoalkylation of 2-
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alkyl-substituted 1,1-dichloro- or 1,1-dibromo- 1 -alkenes under the same conditions
failed.76 a
C4 H19  C49
nC1 4H9ZnCI nC6H13MgBr
r4 9 Cl PdC12(dppb) Cl NiC12(dppp) C6H t3
45 81% 46 77%
Ci
44 nC 4H(M Br No desired procuct
PdCI2 (dppb)
dppb
Scheme 15. Pd-catalyzed double-alkylation of /,p-dichlorostyrene. 76a
Since the discovery of the Pd-catalyzed highly trans-selective monosubstitution of
1,1-dichloro- 1 -alkenes followed by the second Pd-catalyzed substitution to produce
trisubstituted alkenes (Scheme 16)76a, its development as a method for not only the
selective synthesis of monosubsituted products7 4c,10' but also for disubstitution
products 74,76a has attracted considerable attention from synthetic chemists.
R1 X R2ZnX R1  X R3ZnX R1  R3
H X cat[ PdLn] H R2  cat[PdLn] H R2
X =Cl, Br, I
Scheme 16. Pd-catalyzed trans-selective monoalkylation of 1,1 -dichloro- 1 -alkene
and Pd-catalyzed second substitution.
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In this regard, recently Tan and Negishi76b reported a widely applicable Pd-
catalyzed trans-selective method for the monoalkylation of unactivated 1,1-dichloro- 1-
alkenes followed by the second Pd-catalyzed substitution for the selective synthesis of the
E and Z trisubstituted alkenes. A systematic screening of Pd catalysts, additives, and
solvents was conducted, which led to an optimized set of conditions that involve 5 mol%
of [PdC12(dpephos)] (dpephos = bis(o-diphenyl-phosphanylphenylether) as a
catalyst/ligand and dimethylformamide (DMF) as solvent (scheme 17). In some cases, the
use of one molar equivalent of N-methylimidazole (NMI) relative to an alkyl zinc reagent
has been shown to improve the yields.
R' Cl R2ZnX RI Cl R' R2
H Cl 5% [PdCl 2(dpephos)] H R2 H R2
DMF monosubstituted disubstituted
product product
lP O P
dpephos
Scheme 17. Pd-catalyzed trans-selective monoalkylation of 1,1-dichloro-1-alkenes
with alkylzine reagents.
There is no example in literature on the monoalkylation of 1,1-dibromo- 1 -alkenes.
In fact, Negishi76b reported that coupling of 1,1-dibromo-1-alkenes has a very high
tendency to produce dialkylated products. Thus, even 8,8-dibromostyrenes would
produce only their dialkylation products. The success observed with 1,1-dichloro- 1-
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alkenes but not with 1,1-dibromo- 1 -alkenes was explained in the mechanistic terms
(Scheme 1 8 ).76b
R2ZCX CI
R 1 CI cat.[PdL ] R_ ___4 R2ZnX R_____
H C oxidative addition H PdLnCI transmetalation PdLn
R2
CI
dissoc. R Mono
R1 CI H R
reductive 
R2
elimination H PdLLnCI R2 ZnX reductive R1  2PdLn R_ R2_X__reuctv__
Aadiion H Ci transmetalation elimination H R2
HDi
Scheme 18. Putative mechanism for the competitive formation of the mono- and
dialkylation products.
Although the intricate mechanistic details remain unclear, the following
characteristics are worth mentioning: the difference between dppb and dpephos ligands in
the selective monoalkylation of alkyl-substituted 1,1-dichloroalkenes is noticeable, and it
is clear that competitive formation of the disubstitution products is the major side
reaction to be minimized. In order to minimize this side reaction, the suppressing of the
second substitution through promotion of catalyst dissociation from the putative
monosubstituted alkene-Pd 7t-complex A (scheme 18) is required. It is possible that the
ethereal oxygen atom of dpephos may exert a chelation effect to facilitate the dissociation
of alkenes. Although unwanted, the formation of the disubstitution product must
undoubtedly be responsible for the high stereoselectivity (> 98%) attainable by Pd-
catalyzed trans-selective monosubstitution through kinetic resolution in the second stage
of disubstitution, in which the undesired cis-monosubstituted isomer of A must be
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significantly more reactive than A itself. In this sense, the observed formation of the
disubstitution products must be a good thing in disguise to a certain extent.76b
With the development of a widely applicable and satisfactory protocol for the trans-
selective monoalkylation of 1,1-dichloro- 1 -alkenes, the second Pd-catalyzed substitution
of relatively unreactive internal Z chloroalkenes was also investigated. Negishi76b
reported that the use of Cy3P (Cy = cyclohexyl) or Cyp3P (Cyp = cyclopentyl) as ligands,
led to the formation of the desired alkylation products in high yields (scheme 19). Pd-
complexes with Cy3P or Cyp3P appear to be generally satisfactory catalysts for the
second substitution with Grignard reagents containing alkyl, aryl, alkenyl and allyl
groups. Although this protocol has not yet been applied to the synthesis of natural
products, it promises to be applicable to the synthesis of natural products containing Z
trisubstituted alkenes, such as discodermolide 92b,1ol and hennoxazole A.10 2
nOctMgBr PhMgBr /
nOct cat.[Pd(Cy 3P)2  C1 cat. [Pd(Cy 3P)2]
TBSO - THF, 23 0C, 2h TBSO - THF, 23 0C, 20h, _ TBSO
H Me 95% H Me 88% H Me
PhZnBr
Hex Hex MgBr 5% Pd(OAc) 2
cat[Pd(Cy 3P)2] 10% Cyp3P
TBSO - THF, 50 0C, 20h TBSO Cl THF, 75 0C,24h TBSO -
H Me 73% H Me 87% H Me
Scheme 19. Cross-coupling of internal Z-chloroalkenes with Grignard reagents in the
presence of Pd catalysts containing bulky trialkylphosphines.
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2. RESEARCH OBJECTIVES
The purpose of this dissertation was to design and to synthesize potential
inhibitors of S-adenosyl-L-homocysteine (AdoHey) hydrolase, which should utilize the
hydrolytic activity of the enzyme during the inhibition process. The first targets were L-
adenosine A and its 5'-aldehyde oxime derivative B, enantiomers of the natural substrate
(Figure 10). They were designed on the basis that some unnatural L-nucleoside analogues
possess more potent antiviral activity against HIV and HBV viruses than their natural D-
counterparts. We have planned to examine the possibility of whether L-adenosine and its
derivatives can act as (un)likely substrates and/or inhibitors of AdoHcy hydrolase. The
enzymatic studies on the interaction of L-adenosine and its 5'-oxime derivatives with
AdoHcy hydrolase and computational studies of substrates specificity of the enzyme
toward L-adenosine were performed in order to evaluate these targets.
A O OH A O N
OH OH OH OH
A B
Figure 10. L-adenosine and its 5'-aldehyde oxime
The second targets were AdoHcy analogues of type C in which the sulfur and C5' atoms
in the S-adenosyl-L-homocysteine were replaced by the vinyl or the halovinyl "unit".
Such compounds should be substrates for the hydrolytic activity of the enzyme. They
should form "stable" complexes with the enzyme that would help to identify key binding
groups at the active site of AdoHcy that interact with Hcy moiety and participate in
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subsequent elimination and hydrolytic activity steps. However, such analogs due to the
lack of the leaving group (sulfur replaced by sp 2 carbon) can not undergo elimination of
the Hcy surrogate upon oxidation of the 3'-hydroxyl to its 3'-keto derivative. It is
believed that, the individual steps can be "frozen" and the proteins at the active site of the
enzyme identified. These unsaturated AdoHcy analogues were attempted to be
synthesized via metathesis between 5'-deoxy-5'-methylene adenosine G and racemic or
chiral unsaturated amino acid derivatives F (Scheme 20). Successive bromination-
dehydrobromination at the C5'-C6' double bond of C (X = H) was expected to afford
AdoHcy analogues with C5' and sulfur atom replaced by the halovinyl unit.
NH 2
NH2  N N
HO 2C S 0
HO OH
AdoHcy
(NH 2) 7' 5' A
RO 2C 9' 8' 6' O
10' (X)
HO OH
Cross-coupling C Metathesis
C6'-C7' C5'-C6'
NH 2  Y 5' A NH 2  5' A
7' 0 7. 0
RO 2 C 9' ZnBr + X 6' RO 2C ' ', +
10' 8' 10'
HO OH HO OH
D E (X, Y = halogen) F G
Scheme 20. Retrosynthetic analysis of AdoHcy analogues
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The analogues with halovinyl "units" were also envisioned to be synthesized
directly via the Pd-catalyzed cross-coupling reactions between dihalohomovinyl
nucleoside derivatives E and organozinc reagents D (Scheme 20). Since the literature
reports on the Pd-catalyzed monoalkylation of dihaloalkenes (sp 2-sp 3 coupling) were
scarce, we were prompted to undertake model studies on Pd-catalyzed cross-coupling
between vinyl dihalides and alkyl organometallics. We undertook effort to develop a
novel Negishi monoalkylation of 1-fluoro- 1 -iodo, bromo or chloro- alkenes, derived from
the conjugated or unconjugated aldehydes and ketones with primary, secondary and
tertiary alkylzinc bromides as a novel method for the synthesis of the internal
fluoroalkenes. We have also attempted cross-couplings between 1,1-dichloroalkenes and
1,1-dibromoalkenes with alkylzinc bromides. This type of coupling required developing
of a novel methodology to differentiate two identical halogens in order to provide access
to the multisubstituted chloro or bromo alkenes.
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3. RESULTS AND DISCUSSION
3.1 Are L-adenosine and its derivatives substrates for S-adenosyl-L-homocysteine
hydrolase?
3.1.1 Synthesis of L-adenosine and L-adenosine 5'-oximes.
The first targets of this thesis were L-adenosine 52 and its 5'-aldehyde oxime derivative
55. The L-adenosine 52 was prepared from L-xylose 44 utilizing the Moyround and
Strazewski protocol (Scheme 21).103 In the first step of synthesis, L-xylose was
acetonated in the presence of sulfuric acid to give the 1,2-0-isopropylidene-a-L-
xylofuranose 45. Compound 45 was then silylated with tert-butyldiphenylsilyl chloride at
the primary 5- hydroxyl group under standard conditions to give 46 in 90% yield. The
inversion of configuration at C3 was accomplished via an oxidation/reduction procedure.
Thus, ketone 47 was obtained by treatment of 46 with CrO3/pyridine complex in CH 2Cl 2.
The subsequent reduction step was performed with NaBH4 in EtOH and led to the L-
ribosyl derivative 48. Deacetonization of 48 with MeOH/H 2SO 4 and 0-methylated at Cl
in one pot followed by 0-benzoylation gave 1-0-Methyl-2,3,5-tri-O-benzoyl-L-
ribofuranose 49 (as a mixture of a and /p-anomers) in 80% yield of sufficient purity to be
used in the next glycosidation step. According to Vorbruggen1o 4a the best leaving group
for the formation of the required oxonium intermediate is acetate at C1 and in the #
position. Treatment of 49 with a mixture of glacial acetic acid, acetic anhydride and
sulfuric acid at 0 0C led to the standard ribosyl donor 1-0-acetyl-2,3,4- tri-O-benzoyl-L-
ribofuranoside 50 as an a/p8 mixture (1:3). The pure P-anomer was obtained after column
chromatography. The introduction of the j-N-glycosidic bond was accomplished through
the well-establish procedure reported by Vorbruggen. 104b,c Thus, subjection of 50 with 6-
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N-benzoyladenine in the presence of TMSOTf, MFSTA in 1,2-dichloroethane gave
protected L-adenosine derivative 51 in 86% yield. The standard deprotection of 51 with
NH3/MeOH furnished the L-adenosine 52 in high yield.
H OH o OH O OSiPh2tBu
HO V 7 HO 1 acetone/H 2S5O, J~HO tBuPhSiCI HO
2.KOHIH 2 O imidazole,DMF
OH 44 45 9 o 46
L-xylose
O OSiPh2tBu O OSiPh2tBu
CrO3/pyridine NaBH 4  1. MeOH,H 2SO4
CH2C0, 97% O EtOH O O 2. BzClpyridine
o 47 O O 4
O OCOPh OAc O OCOPh ANHBzO OCOPh
MeO Ac20/ AcOH 6N-benzoyladenine
~iv.~iI 3~iF 0  H2S04  ir TMSOTf, MFSTA,a
PhOCO OCOPh PhOCO OCOPh C2H4C12  PhOCO OCOPh
49 50 51
A A
NH 3/MeOH HCH(OEt) 3, Me 2CO 1) DMSO, DCC, CI2CHCO2H
OH OH p-CH3C6H4SO3H O O 2) NH 2OH, pyridine
52 53
A __ N OH A OH
TFA/H20
O O 9:1 OH OH
54 55
Scheme 21. Synthesis of L-adenosine and L-adenosine 5'-oximes.
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The 2',3'-O-isopropylidene-L-adenosine 53 was prepared by treatment of L-
adenosine 52 in the presence of trietyl orthoformate in dried acetone with p-
toluenesulfonic acid monohydrate. Moffat oxidation of 2',3'-O-isopropylidene-L-
adenosine 53 gave crude 5'-aldehyde that was treated with hydroxylamine hydrochloride
in pyridine to give the protected oxime 54 (E/Z, ~6:1; 80%). Acid-catalyzed removal of
isopropylidene group gave 55 (E/Z, 6:1; 89%). Oximes 55 have spectroscopic properties
identical to those of their known enantiomer, adenosine 5'-carboxaldehyde oximes.105
3.1.2 Theoretical studies of L-adenosine
3.1.2.1 Computational results with L-adenosine.
In order to find the differences for the preferred protein:ligand binding modes,
interaction strengths and binding specificity for the adenosine and L-adenosine the
AutoDock simulations were perfomed. For each protein:ligand pair 128 LGA
(Lamarckian Genetic Algorithm) docking runs were performed, with each run producing
one possible binding mode or solution. The 128 solutions were first sorted in terms of the
binding mode, i.e. the position and orientation of the ligand relative to the protein target.
The solutions having rms (root mean square) deviations in ligand atomic positions of less
than 0.5 A were grouped into a cluster. The total number of clusters generated measures
the specificity of binding. A small number of clusters indicates that the ligand has only a
few possible binding modes, and interacts with a specific site (or sites) on the target
protein. On the other hand, a large number of clusters implies the existence of a wide
range of binding modes and lack of specific ligand:target interactions. The second step in
sorting solutions involves identification of the solution of lowest binding energy within
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each cluster and ranking the different clusters according to this energy value. The
solution with the lowest energy in the top ranked (i.e. lowest-energy) cluster, as well as
all solutions with energies higher by up to 5.0 kcal/mol were considered as possible
binding modes for ligand and target.
3.1.2.2. Docking of L-adenosine to the closed structure of AdoHcy hydrolase
A summary of the AutoDock results is presented in Table 2. For the L-Ado,
AutoDock produced 24 clusters out of 128 runs (Table 2). The first cluster consisted of
26 solutions, with the average docking energy of -16.3 kcal/mol. The positions of the first
and second clusters are about 2 A away from the substrate in the 1A7A crystal structure,
indicating that L-Ado does not fit into the inhibitor/substrate binding site. Comparison of
the AutoDock results suggests that L-Ado should be a poor substrate of AdoHcy
hydrolase compared to D-Ado. The binding of L-Ado to the protein is both weaker
(higher energy) and less specific (larger number of clusters) compared to D-Ado. The
binding energy difference AE = -18.9 - (-16.3) = -2.6 kcal/mol corresponds to a change
in the binding constant by a factor of exp(-AE/RT) = 76 at room temperature. The
microscopic reason for these effects appears to be a lack of fit between L-Ado and the
inhibitor/substrate binding site. Lack of the structural fit was recently observed by
computer overlaid structures of D and L enantiomers of 6'(E)-
(bromohomovinyl)adenosine (e.g., C: X = Br, Y = H).10 6
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Table 2. Summary for autodock results for D-Ado and L-Ado docking to the
closed form of AdoHcy hydrolase
Total number of Av. Energy of top Number of solutions
clustersa cluster (kcal/mol) in
top of cluster
D-Ado 16 -18.9 +/- 0.3 21
L-Ado 24 -16.3 +/- 0.3 26
a Clustering of a total of 128 runs. Average binding energy of the first cluster for L-Ado
and second cluster for D-Ado. ' Standard deviation over solutions within cluster.
The docking results are approximate. The scoring is based on an empirical energy
function, solvation effects treated with a highly simplified model, and only ligand
flexibility taken into account, with the protein structure kept fixed. 07 The binding energy
difference calculated here, -2.6 kcal/mol, is only slightly greater in magnitude than the
estimated standard error of the method, 2 kcal/mol. Thus, the AutoDock results should
be only considered as qualitative. The calculated binding energy results are in qualitative
agreement with the observed inhibitory effects. Additionally, the simulations suggest that
L-Ado has a lower specificity and worse fit into the known active site than D-Ado.
3.1.3. Interaction of AdoHcy hydrolase with L-Adenosine
L-Adenosine 52 and its 5'-oxime derivatives 55 were evaluated for their ability to
inhibit the activity of recombinant human placental AdoHcy hydrolase by incubating the
enzyme with the compounds at 200 pM for 20 min at 370 C. The AdoHcy hydrolase
activity was determined by assaying the enzyme's ability to catalyze the conversion of
Ado and Hcy to AdoHcy. Under these conditions, both 52 and 55 were inactive as
inhibitors of the AdoHcy hydrolase. In contrast, adenosine-5'-carboxaldehyde oximes
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under these conditions produce 72% inhibition of the enzyme. Adenosine-5'-
carboxaldehyde oxime is known to be a potent inhibitor of AdoHcy hydrolase with Ki
and kinact values of 0.67 pM and 0.16 min', respectively105 and is a substrate for the
enzyme hydrolytic activity.108
Our findings 10a are in agreement with a recent report where the
(halohomovinyl) and acetylenic derivatives of L-adenosine were found to be much
weaker inhibitors than the corresponding analogues derived from adenosine. 5 In
conclusion, docking calculations showed that binding of L-Ado is not as specific as that
of D-Ado for human AdoHcy hydrolase and that the binding energy of the D-
Ado/enzyme complex is lower than that of the L-Ado/enzyme complex. These results
might explain why L-Ado and its analogues were found to be inactive as inhibitors of
AdoHcy hydrolase, and therefore not good candidates for drug design targeting AdoHcy
hydrolase and/or transmethylation enzymes.
3.2. Design and synthesis of S-adenosylhomocysteine analogues with the sulfur
and C5' atoms replaced by the vinyl unit.
The second targets of this thesis were S-adenosyl-L-homocysteine analogues of
type A and B with the sulfur and C5' atoms replaced by the vinyl or homovinyl unit
(Scheme 22). Retrosynthetic analyses of compound A indicate that the easiest approach
would be to start synthesis from the parental nucleoside and the suitable constructed
amino acid units. First approach was envisioned to be metathesis via construction of a
new C5'-C6' double bond using two terminal alkenes in the presence of Grubbs catalyst.
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The second approach employed Negishi coupling to construct a new C6'-C7' single bond
between dihalonucleoside derivative with the corresponding organozinc reagent.
NH 2
N N
NH 2  N N
H02C S 0
HO OH
AdoHcy
NH 2
NN
NH 2  N N
7' 5'
HO 2C 0
X
HO OH
AX=H
B X = halogen
Metathesis Negishi cross-coupling
(C5'-C6'double bond) (C6'-C7'single bond)
Scheme 22. Retrospective analysis for the unsaturated S-adenosyl-L-homocysteine
analogues.
3.2.1 Metathesis approach between the 5'-deoxy-5'-methyleneadenosine and the
racemic homoallylglycine precursors.
In order to explore the metathesis approach the protected 5'-deoxy-5'-
methyleneadenosine derivatives (e.g. 60 or 61) and the 6-carbon amino acid, e.g.
homoallylglycine 65 or 66 bearing a terminal double bond were prepared. Synthesis of
the protected 5'-deoxy-2',3'-O-isopropylidene-5'methyleneadenosine started with
adenosine 56 which was dissolved in acetone and treated with p-toluenesulfonic acid and
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ethyl orthoformate. Crystallization of the crude product from MeOH gave 2',3'-0-
isopropylidene adenosine 57 in 97% yield (Scheme 21). Moffat oxidation of the 5'-OH
group in 57 with dicyclocarbodiimide (DCC) in DMSO in the presence of dichloroacetic
acid at ambient temperature afforded crude 5'-aldehyde which was in situ treated with
(toluenesulfonylmethylene)triphenylphosporane 35 to produce 9-[5,6-dideoxy-2,3-0-
isopropylidene-6-(p-toluenesulfonyl)-j-D-ribo-hex-5(E)-enofuranosyl]adenine 58 in 80%
yield after purification on silica gel column. 'H NMR spectrum confirmed the structure
and the trans configuration was assigned on the basis of the magnitude of the coupling
constant (J6 ,_5 , = 15.1 Hz). Reflux of 58 in toluene with tributyltin hydride in the presence
of AIBN effected stanylo-detosylation via a radical addition-elimination reaction. The 9-
[6-(tributylstannyl)-5,6-dideoxy-2,3-O-isopropylidene-[3-D-ribo-hex-5-enofuranosyl]
adenine 59 was obtained in 71% yield as a separable mixture of E/Z isomers (~5:1). The
stereochemical composition of the mixture was established based on the coupling
constant analysis in 1H NMR spectrum [59(E) (J6'. 5' = 19.1Hz), 59(Z) (J5'-6' = 12.8 Hz)].
Treatment of 59 (E/Z) with NH4F in MeOH at reflux for 48 h produced a more polar 9-
[5,6-dideoxy-2,3-0-isopropylidene-p-D-ribo-hex-5-enofuranosyl]adenine 60 in 90%
yield after purification on silica gel column. Splitting pattern for protons of the terminal
alkene group at 6 5.13 [(d, J6'.5'= 10.4 Hz (cis), J6'-6" = 1.2 Hz) and 5.25 [J 6 -5' = 17.2 Hz
(trans) H6"] were confirmed on 'H NMR spectrum. In order to protect the amino group
from the adenine ring, compound 60 was dissolved in dried pyridine and reacted with
benzoyl chloride to provide 61a in 95% yield. Treatment of 60 with excess of benzoyl
chloride afforded 61b in 98% yield.
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HOA HA TsAHo Q ethyl orthoformate ,, HO o 1.DCC/DMSO/C12CHCO2H_ 
-- Q
acetone/p-toluenesulfonic acid 2.Ph3P=CHTsOH OH O O O O
56 57 58Bu3SnH
AIBN
toluene
Bu 3Sn
B A A A
4  / B zCl/Py  NH 4F/MeOH Bu3Sn +
61 60 59 Z 59E
a.B=ANHBz
b.B=ABZ2
Scheme 23. Synthesis of the protected 5'-deoxy-2',3'-O-isopropylidene-5'-methylene
adenosine
The synthesis of the unsaturated amino acid precursors (homoallylglycine) for the
metathesis approach is depicted in scheme 24. Thus, the unsaturated a-amino acid 63 was
obtained in 72% in phase-transfer catalyzed SN2 reaction 09 between commercially
available N-(diphenylmethylene)glycine ethyl ester 62 and 4-bromo- 1 -butene. 'H NMR
spectrum of 63 confirmed the presence of the characteristic splitting for a terminal
alkene. Acid deprotection" 0 of 63 afforded the corresponding racemic mixture of amino
acid 64 in 96% yield with the appropriate number of carbons suitable for the metathesis
approach. It is worthy to note that there is an extra carbon in chain as compared with
homocysteine, because one of the carbon will be lost during metathesis with 5'-deoxy-5'-
methyleneadenosines 60 or 61. Benzoylation of the amino group in 64 with BzCl in
pyridine gave the N-benzoyl aminoacid 65 in 89% yield as a white solid after purification
on silica gel column. 'H NMR spectrum of 65 showed peaks from the aromatic protons at
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6 7.38-7.52 (m, 5H, Ar). Compound 65 had also UV for better control of the subsequent
metathesis reaction. Treatment of 64 with (tBuO)2CO and NaHCO 3 in dioxane provided
N-Boc aminoacid derivative 66.
Ph 2 CPh2CN OEt Br 2 "N OEt HCI/H20/Et20 NH2
O K2CO 3/MeCN/TBABr62 63 0 64
(tBuO)2CO
NaHCO3
dioxane BzC/Py
NHBoc NHBz
OEt OEt
66 0 65 0
Scheme 24. Synthesis of the amino acid precursors for metathesis approach.
Attempted cross-metathesis4 5'46'47b'70 between 5'-deoxy-2',3'-O-isopropylidene-
5'-methylene adenosine 60 with N-benzoyl 65 or N-Boc 66 protected amino acids bearing
the terminal double bond in the presence of 1St and 2 "d (2-imidazolinylidene-Ru)
generation Grubbs catalysts46 '47b failed to give desired products 67a or 68a (Scheme 25).
Also, metathesis of the 6-N-benzoyl adenosine substrate 61a with 65 or 66 in the
presence of the same catalysts did not afford the desired products. However, treatment of
61a with 65 in the presence of Hoveyda-Grubb's catalyst I1a,b led to the formation of
metathesis product 67b (51%) in addition to dimer 73 (11%) as a less polar compound.
Self-metathesis of adenosine substrate 61a was not observed. Metathesis of the 6-N,N-
dibenzoyl 61b with 65 gave 67c in 60% yield in addition to dimer 73 (18%).
Interestingly, metathesis of the 5'-deoxy-5'-methylene adenosine 60 having 6-amino
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group unprotected with 65 or 66 even in the presence of Hoveyda-Grubb's catalyst did
not yield the corresponding cross-metathesis products 67a or 68a. This means that the
protection of 6-amino group of adenine plays an important role in cross-metathesis
reaction and more than likely is necessary.
The cross-metathesis reaction (CH 2Cl 2, at 650C) between protected 5'-deoxy-5'-
methylene adenosine 61a or 61b with racemic N-Boc protected aminoacid 66 in the
presence of Hoveyda-Grubbs catalyst gave the desired products 68b (61%) and 68c" "1
(76%) respectively, (Scheme 25). The self-metathesis of nucleosides substrates or amino
acid byproducts were not isolated from the reaction mixtures. In agreement with literature
reports,12 the cross-metathesis products 67 and 68 were found to be predominantly the
trans-isomers. Column chromatography on silica gel afforded products 67 and 68 as pure
5'E isomers of the 1:1 mixture of 9'R/S diastereomers. 1H NMR and mass spectrometry
confirmed the structure of 67 and 68. The E stereochemistry for 67 and 68 was
established from 1H NMR spectra based on the magnitude of JH5'-H6'. For example, the 5'
proton in 68c appears at 6 5.58 (dd, JH5'-H4' = 7.3 Hz and JH5 '-H6' = 15.2 Hz) while the 6'
proton resonates at 8 5.73 (dt, JH6'-H7'/7"= 6.5 Hz and JH5'-H6' = 15.2 Hz).
The next step in the synthesis of desired AdoHcy analogues was deprotection of
products 67 and 68. Thus, treatment of 68c (or 68b) with 1:1 mixture of the saturated (at
0 °C) methanolic ammonia solution and methanol for 48 h at ~ 0 °C removed the 6-N-
benzoyl group(s) and afforded a partially separable mixture of methyl 69 and ethyl 70
esters (~ 3:2, ~92% total yield). The use of diluted methanolic ammonia solution was
important since saturated solution of NH 3/MeOH led to the formation of the amidation
byproducts in substantial yield (up to 40%).
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Scheme 25. Cross-metathesis between 5'-deoxy-5'-methylene adenosine and
unsaturated N-Boc or N-benzoyl protected aminoacids.
Acid catalyzed deprotection of 69 and 70 with aqueous solution of trifluoroacetic acid
(TFA) effected removal of both Boc and the isopropylidene protection groups to give the
esters 71a and 71b in high yields. It is worthy to note that debenzoylation of 68 (or 67)
should be performed as the first deprotection step, because treatment of 68 (or 67) with
TFA/H 20 resulted in the substantial cleavage of glycosylic bond. Saponification of 71a
and 71b with NaOH in H20/MeOH solution followed by purification on RP-HPLC
afforded the sodium salt of 72 in 67% percent yield as a single E isomer of the 1:1
mixture of 9'R/S diastereomers.
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3.2.2 Metathesis approach between the 5'-deoxy-5'-methylene adenosine and the
chiral homoallylglycine precursors.
In order to synthesize AdoHcy analogue having the L-configuration for the amino
group which corresponds to the natural aminoacids, we first attempted separation of
9'R/S diastereomers in products 67 and 68. Unfortunately, separation of 9'R/S
diastereomers in 67 or 68 was unsuccessful. Then we turned our attention to the synthesis
of AdoHcy analogue with 9'S configuration employing a chiral amino acid precursor,
e.g., (S)-homoallylglycine. Given that the methods available for the preparation of
enantiomerically pure unnatural aminoacids usually require multistep synthesis,"3 we
chose the enantioselective hydrolysis of racemic 66 as a way to provide chiral (S)-
homoallylglycine.
Treatment of 66 with a-chymotrypsin in phosphate buffer" 4 (0.1M, pH 8)
produced the unreacted (R)-ester 66 (~50%) and (S)-acid 74 (-50%) (Scheme 26). In
order to establish the enantiomeric purity of 66 as R enantiomer, the Mosher test was
applied. Optically active a-methoxy-u-(trifluoromethyl)phenyl acetic acid (MTPA acid),
known as the Mosher reagent, was originally developed in 1969115 for use in
determination of the enantiomeric purity of chiral alcohols and amines by NMR
spectroscopy. The use of of this reagent was subsequently expanded to chromatographic
resolution of chiral alcohols"'6 and assigning the absolute configuration of its chiral esters
based on the empirical correlation between their NMR chemical shift and the absolute
stereochemistry of the alcohol." 7 In our case, treatment of ester 66-R with TFA/H 20
followed by acylation with (R)-2-methoxy-2-(trifluoromethyl)phenyl-2-phenylacetyl
chloride" 8 [(R)-MPTA-Cl] gave 76 R/S. Analysis of the 19F NMR spectra [6 -69.55 (s,
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0.98F) and -69.8 (s, 0.02F)] established the stereochemistry for 66 as R in agreement with
Mosher' correlations. The acid 74-S was next converted into the methyl ester 75-S in
reaction with diazomethane in ethanol (Scheme 26). It is worthy to note that the
metathesis of the "free" carboxylic acid precursor 74-S with 61a or 61b in the presence of
Hoveyda-Grubbs catalyst did not yield the desired product.
NHBoc NHBoc NHBoc
EtO2C a-chymotrypsin EtO2C C + HO 2C
66 0.1 M phosphate buffer 66R 743
pH 8.0, 37 C, 36 h e.e. >96%Yield: 90%
TFA/H 20 CH 2N2/EtOH
0 OMe 0 ,Me
HN CF3 Cl CF3  NH2  NHBoc
Ph Et0 2C MeO 2C
Et62C (R-Mosher reagent) 64R 75S
76R/S
DMAP/py/C6 H6 /rt
Scheme 26. Enantioselective hydrolysis of alkenyl-a-amino acid ester.
Once the chiral amino acid precursor 75-S was synthesized, we attempted the
cross-metathesis reaction between 61b and 75-S which afforded 77-S in 77% yield
(Scheme 27). Standard deprotection of 77-S with diluted NH3/MeOH gave 69-S in 91%
yield. Acid deprotection with TFA/H 20 yielded methyl ester 71a-S (90%) as a single E
isomer after purification on RP-HPLC. Alterantively, metathesis of 61b with 66-R gave
ethyl ester derivative 68c-R. Contrary to the products 67-72 obtained from racemic
homoallylglycine, the 13 C NMR spectra for the products obtained from (S)- and (R)-
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homoallylglycine substrates showed a single set of peaks. 'H NMR spectrum also showed
some spectral differences especially for H2 and H8 from the adenine base.
Az2NH Boc ANBz2
NHBoc ANBZ2 Ru-catalyst McA
Me2O Hovey da-Grubbs 
MeO O
CH 2C12/ 550C 0
75-S O0 0 0
61b 77-S
NH 3/MeOH
NH 2  A NHBoc A
MeO 0 MeO 0
O TFA/H 20 o
HO OH O0
71a-S 69-S
Scheme 27. Cross-metathesis of adenosine precursor with S-amino acid derivative.
3.2.3. Synthesis of the halovinyl S-AdoHcy analogue.
Taking into consideration that AdoHcy hydrolase is able to add water across to the
isolated 5',6'-double bond of a 6'-halo(vinyl)homoAdo derivative, 35,36 we have also
attempted the synthesis of bromovinyl analogue of type B (scheme 22). This synthesis
was executed using the bromination-dehydrobromination strategy (Scheme 28). Thus,
treatment of 68c with pyridinium tribromide"19 in dioxane gave the 5',6'-dibromo
diastereomers 78 in a very high yield. 'H NMR and LC-MS spectra confirmed the
structure of 78. In fact, 'H NMR spectrum showed no presence of the olefinic protons
and the LC-MS spectrum showed the characteristic peaks pattern (M+ + 2 and M+ + 4)
due to the presence of two bromine atoms. Compound 78 underwent dehydrobromination
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with 1,8-diazobicyclo[5.4.0]undec-7-ene (DBU) in THE yielding 79b as a single isomer.
Also one of the 6-N-benzoyl protective group was partially cleaved and formation of 79a
was observed. Standard deprotection of 79a/79b mixture with diluted NH3 /MeOH gave
80 as an inseparable mixture of methyl and ethyl esters. Treatment of 80 with TFA/H2 0
removed both Boc and isopropylidene protection group affording 81. Saponification of
81 with solution of NaOH followed by RP-HPLC purification gave 82 as a single E
isomer in 54% overall yield (Scheme 28).
NHBoc ANBz2 NHBoc Br ANBz 2  Br ANRR
EtO A C5H5NH.Br3 EtO 0 DBU EtO NH oc BrO A
0 Br HHEo
68c 2K 78 79a R = H; R'= Bz
79b R = R'= Bz
O O O
ROBr A ROBr A HO"T BrO ARO O R NaOH/H O NH2NH 3/MeOH NHBoc TFA/H 20 NH2  A H A
80 00 81 OH OH 82 OH OH
R=Me or Et
Scheme 28. Synthesis of the halovinyl S-AdoHcy analogue.
The regioselectivity of the HBr elimination and therefore position of the bromine
at 5' (versus 6') in 79-82 was assigned based on the COSY experiment. The COSY
experiment showed a strong cross-peak correlation between protons H6'-H7' but did not
show any cross-peak between protons H4'-H5'. Also 'HNMR spectrum supported this
assignment. In fact, 'H NMR spectrum showed the presence of the H6' as a triplet at S
6.40 (J-.7 7= 7.6 Hz), rather then the expected doublet with J5'.4 for H5' in the case of 6'-
bromo regioisomer.
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The E configuration of products 79-82 is expected from a specific anti-addition in
the pyridinium tribromide bromination of the E alkene 68c which is followed by an E2
(anti elimination) process of HBr from 78. This was also supported by the NOESY
analysis of 82 in which the cross-peak between H4' and H7/7" was observed while no
cross-peak between H4' and H6' was detected.
3.3 Negishi cross-coupling approach
3.3.1 Coupling with 1-fluoro-1-haloalkenes
Since the elimination of HBr gave 5'-bromovinyl analogue 82 instead of the
more desired 6'-bromo analogue, we turned our attention to the coupling approach. On
the basis of retrosynthetic analysis, the synthesis of analogue type A or B (see scheme 22)
can be accomplished using Pd-catalyzed cross-coupling reaction between sp2 hybridized
carbon of dihalohomovinyl precursor of adenosine and spa hybridized carbon of the
corresponding organozinc reagent, Negishi coupling, to form a new C6'-C7' single bond
as a key step. Since literature reports on the Pd-catalyzed monoalkylation of
dihaloalkenes (Csp2-Csp 3 coupling) were scarce 76 99, we were prompted to undertake
model studies on Pd-catalyzed cross-coupling between vinyl dihalides and alkyl
organometallics.
Taking into account that the fluoride is unreactive7a towards couplings, we first
accomplished Pd-catalyzed monoalkylation between a series of 1-fluoro-1-haloalkenes
86-88, derived from the conjugated or unconjugated aldehydes and ketones with alkyl
zinc-bromides reagents. The corresponding 1-fluoro- 1 -haloalkenes were synthesized
using McCarthy's procedure.' 2 0 In the first step aldehydes 83a-c and ketone 83d
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underwent condensation with sulfonyl-stabilized fluorophosphonates to give
(fluoro)vinyl sulfones 84 in high yield. The radical-mediated stannyldesulfonylation of
84 with Bu 3SnH/AIBN yielded (fluoro)vinyl stannanes 85. In the last step of synthesis,
85 underwent the halodestannylation35 with NIS or NBS or Cl 2 to give 1-fluoro-l-iodo-
(86), 1-fluoro-1-bromo- (87) and 1-fluoro-1-chloroalkenes (88) (Scheme 29). It is
noteworthy that dihaloalkenes of series c with a benzyloxy substituent at allylic carbon
are structural analogues of the dihalohomovinyl nucleoside or ribofuranosyl precursors
which also possesses oxygen atom at carbon 6 from the a-halovinyl carbon.
oR 1 O~ R1Sn/A
PhSOCHFPO(OEt)2 R sr- BuRSnH/AIBN Bu 3Sn
R R1  LHMDS/THF/-78 "C R 0 benzene/ R
83 84 F F 85
NIS
CH2CL2 NBS C 2
CH2CLI
H-,CI CR1 R1 R1
R I R Br R Cl
86 F 87 F 88 F
Compds 83-88 R R
a Ph H
b PhCH 2CH 2  H
C PhCH 20CH 2  H
d Ph CH 3
Scheme 29. Stereoselective synthesis of 1-fluoro- 1 -haloalkenes.
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Having the desired starting materials synthesized, we attempted couplings of the
1-fluoro- 1 -haloalkenes 86-88 with different types of primary alkylzine bromides in the
presence of Pd catalyst in benzene at 650C (Scheme 30). Thus, treatment of 1-fluorovinyl
iodide 86a (E/Z, 95:5) with 2 equiv. of primary alkylzinc bromide [BrZn(CH 2)3CO 2Et] in
the presence of Pd(PPh3)4 in benzene (65 °C, 10 h) gave fluoro alkenoate 89a as a single
Z isomer (JF-H(trans) 39.8 Hz) in 70% yield (Scheme 30; Table 3, entry 1). Analogous
treatment of 86a (E/Z, 95:5) with alkylzinc bromides containing double bond
[BrZn(CH 2)3CH=CH 2] or acetal functionality [BrZn(CH 2)2CH(OCH 2)2] gave 90a(Z) or
91a(Z), respectively (Table 3, entries 5 and 6). The couplings occurred with retention of
configuration via trans-selective alkylation, but E/Z descriptors changed due to the
change in Cahn-Ingold-Prelog priority at the reaction center carbon. The 1-fluorovinyl
bromides 87a and chlorides 88a also underwent efficient couplings with
BrZn(CH 2)3CO2Et to give 89a(Z) in 70% and 80% yield (Table 3, entries 3 and 4).
R1 R1
R X BrZnCH 2CH 2R2  R R2
F Pd(0)/C6H6/50-65 *C F
86 X = 1 89 R2 = CH2CO 2Et
87 X = Br 90 R2 = CH 2CH=CH 288 X = CI 91 R2 = CH(OCH 2)2
Compds 86-91 R R
a Ph H
b PhCH 2CH 2  H
C PhCH 20CH 2  H
d Ph CH 3
Scheme 30. Couplings of 1-fluoro-1-haloalkenes with alkylzincs.
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In order to optimalize reaction conditions, we tested efficiency of various Pd
catalysts for such Negishi monoalkylation (Scheme 31).We found that
tris(dibenzylideneacetone)palladium [Pd 2(dba)3] and 1,4-
bis(diphenylphosphinobutane)palladium chloride [PdCl2(dppb)] gave smooth conversion
of 86a into 91a in 2 h at 50 0C. Pd(PPh3)4 effected only 11% conversion of 86a into 91a
under analogous conditions. The Pd(OAc) 2 and 1,1'-bis(diphenylphosphinoferrocene)
palladium chloride [PdCl 2(dppf)] were also found to be less effective. In comparison
with Pd(PPh3)4, coupling of 86a with BrZn(CH 2) 3CO 2Et in the presence of PdCl 2(dppb)
gave a higher yield of 89a(Z) (93%, entry 2 vs. entry 1) under milder conditions (50 "C, 2
h). The cross-coupling reactions of the unconjugated 1-fluorovinyl halides 86b (E/Z,
78:22) with primary alkylzinc bromides in the presence of Pd(PPh3)4 gave 89b, 90b, and
91b in high yields ( Table 3; entries 9, 13,and 14). The conversion of 86b into 89b was
achieved in higher yield under milder conditions with PdCl2(dppb) as catalyst ( Table 3,
entry 12).
The vinyl iodide 86c (E/Z, 75:25) with benzyloxymethyl substituent at carbon '8
(analogue of the nucleoside precursor) reacted with BrZn(CH2)3CH=CH 2 [Pd(PPh3)4] to
give the internal fluoroalkene 90c(Z) in moderate yield (56%, Table 3, entry 17) in
addition to unchanged 86c with enriched Z to E ratio (56:44). It seems that the
PdCl2(dppb) catalyst not only increased the yield but also led to the formation of 90c as
mixture of E/Z isomers (20:80, 86%; Table 3, entry 18). Also bromide 87c yielded 90c as
E/Z mixture in high yield (Table 3, entry 19).
The 1-fluorovinyl halides derived from acetophenone (series d) served as
convenient starting material for the synthesis of multisubstituted alkenes. 2 1 Thus, Pd-
60
catalyzed monoalkylation of 86d (E/Z, 49:51) in the presence of Pd(PPh3)4 produced
89d(Z), 90d(Z), and 91d(Z) (Table 3, entries 20, 22, 23). Analogous coupling of 86d
with more reactive PdCl2(dppb) gave 89d as a mixture of E/Z (16:84) isomers (Table 3,
entry 21).
In order to learn more about the stereochemistry of coupling reactions, the pure E
isomer and a mixture enriched in Z isomer (E/Z, 15:85) of fluoro(iodo)alkenes 86b were
synthesized by separation of the corresponding (fluoro)vinyl stannanes 85b followed by
the stereospecific iododestannylation. Treatment of 86b(E) with BrZn(CH 2)3CO 2Et or
BrZn(CH 2)2CH(OCH 2)2 [Pd(PPh3)4/12 h/65 °C] resulted in smooth conversion (GC/MS,
'
9F NMR) to 89b(Z) or 91b(Z) with the isolated yields of 88% and 89%, respectively
(Table 3, entries 10 and 15). On the other hand, analogous Negishi treatment of 86b (E/Z,
15:85) yielded 89b(Z) or 91b(Z) in 14% (96% conversion of E isomers) while the
corresponding 89b(E) or 91b(E) were not formed (Scheme 32). Prolonged reaction time
and harsher condition resulted in decomposition of the 86b(Z) isomer (GC/MS, 19F
NMR).
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Table 3. Pd-catalyzed alkylation of 1-fluoro-l-haloalkenes 86-88".
Entry substrate E/Z product (Z) time (h) yield yield'
1 86a 95/5 89a 10 70% 74%
2 86a 95/5 89a" 2 93% 97%
3 87a 93/7 89a 10 70% 75%
4 88a 93/7 89a 10 80% 86%
5 86a 95/5 90a' 10 65% 69%
6 86a 95/5 91a 12 90% 94%
7 86a 95/5 91af 2 92% 96%
8 86a 95/5 91a" 2 94% 98%
9 86b 78/22 89b 24 60% 78%
10 86b 100/0 89b 12 88% 88 %9
11 86b 15/85 89b 24 14% 96%
12 86b 84/16 89bd 8 82% 98%
13 86b 78/22 90bh 20 76% 98%
14 86b 78/22 91b 20 74% 94%
15 86b 100/0 91b 12 89% 89%'
16 86b 15/85 91b 24 14% 96%
17 86c 75/25 90c 48 56%1 74%
18 86c 67/33 90cdk 4 86
19 87c 77/23 90cd'k 6 84%
20 86d 49/51 89d 24 45% 94%
21 86d 49/51 89dd/ 8 60%
22 86d 49/51 90d 24 45% 92%
23 86d 49/51 91d 24 46% 90%
a Pd(Ph3P)4 was used as a catalyst unless otherwise specified (50-65 4C). isolated yield. isolated
yield based on the conversion of the E isomer only. " PdCl 2(dppb) catalyst. (ZZ)-2,3-difluoro-1,4-
diphenyl-1,3-butadiene 94 was also isolated (8%; 16% consumption of 86a). -Pd 2(dba) 3 catalyst. 9 96%
based on GC-MS. h (Z)-l-fluoro-4-phenyl-1-butene, E isomer of 90b and (ZZ)-4,5-difluoro-1,8-diphenyl-
3,5-octadiene was also detected in crude reaction mixture (' 9F NMR). '98% based on GC-MS. /56% based
on '9 F NMR. k(E/Z, 20:80). '(E/Z, 16:84; based on 1F NMR and GC-MS).
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BrZnCH 2CH 2CH(OCH 2)2  O
F Pd/C 6H6 /50 °C/2 h F
86a (E/Z, 95:5) 91a (Z)
Catalysta Yieldbc
Pd(PPh 3)4  11%
PdCl 2(dppf) 8%
Pd(OAc) 2  75%d
Pd 2(dba)3  93%e
PdCI2(dppb) 95%'
Key: a 5% molar; b GO/MS and 19F NMR; c only Z product was detected;
d9 5% after 3.5 h; e Isolated yield 92%; ' Isolated yield 94%.
Scheme 31. Effect of the Pd catalyst on the efficiency of Negishi coupling
I BrZn OEt 0
Pd(Ph 3P)4/C6H6/65 0 C86b(E) 89b(Z), 88% isolated yield
96% based on GC-MS
BrZn 0Et O
F Pd(Ph3P)4/C6H6/650 C F 0
86b(E/Z; 15:85) 89b(Z), 14%
96% conversion of E isomer
Scheme 32. Establishing the stereochemistry of couplings with 1,1 -dihaloalkenes.
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Generally, we only observed formation (above detection limit'22 of 1-2%, 9 F
NMR) of the corresponding E isomers via cis-couplings in a few instances (Table 3, entry
13, 18, 19, 21). For example alkylation of 86c (iodide) and 87c (bromide) in the presence
of PdCl 2(dppb) produced 90c as E/Z (20:80) mixture. These results are in agreement with
trans-selective mono cross-coupling of 1,1-dihaloalkenes reported previously.72, 76,00 ,12 3
Burton and coworkers showed that trans selectivity with 1-bromo- 1 -fluoroalkenes
originate in oxidative addition step since formation of the E-palladium complex is faster
than the formation of the Z-palladium complex which is hampered by steric hinderence of
vicinal cis-substituent.123a They applied this finding for the kinetic resolution of the E and
Z coupling products.' 23 The major by-product isolated from the coupling reactions
resulted from the reductive homocoupling of dihalide components. For example, self-
coupling product of 86a, e.g., (E,E)-2,3-difluoro-1,4-diphenyl-1,3-butadiene 94, was
isolated in 8% yield from the reaction of 86a with BrZn(CH 2)3CH=CH 2 (Table 3, entry
5).
We have also examined the Pd-catalyzed 1,1-dihaloalkenyl coupling with
branched alkylzincs. Thus, PdCl2(dppb) was found to be effective for monoalkylation of
86a (E/Z, 95:5) with tert-BuZnBr (92a) to provide 93a (80%; 3 h, 50 °C; Scheme 33).
The Pd2(dba)3 and Pd(PPh 3)4 catalysts were less effective leading to the formation of the
significant amount of self-coupling (E,E)-2,3-difluoro-1,4-diphenyl-1,3-butadiene 94 by-
product. Interestingly, attempted couplings of 86a (E/Z, 95:5) with secondary 2- and 3-
pentylzinc bromide (92b,c) in addition to various amount of desired products 93b and
93c gave also isomerization byproduct 93d (35-70%) in addition to selfcoupled diene 94
and reduced (Z)-/3-fluorostyrene (in some cases). Formation of byproducts derived from
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isomerization of the alkyl group (secondary to primary) during Negishi cross-coupling
reaction is known.' 23 c,124
BnR(9 F Pd(O)/C 6 H6  
F 1
86a 93 94(E/Z, 95:5)
Compounds 92, 93: Series a R = tert-Bu
b R = 2-pentyl
c R = 3-pentyl
d R = n-Bu
Scheme 33. Couplings with branched alkylzincs.
3.3.2. Coupling with 1,1-dichloro- and 1,1-dibromoalkenes
In order to investigate the differentiation of the two identical halogens in 1,1-
dihaloalkenes for the selective monoalkylation with alkylzincs, we attempted Pd-
catalyzed selective monosubstitution of 1,1-dichloro- and 1,1-dibromoalkenes with
alkylzinc reagents. The corresponding 1,1-dichloro- and 1,1-dibromoalkenes were
prepared using Rabinowitz and Marcus' 25 procedure. Thus, a solution of
triphenylphosphine and the corresponding carbonyl compound in carbon tetrachloride (or
carbon tetrabromide) were heated at 60 °C for 3 h. Analysis of GC-MS spectrum
revealed that the carbonyl compound disappeared while /,/-dihaloalkenes 96-97 were
formed (Scheme 34).
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CX4 / PPh3 R' X
S60°C, 3A
R X = Cl; Br R X
95 96X=C
97 X Br
Cmpds 96-97 R R
a Ph H
b (4)CH 3OPh H
c Ph CH 3
Scheme 34. Synthesis of 1,1-dichloro- and 1,1-dibromoalkenes.
In order to find the optimal reaction conditions for the monoalkylation reaction,
we conducted a systematic screening of Pd-catalysts (Scheme 35). Screening of the Pd-
catalyst in the monoalkylation of /3,f-dichloro-4-methoxystyrene 98b revealed that
PdCl2(dppf) was the best catalyst for this reaction giving the desired monocoupling
product in 70% isolated yield. PdCl2(dppb) effected conversion of 96b into 98b in 63%
yield under analogous conditions. On the other hand Pd(PPh3)4, Pd(OAc) 2 and Pd 2(dba)3
were found to be less effective. It is worthy to note that the monoalkylation reaction was
improved in the presence of DPEPhos [bis(o-diphenylphosphanylphenylether)]126 as an
extra ligand.
Negishi and Tan76b explained that DPEPhos plays an important role in the Pd-
monoalkylation reaction and it is possible that the ethereal oxygen atom of DPEPhos may
extert a chelation effect to facilitate the dissociation of alkenes (see section 1.3.4). Once
the reaction conditions were established, we examined the Pd-catalyzed monocoupling
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using different 1,1-dichloro- and 1,1-dibromoalkenes (Scheme 36, Table 4). In agreement
with literature reports, 76 the Pd-catalyzed monoalkylation of 1,1 -dihaloalkenes was found
to be trans-selective.
CI BrZn(CI-I9 3CO2Et \OEt
MC Pd catalyst/DPEPhos/ OMe C6H6/50-65 °C/8 h MeO
96b 98b
Catalysta Yieldb,c
PdCI2(dppf) 70
PdCI2(dppb) 63
Pd(PPh 3)4  55
Pd(OAc) 2  15
Pd 2(dba) 3  9
Key: a 5% molar. blsolated yields.cOnly Z product was detected
Scheme 35. Screening of Pd catalyst for the monoalkylation reaction.
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x BrZn(CH,) 3CO2Et "\'~ OEt +Q Et
R2 Pd catalyst /C6 H6/50-65 °C R20 o R R o
96 X = Cl 98 X = CI 100 R3 = CH,(CH2)2CO 2Et
97X=Br 99X=Br 101 R3 =H
Cmpds.96-101 R R2
a H H
b H OCH 3
C CH3 H
Scheme 36. Pd-catalyzed trans-selective monoalkylation of 1,1 -dichloro- and
1,1-dibromoalkenes with alkyl zinc reagent.
Table 4. Pd-catalyzed monoalkylation of 1,1 -dichloro- and 1,1 -dibromoalkenes.
Entry Substrate Conditions Conditions Conditions Yielda(%) Yielda (%) Yielda
Catalyst Ligand Time Mono Dialkylated Reduced
1 96a PdC12(dppf) 14 65 0 22
2 96a PdCi 2(dppb) 12 53 27 15
3 96a Pd(PPh 3) 4  12 0 68 28
4 96b PdC 2(dppf) DPEPhos 8 70 27 0
5 96b PdC12(dppb) DPEPhos 8 63 27 10
6 96b Pd(PPh 3)4  DPEPhos 8 55 35 10
7 96c PdC12(dppb) DPEPhos 10 0 90 10
8 97a PdCl 2(dppf) 10 0 69 28
9 97a PdCI 2(dppb) 10 0 75 24
10 97a Pd(PPh 3)4  10  0  6 0  3 8
11 97b PdC12(dppf) DPEPhos 7 47 52 0
12 97b PdCI2(dppb) DPEPhos 7 0 78 21
13 97b Pd(PPh3)4  DPEPhos 10 40 59 0
14 97b Pd(PPh 3)4  10  0  72  26
15 97c PdC12(dppb) DPEPhos 12 0 87 10
a isolated yield
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We found that the /,/-dichlorostyrene 96a coupled with BrZn(CH 2)3 CO 2 in the
presence of PdCl2(dppf) to give the desired trisubstituted chloroalkene 98al2lb (Z, 65%
Table 4, entry 1) in addition to the monocoupled/reduced byproduct 101a (22%).
Analogous coupling of 96a in the presence of PdCl2(dppb) also produced 98a (Z, 53%,
Table 4, entry 2). Besides the desired monoalkylated product 98a, the formation of
dialkylated byproduct 100a (27%) and reduced byproduct 101a (15%) was also observed.
Similar couplings with more reactive f,/l-dibromostyrene 97a did not produced the
desired trisubstituted bromoalkene 99a. In fact coupling of 97a with BrZn(CH 2)3CO 2 in
the presence of PdCl2(dppf) or PdCI2(dppb) produced mainly the dialkylated 100a (69%
or 75%, Table 4, entries 7 and 8) in addition to the reduced by-product 101a.
We found that the addition of an extra ligand such as DPEPhos (bis-o-
diphenylphosphanylphenylether) can control the Pd-catalyzed monoalkylation reaction of
1,1 -dihaloalkenes. Thus, treatment of 96b with BrZn(CH 2)3CO 2 in the presence of
PdCl 2(dppf) as a catalyst and DPEPhos as a ligand gave the desired trisubstituted
chloroalkene 98b in a higher yield (Z, 70% Table 4, entry 4). The major improvement of
using DPEPhos was observed in coupling of pp-dibromostyrene derivative 97b with an
alkylzinc reagent. Thus, treatment of 97b with BrZn(CH2)3CO 2/PdC 2(dppf) and
DPEPhos as a ligand afforded the desired trisubstituted bromoalkene 99b (Z, 47%, Table
4, entry 11) in addition to the dialkylated by product 100b. Analysis of 'H NMR and GC-
MS spectra showed the characteristic peaks for a trisubstituted bromoalkene. Analogous
coupling of 97b with organozinc reagent in the presence of Pd(PPh3)4 as a catalyst and
DPEPhos as ligand also furnished the desired bromoalkene 99b (Z, 40%, Table 4, entry
13). It is noteworthy that coupling of 97b using only Pd(PPh3)4 (without ligand) did not
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afford 99b (Table 4, entry 14). Treatment of 1,1-dihaloalkenes derived from the
acetophenone (96c or 97c) with PdCl 2(dppb) and DPEPhos yielded mainly the
dialkylated products (Table 4, entry 7 and 15).
Generally speaking, the major byproduct isolated from the Pd-catalyzed trans-
selective monoalkylation of 1,1-dihaloalkenes was the dialkylated byproduct. It is clear
that competitive formation of this type of byproduct is the major side reaction to be
minimized in future work.
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4. EXPERIMENTAL SECTION
4.1 General procedures
UV spectra were measured with solutions in MeOH. 1H (400 MHz and 600
MHz), '3C (100 MHz) and 9F NMR (376.4 MHz) spectra were determined with
solutions in CDCl 3 unless otherwise noted. Mass spectra (MS) were obtained with
atmospheric pressure chemical ionization (APCI) technique and HRMS using AP-ESI
mode unless otherwise noted. Reagent grade chemicals were used, and solvents were
dried by reflux over and distillation from CaH2 (except THE/potassium) under an argon
atmosphere. TLC was performed with Merck kieselgel 60-F 254 sheets with MeOH/CHCl 3
(1:19), EtOAc/hexane (2:1) and EtOAc/i-PrOH/H 20 (4:1:2, upper layer) as developing
systems. Products were detected with 254 nm light or by development of color with
Ce(S0 4)2/(NH 4)6Mo 70 24 .4H2 0/H2SO 4/H20 or 12 or 10% H2SO 4/MeOH. Merck kieselgel
60 (230-400 mesh) was used for column chromatography. HPLC purifications were
performed using XTerra® preparative RP1s OBDTM column (5pm 19 x 150 mm) with
gradient program using CH 3CN/H 20 as a mobile phase. Purity and identity of some
products (crude and/or purified) were established using a Hewlett-Packard (HP) GC/MS
(El) system with a HP 5973 mass selective detector [capillary column HP-5MS (30 m x
0.25 mm x 25 pm)]. Elemental analyses were determined by Galbraith Laboratories,
Knoxville, TN.
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4.2. Synthesis
L-2',3'-0-Isopropylideneadenosine (53). L-Adenosine° (52, 200 mg, 0.75
mmol) was suspended in dried acetone (6 mL) containing p-toluenesulfonic acid
monohydrate (470 mg, 2.5 mmol). Triethyl orthoformate (1.5 mL, 1.34 mg, 9.0 mmol)
was then added over a period of 10 to 20 min at ambient temperature with vigorous
mechanical stirring until a clear solution was obtained. After 18 h, water (4.5 mL) and
concentrated ammonium hydroxide (0.1 mL) were added (to pH ~ 7-8). Volatiles were
evaporated and the residue was column chromatographed (EtOAc -* 5% MeOH/EtOAc)
to give 53 (206 mg, 90%) with spectroscopic data identical to the commercial sample of
2',3'-O-isopropylideneadenosine.
L-2',3'-O-Isopropylideneadenosine-5'-carboxaldehyde Oximes (54). A
solution of 53 (100 mg, 0.33 mmol) and N, N'-dicyclohexylcarbodiimide (DCC; 235 mg,
1.13 mmol) in dried DMSO (1.5 mL) was stirred under argon at ambient temperature.
The Cl2CHCO 2H (0.013 mL, 21 mg, 0.16 mmol) was then added and stirring was
continued for 90 min. Pyridine (0.5 mL) and NH2OHeHCl (226 mg, 3.25 mmol) were
added to the solution of the crude L-adenosine-5'-carboxaldehyde and stirring was
continued at ambient temperature overnight. Volatiles were evaporated, CHCl3 was
added and the precipitated dicyclohexylurea (DCU) was filtered. The mother liquor was
partitioned (1% AcOH/H 20//CHCl 3) and the aqueous layer was extracted (4 x CHCl 3).
The combined organic phase was washed (NaHCO 3/H20, brine), dried (Na2SO 4), and
was concentrated and column chromatographed (2 -* 4% MeOH/CHCl 3) to give 54 (E/Z,
~ 6:1; 83 mg, 80%): MS (APCI) m/z 321 (100, MH*) and other spectroscopic data as
described for D-enantiomer. 05
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L-Adenosine-5'-carboxaldehyde oximes (55). A solution of 54 (83 mg, 0.08
mmol) in CF 3CO 2H/H 20 (9:1, 5 mL) was stirred at 0 0C for 45 min under argon.
Volatiles were evaporated and the residue was coevaporated (3 x toluene) and then
column chromatographed (EtOAc -+ 8% MeOH/EtOAc) to give 55 (E/Z, ~ 6:1; 20 mg,
89%) as an amorphous white solid: MS (APCI) m/z 281 (100, MH+); UV (MeOH) max
260 nm (s 14 100), min 228 (s 4000). 'H NMR (MeOH-d 4) for 55(E) 6 4.50 (t, J= 4.7, 1,
H3'), 4.58 (dd, J= 6.9, 4.4 Hz, 1, H4'), 4.83 (t, J= 5.0 Hz, 1, H2'), 6.06 (d, J= 5.0 Hz, 1,
H1'), 7.64 (d, J= 6.9 Hz, 1, H5'), 8.24 (s, 1, H2), 8.32 (s, 1, H8). 55(Z) S 4.38 (dd, J=
4.6, 1.5 Hz, 1, H3'), 5.08 (dd, J= 7.5, 4.8 Hz, 1, H2'), 5.22 (dd, J= 5.2, 1.6 Hz, 1, H4'),
6.03 (d, J= 7.5 Hz, 1, Hi'), 7.28 (d, J= 5.2 Hz, 1, H5'), 8.24 (s, 1, H2), 8.32 (s, 1, H8).
6-N,N-Dibenzoyl-5'-deoxy-5'-methylene-2,3-O-isopropylideneadenosine (61b).
Benzoyl chloride (323.4 mg, 0.23 mmol) was added dropwise to a stirred solution of
603 (350 mg, 1.15 mmol) in pyridine (5 mL) at 0 °C (ice bath) and the resulting
mixture was stirred overnight at ambient temperature. NaHCO 3/H 20 (3 mL) was added
and the volatiles were evaporated. The residue was partitioned (HC1/H 20/EtOAc) and the
organic layer was washed (NaHCO3, brine), dried (Na2SO 4) and evaporated. Column
chromatography (30 -+ 50% EtOAc/hexanes) gave 61b (560 mg, 97%): 'H NMR 6 1.41
(s, 3, CH 3), 1.65 (s, 3, CH 3), 4.73-4.75 (m, 1, H4'), 4.95 (dd, J= 3.3, 6.2 Hz, 1, H3'), 5.14
("d", J = 10.4 Hz, 1, H6"), 5.22 ("d", J= 17.1 Hz, 1, H6'), 5.50 (dd, J= 1.9, 6.3 Hz, 1,
H2'), 5.90 (ddd, J= 6.8, 10.4, 17.2 Hz, 1, H5'), 6.20 (d, J= 1.9 Hz, 1, Hi'), 7.35 (t, J=
7.6 Hz, 4, Ph), 7.46 (t, J= 7.4 Hz, 2, Ph), 7.85 (d, J= 7.2 Hz, 4, Ph), 8.16 (s, 1, H2), 8.68
(s, 1, H8); 13C NMR 6 25.7 & 27.5 (CMe2), 84.6 (C3'), 84.7 (C2'), 88.6 (C4') 91.1 (Cl'),
115.1 (CMe 2), 118.9 (C6'), 128.3 (C5), 129.1 (Ph), 129.8 (Ph), 133.4 (Ph), 134.4 (Ph),
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135.0 (C5'), 144.5 (C8), 152.4 (C4), 152.7 (C2), 152.8 (C6), 172.6 (CO); MS m/z 512
(100, MH+). Anal. Caled for C28H2 SN 50 5 (511.1856): C, 65.74; H, 4.93. Found: C, 65.72;
H, 4.90.
Ethyl 2-Aminohex-5-enoate (64). Step a. The 4-bromo-1-butene (1.7 mL, 2.27 g,
16.8 mmol) was added to a heterogeneous mixture of N-(diphenylmethylene)glycine
ethyl ester 62 (3 g, 11.2 mmol), finely grounded K2CO 3 ( 4.5 g, 32 mmol), and
tetrabutylammonium bromide (0.36 g, 1.12 mmol) in CH 3CN (10 mL) and the resulting
mixture was refluxed with stirring (oil bath, 98 "C). After 24 h, the reaction mixture was
cooled down to room temperature and was filtered. The filtrate was evaporated and the
oily residue was partitioned (H20/EtOAc). The organic layer was dried (Na2SO 4),
evaporated and column chromatographed (hexane/EtOAc, 85:15) to give 63 (2.77 g,
77%): 'H NMR 6 1.30 (t, J = 7.0 Hz, 3, CH 3), 1.98-2.13 (m, 4, H3,3',4,4'), 4.08 (t, J = 6.1
Hz, 1, H2), 4.21 (q, J = 7.0 Hz, 2, CH 2), 4.92 (dd, J = 1.8, 10.2 Hz, 1, H6), 4.98 (dd, J =
1.8, 17.2 Hz, 1, H6'), 5.64-5.77 (m, 1, H5), 7.12-7.85 (m, 10, Ar); MS m/z 321 (100,
MH+). Step b. 1 N HCl (5.6 mL, 5.6 mmol) was added dropwise to a stirred solution of
63 (2.0 g, 6.23 mmol) in Et20 (12 mL) at 0 oC (ice-bath). After 30 min, the reaction
mixture was allowed to warm-up to ambient temperature and stirring was continued for 5
h. The resulting two layers were separated, and the aqueous layer was neutralized with
NaHCO 3 to pH ~ 8 and was then extracted with ether (3 x 15 mL). The combined organic
layer was evaporated to give 64127 (0.93 g, 95%) of sufficient purity for direct use in next
step: 'H NMR S 1.25 (t, J = 7.1 Hz, 3, CH 3), 1.52 ( br s, 2, NH 2), 1.56-1.65 (m, 1, H3'),
1.76-1.85 (m, 1, H3), 2.07-2.10 (m, 2, H4,4'), 3.39 (t, J = 7.7 Hz, 1, H2), 4.15 (q, J = 7.1
Hz, 2, CH 2,), 4.97 (dq, J = 10.2, 1.7 Hz, 1, H6'), 5.04 (dq, J = 15.7, 1.6 Hz, 1, H6), 5.73-
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5.83 (ddt, J = 15.7, 10.2, 6.6 Hz, 1, H5); 3 C NMR 6 14.6 (CH 3), 30.2 (C4), 34.4 (C3),
54.3 (C2), 61.1 (CH 2), 115.6 (C6), 137.9 (C5), 176.4 (Cl); MS m/z 158 (100, MH+).
Ethyl 2-N-Benzoyl-2-aminohex-5-enoate (65). Benzoyl chloride (0.82 mL, 992
mg, 7.06 mmol) and DMAP (12 mg, 0.1 mmol) were added to a stirred solution of 64
(554 mg, 3.53 mmol) in pyridine (5.5 mL) at ambient temperature. The resulting mixture
was stirred for 3 h at ambient temperature. Volatiles were evaporated and the residue was
partitioned (HCl/H 20//CHC 3). The organic layer was washed (NaHCO 3, brine), dried
(MgSO 4), evaporated and chromatographed (CHCl 3) to give 65 (765 mg, 84%) as a white
solid: 'H NMR 6 1.33 (t, J= 7.1 Hz, 3, CH 3), 1.89-1.95 (m, 1, H3'), 2.15-2.23 (m, 3,
H3,4,4'), 4.26 (q, J= 7.1 Hz, 2, CH 2), 4.87 (ddd, J= 5.4, 6.9, 7.9 Hz, 1, H2), 5.04 ( br d, J
= 10.2 Hz, 1, H6), 5.10 (br d, J= 15.6 Hz, 1, H6'), 5.79-5.89 (m, 1, H5), 6.73 (br d, J=
7.0 Hz, 1, NH), 7.45 (t, J= 7.5 Hz, 2, Ph), 7.55 (t, J= 7.2 Hz, 1, Ph), 7.82 (d, J= 7.0 Hz,
2, Ph); 13C NMR s 14.5 (CH 3), 29.9 (C4), 32.2 (C3), 52.6 (C2), 61.8 (CH 2), 116.0 (C6),
127.4 (Ph), 128.9 (Ph), 132.1 (Ph), 134.4 (Ph), 137.5 (C5), 167.4 (CO), 173.0 (C1); MS
m/z 262 (100, MH+). Anal. Caled. for C15H19NO3 (261.32): C, 68.94; H, 7.33; N, 5.36.
Found: C, 69.03; H, 7.46; N, 5.28.
Ethyl 2-N-(tert-Butoxycarbonylo)-2-aminohex-5-enoate (66). NaHCO 3 (668
mg, 7.95 mmol) and di-tert-butyl dicarbonate (867 mg, 3.98 mmol) were added to a
stirred solution of 64 (416 mg, 2.65 mmol) in dioxane/H 20 (1:1, 8 mL) at ambient
temperature. After 18 h, the reaction mixture was partitioned (EtOAc/H 20) and the
organic layer was washed (brine), dried (Na2SO 4) and evaporated. Column
chromatography (CHCl 3 -+ 2% MeOH) gave 66113c,128 (540 mg, 79%): 'H NMR 6 1.28 (t,
J= 7.1 Hz, 3, CH 3), 1.44 (s, 9, t-Bu), 1.66-1.77 (m, 1, H3'), 1.85-1.96 (m, 1, H3), 2.08-
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2.16 (m, 2, H4,4'), 4.20 (q, J= 7.1 Hz, 2, CH 2), 4.25-4.35 (m, 1, H2), 4.98 (br d, J= 10.2
Hz, 1, H6), 5.02 (br d, J= 15.6 Hz, 1, H6'), 5.04 (br, 1, NH), 5.76-5.80 (m, 1, H5); 13C
NMR 8 14.5 (CH 3), 28.7 (t-Bu), 29.8 (C4), 32.4 (C3), 53.4 (C2), 61.6 (CH 2), 80.2 (t-Bu),
115.9 (C6), 137.4 (C5), 155.7 (Boc), 173.1 (C1); MS m/z 258 (20, MH+).
Ethyl 2-N-(tert-Butoxycarbonylo)-2-aminohex-5-enoate (66-R) and 2-N-(tert-
butoxycarbonylo)-2-aminohex-5-enoic acid (74-S). Ester 66 (250 mg, 0.97 mmol) was
suspended in phosphate buffer (15 mL, 0.1 M; pH 8.00) and a-chymotrypsin (1.25 mg,
61 units/mg; Sigma) was added. The resulting mixture was gently stirred at 37 *C for 24
h (pH decreased to 7.65) and extracted with ethyl acetate. The combined organic layer
was evaporated to give unreacted ester 66-R 113c,128 (122 mg, 49%) with data as reported
above for 66. The aqueous solution was acidified to pH 2.5 with iN HCl and extracted
with ethyl acetate (5x). The combined organic layer was dried (Na2SO 4) and evaporated
to give 74-S1 (109 mg, 49%): 'H NMR 6 1.46 (s, 9, t-Bu), 1.70-1.85 (m, 1, H3), 1.90-
2.05 (m, 1, H3'), 2.10-2.22 (m, 2, H4,4'), 4.32-4.42 (m, 1, H2), 5.00 (br d, J= 10.0 Hz, 1,
H6), 5.07 (br s, 1, NH), 5.10 (br d, J= 16.1 Hz, 1, H6'), 5.76-5.86 (m, 1, H5), 9.06 (br s,
1, COOH); MS m/z 230 (100, MH+).
Notes. The enantiomeric purity of 66-R was determined using Mosher test with
(R)-2-methoxy-2-trifluoromethyl-2-phenylacetyl chloride (R-MTPA-Cl):1"9 Step a
(Deprotection). Treatment of 66-R (30 mg, 0.11 mmol) with CF 3CO 2H/H 20 (9:1, 2 mL)
by procedure C [column chromatography (CHCl3/MeOH, 95:5)] gave 64-R (16 mg,
90%). Step b (Acylation). DMAP (0.46 mg, 0.0038 mmol) and (R)-MTPA-Cl (57.5 mg,
0.22 mmol) was added to a stirred solution of 64-R (30 mg, 0.19 mmol) in
pyridine/benzene (3 mL, 1:2) at ambient temperature. After 2 h, volatiles were
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evaporated and the residue was partitioned (NaHCO3/H20//EtOAc). The separated
organic layer was washed (brine), dried (Na2SO 4), evaporated, and chromatographed (0
-+ 15% EtOAc/hexane) to give 76-R/R (53 mg, 73%; ee 96): ' 9F NMR 6 -69.55 (s, R/R,
0.98 F) and -69.15 (s, SIR, 0.02 F).
Subjection of racemic 66-R/S to the analogous sequence with (R)-MTPA-Cl gave 1:1 (19F
NMR) mixture of 76-R/R and its diastereomer 76-S/R.
Ethyl 1,5,6,7,8,9-Hexadeoxy-9(R/S)-benzamido-1-(6-N-benzoyladenin-9-yl)-
2,3-O-isopropylidene-p-D-ribo-dec-5(E)-enofuranuronate (67b). Procedure A.
Compounds 61a (100 mg, 0.25 mmol), 65 (65 mg, 0.25 mmol) and 1,3-[bis(2,4,6-
trimethylphenyl)-2-imidazolidinylidene]dichloro (isopropoxyphenylmethylene)ruthenium
(7.8 mg, 0.0125 mmol) were dissolved in dried CH 2Cl 2 (6 mL) at ambient temperature
under N2 and the resulting mixture was heated overnight at 65 *C (oil bath) in a pressure
tube (Ace glass). Volatiles were evaporated and the residue was partitioned
(NaHCO 3//H 20/CHCl3). The organic layer was washed (brine), dried (Na2SO 4 ),
evaporated, and chromatographed (50 -+ 90% EtOAc/hexane) to give 67b (82 mg, 51%,
9'R/S~ 1:1) and dimer 73 (14 mg, 11%) as a less polar byproduct. 67b: 'H NMR 6 1.12
("dt", J= 2.5, 7.1 Hz, 3, CH 3), 1.25 (s, 3, CH 3,), 1.48 (s, 3, CH 3), 1.52-2.02 (m, 4H, 7',7",
8',8"), 4.06 ("dq", J= 3.0, 7.1 Hz, 2, CH 2), 4.54 ("dt", J= 2.9, 7.4 Hz, 1, H4'), 4.62 (t, J=
7.4 Hz, 0.5, H9'), 4.63 (t, J= 7.4 Hz, 0.5, H9'), 4.81-4.86 (m, 1, H3'), 5.39-5.43 (m, 1,
H2'), 5.43 (dd, J= 7.1, 16.2 Hz, 1, H5'), 5.56 ("dt", J= 7.3, 16.4 Hz, 1, H6'), 6.00 (s, 1,
H1'), 6.59 ("t", J= 7.2 Hz, 1, NH), 7.24-7.30 (m, 2, Ph), 7.32-7.40 (m, 3, Ph), 7.43-7.49
(m, 1, Ph), 7.62-7.67 (m, 2, Ph), 7.87-7.90 (m, 2, Ph), 7.96 (s, 0.5, H2), 7.97 (s, 0.5, H2),
8.66 (s, 0.5, H8), 8.67 (s, 0.5, H8), 9.00 (br s, 1, NH); 13C NMR 6 14.2 (CH 3), 25.4
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(CH 3), 27.1 (CH 3), 28.0 (CT) 31.66 & 31.75 (C8'), 52.01 & 52.13 (C9'), 61.7 (CH 2),
84.2 (C2'), 84.49 & 84.54 (C3'), 88.04 & 88.09 (C4'), 90.78 & 90.85 (C 1'), 114.5 (CMe2),
123.64 & 123.70 (C5'), 127.0 (Ph), 127.7 (C5), 127.9 (Ph), 128.6 (Ph), 128.8 (Ph), 131.8
(Ph), 132.8 (Ph), 133.5 (C6'), 133.84 (C4), 133.94 (C6), 142.27 & 142.32 (C2),
151.4(C8), 167.0 (Bz), 172.34 (Bz), 172.38 (CIO'); MS m/z 641 (100%, MH+). HRMS
calcd. for C34H36N60 7 (M + Lie) 647.2806, found 647.2809.
Dimer 73 [Diethyl 2,9-bis(benzamido)dec-5-enedioate] separated as a mixture of
two isomers (~9:1). The major isomer had: 'H NMR 6 1.22 ("dt", J= 1.2, 7.1 Hz, 6, 2 x
CH 3), 1.70-1.85 (m, 2, H3/8), 1.90-2.15 (m, 6, H3',4,4'/7,7',8'), 4.16 (q, J= 7.0 Hz, 4, 2 x
CH 2), 4.67-4.76 (m, 2, H2/9), 5.40 ("t", J= 3.4 Hz, 2, H5/6), 6.62 (d, J= 7.6 Hz, 2, 2 x
NH), 7.35-7.44 (m, 6, Ph), 7.71-7.73 (m, 4, Ph); 13CNMR 6 14.6 (CH 3), 28.8 (C4/7), 32.7
(C3/8), 52.6 (C2/9), 61.9 (CH 2), 127.4 (Ph), 128.9 (C5/6), 130.3 (Ph), 132.1 (Ph), 134.4
(Ph), 167.3 (CO), 172.9 (Cl/10); MS m/z 495 (100%, MH+). HRMS calcd for
C28H34N20 6 (M + Lie) 501.2577, found 501.2573.
Ethyl 1,5,6,7,8,9-Hexadeoxy-9(R/S)-benzamido-1-(6-N,N-dibenzoyladenin-9-
yl)-2,3-O-isopropylidene-p-D-ribo-dec-5(E)-enofuranuronate (67c). Treatment of 61b
(92 mg, 0.18 mmol) with 65 (47 mg, 0.18 mmol) by procedure A [column
chromatography (30 -+ 50 % EtOAc/hexanes)] gave 67c (80 mg, 60%, 9'R/S 1:1) and
73 (16 mg, 18%). 67c: 'H NMR 6 1.20 (t, J= 7.2 Hz, 3, CH 3), 1.32 (s, 3, CH 3), 1.53 (s, 3,
CH 3), 1.54-1.69 (m, 2, H8',8"), 1.81-2.10 (m, 2, H7',7"), 4.14 (q, J= 7.1 Hz, 2, CH 2), 4.63
("dt", J= 3.1, 7.0 Hz, 1, H4'), 4.69 (t, J= 7.6 Hz, 0.5, H9'), 4.70 (t, J= 7.6 Hz, 0.5, H9'),
4.88 ("dt", J= 3.2, 6.3 Hz, 1, H3'), 5.42-5.49 (m, 1, H2'), 5.50 (dd, J= 7.2, 15.9 Hz, 1,
H5'), 5.59-5.68 (m, 1, H6'), 6.06 (s, 1, Hi'), 6.70 ("t", J= 6.2 Hz, 1, NH), 7.25-7.45 (m, 9,
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Ph), 7.68-7.80 (m, 6, Ph), 8.08 (s, 0.5, H2), 8.09 (s, 0.5, H2), 8.58 (s, 0.5, H8), 8.61 (s,
0.5, H8); "CNMR S 14.2 (CH 3), 25.3 (CH 3), 27.0 (CH 3), 28.2 (C7'), 31.7 & 31.9 (C8'),
52.09 & 52.20 (C9'), 61.6 (CH 2), 84.1 (C2'), 84.4 (C3'), 87.8 & 87.9 (C4'), 90.8 (Cl'),
114.6 (CMe 2), 127.1 (C5'), 128.6 (Ph), 128.7 (Ph), 128.8 (C5), 129.5 (Ph), 131.7 (Ph),
133.0 (Ph), 134.0 (C6'), 152.0 (C4), 152.3 (C2), 152.5 (C6), 167.10, 167.13, 172,28 (Bz),
172.32 (ClO'); MS m/z 745 (100%, MH+). HRMS caled for C41H4 0N6O (M + H*)
745.2986, found 745.2990.
Ethyl 1,5,6,7,8,9-Hexadeoxy-9(R/S)-tert-butoxycarbonylamino-1-(6-N-
benzoyladenin-9-yl)-2,3-O-isopropylidene-p-D-ribo-dec-5(E)-enofuranuronate (68b).
Treatment of 61a (36 mg, 0.09 mmol) with 66 (23 mg, 0.09 mmol) by procedure A
[column chromatography (20 -+ 50% EtOAc/hexanes)] gave 68b (35 mg, 61 %, 9'R/S
1:1): 'H NMR 6 1.18 (t, J= 6.9 Hz, 3, CH 3), 1.34 (s, 3, CH 3), 1.35 (s, 9, Boc), 1.46-1.53
(m, 1, H8"), 1.56 (s, 3, CH 3), 1.68-1.78 (m, 1, H8'), 1.92-2.03 (m, 2, H7',7"), 4.10 ("dq", J
= 2,2, 7.1 Hz, CH2), 4.15-4.20 (m, 1, H9'), 4.60-4.65 (m, 1, H4'), 4.92 (dd, J= 3.3, 6.2
Hz, 1, H3'), 4.95-5.00 (m, 1, NH), 5.48 (br d, J= 7.7 Hz, 1, H2'), 5.50 (dd, J= 7.2, 16.1
Hz, 1, H5'), 5.62 (dt, J= 6.7, 15.9 Hz, 1, H6'), 6.08 (br s, 1, Hi'), 7.45 (t, J= 7.2 Hz, 2,
Ph), 7.54 (t, J= 7.3 Hz, 1, Ph), 7.95 (d, J= 7.4 Hz, 2, Ph), 8.04 (br s, 1, H2), 8.76 (s, 0.5,
H8), 8.77 (s, 0.5, H8), 9.03 (br s, 1, NH); MS m/z 637 (100%, MH+). HRMS calcd. for
C32H4 0N608 (M + Lie) 643.3068, found 643.3076. Anal. Calcd. for C3 2H40.N6O8 (636.29):
C, 60.37; H, 6.33; N, 13.20. Found: C, 60.02; H, 6.54; N, 12.88.
Ethyl 1,5,6,7,8,9-Hexadeoxy-9(R/S)-tert-butoxycarbonylamino--(6-N,N-
dibenzoyladenin-9-yl)-2,3-0-isopropylidene-p-D-ribo-dec-5(E)-enofuranuronate
(68c-R/S). Treatment of 61b (200 mg, 0.4 mmol) with 66 (103 mg, 0.4 mmol) by
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procedure A [column chromatography (30 -+ 50% EtOAc/hexanes)] gave 68c-R/S (224
mg, 76%, 9'R/S - 1:1): UV max 270 nm (F 15 000, sh), 250 nm (s 19 000), min 227 nm
(s 12 800); 'H NMR 6 1.23 (t, J= 7.1 Hz, 3, CH 3), 1.39 (s, 3, CH 3), 1.42 (s, 9, Boc), 1.61
(s, 3, CH 3), 1.58-1.65 (m, 1, H8'), 1.78-1.84 (m, 1, H8"), 2.00-2.09 (m, 2, H7',7"), 4.15 (q,
J= 7.1 Hz, 2, CH 2), 4.20-4.28 (m, 1, H9'), 4.62-4.69 (m, 1, H4'), 4.95 (dd, J= 3.6, 6.2
Hz, 1, H3'), 5.07 ("t", J= 8.5 Hz, 1, NH), 5.43-5.50 (m, 1, H2'), 5.58 (dd, J= 7.3, 15.2
Hz, 1, H5'), 5.73 (dt, J= 6.5, 15.2 Hz, 1, H6'), 6.120 (d, J= 2.1 Hz, 0.5, H1'), 6.122 (d, J
= 2.1 Hz, 0.5, Hi'), 7.35 (t, J= 7.6 Hz, 4, Ph), 7.49 (t, J= 7.4 Hz, 2, Ph), 7.85 (d, J= 7.1
Hz, 4, Ph), 8.147 (s, 0.5, H2), 8.149 (s, 0.5, H2), 8.68 (s, 1, H8); 13C NMR 6 14.2 (CH 3),
25.3 (CH 3), 27.1 (CH 3), 28.0 (C7'), 28.3 (Boc), 31.76 & 31.80 (C8'), 52.9 (C9'), 61.3
(CH 2), 80.2 (Boc), 84.16 & 84.19 (C2'), 84.33 & 84.37 (C3'), 87.83 & 87.91 (C4'), 90.58
& 90.67 (C'), 114.7 (CMe 2), 127.47 & 127.51 (C5'), 128.0 (C5), 128.7 (Ph), 129.4 (Ph),
133.0 (Ph), 134.0 (Ph), 134.30 & 134.31 (C6'), 144.0 (C8), 152.0 (C4), 152.3 (C2), 152.4
(C6), 155.3 (Boc), 172.2 (Bz), 172.50 & 172.57 (C10'); MS m/z 741 (100%, MH*).
HRMS (FAB*) calcd for C39H44N609 (M + H*) 741.3248, found 741.3243.
Ethyl 1,5,6,7,8,9-Hexadeoxy-9(R)-tert-butoxycarbonylamino-1-(6-N,N-
dibenzoyladenin-9-yl)-2,3-O-isopropylidene-p-D-ribo-dec-5(E)-enofuranuronate
(68c-R). Metathesis of 61b (25 mg, 0.05 mmol) with 66-R (13 mg, 0.05 mmol) by
procedure A [column chromatography (30 -+ 50% EtOAc/hexanes)] gave 68c-R (28.5
mg, 77%): 'H NMR 6 1.23 (t, J= 7.1 Hz, 3, CH3), 1.39 (s, 3, CH 3), 1.42 (s, 9, Boc),
1.61 (s, 3, CH 3), 1.58-1.65 (m, 1, H8'), 1.78-1.84 (m, 1, H8"), 2.00-2.09 (m, 2, H7',7"),
4.15 (q, J= 7.1 Hz, 2, CH2), 4.20-4.28 (m, 1, H9'), 4.66 (dd, J = 3.4, 7.3 Hz, 1, H4'),
4.95 (dd, J= 3.6, 6.2 Hz, 1, H3'), 5.05 (br d, J= 8.4 Hz, 1, NH), 5.47 (dd, J= 2.2, 6.3 Hz,
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1, H2'), 5.58 (dd, J= 7.3, 15.1 Hz, 1, H5'), 5.73 (dt, J= 6.5, 15.3 Hz, 1, H6'), 6.12 (d, J=
2.1 Hz, 1, H1'), 7.35 (t, J= 7.6 Hz, 4, Ph), 7.49 (t, J= 7.4 Hz, 2, Ph), 7.85 (d, J= 7.1 Hz,
4, Ph), 8.14 (s, 1, H2), 8.68 (s, 1, H8); '3C NMR 6 14.2 (CH 3), 25.3 (CH 3), 27.1 (CH 3),
28.0 (C7'), 28.3 (Boc), 31.80 (C8'), 52.9 (C9'), 61.3 (CH 2), 80.2 (Boc), 84.19 (C2'), 84.37
(C3'), 87.91 (C4'), 90.67 (Cl'), 114.7 (CMe 2 ), 127.51 (C5'), 128.0 (C5), 128.7 (Ph), 129.4
(Ph), 133.0 (Ph), 134.0 (Ph), 134.31 (C6') 144.0 (C8), 152.0 (C4), 152.3 (C2), 152.4
(C6), 155.3 (Boc), 172.2 (Bz), 172.57 (C10'); MS m/z 741 (100%, MH+). HRMS (FAB*)
caled for C39H44N60 9 (M + H*) 741.3248, found 741.3246.
Methyl 2-N-(tert-Butoxycarbonylo)-2-aminohex-5-enoate (75-S).
Diazomethane129 was added to a solution of 74-S (120 mg, 0.52 mmol) in EtOH (2 mL)
at ambient temperature. After 30 min (reaction was monitored by LC/MS), the volatiles
were evaporated to give 75-S" 2 (118 mg, 93%) as an oily residue: 'H NMR 6 1.37 (s, 9,
t-Bu), 1.59-1.69 (m, 1, H3), 1.78-1.91 (m, 1, H3'), 2.00-2.10 (m, 2, H4,4'), 3.67 (s, 3,
OCH3), 4.22 ("q", J = 7.9 Hz, 1, H2), 4.93 ( br d, J = 10.2, 1, H6'), 4.97 (dq, J = 17.1, 1.5
Hz, 1, H6), 4.99 (br s, 1, NH), 5.83 (ddt, J= 17.0, 10.2, 6.7 Hz, 1, H5), 13C NMR 6 27.3
(Boc), 28.4 (C4), 30.9 (C3), 51.2 (OCH 3), 51.9 (C2), 78.8 (Boc), 114.6 (C6), 135.9 (C5),
154.3 (CO), 172.3 (C1); MS m/z 244 (100% MH*).
Methyl 1,5,6,7,8,9-Hexadeoxy-9(S)-tert-butoxycarbonylamino-1-(6-N,N-
dibenzoyladenin-9-yl)-2,3-O-isopropylidene-p-D-ribo-dec-5(E)-enofuranuronate (77-
S). Metathesis of 61b (200 mg, 0.39 mmol) with 75-S (95 mg, 0.39 mmol) by procedure
A [column chromatography (30 -+ 50% EtOAc/hexanes)] gave 77-S (218 mg, 77%): 'H
NMR 6 1.40 (s, 3, CH3), 1.44 (s, 9, t-Bu), 1.61 (s, 3, CH3), 1.56-1.63 (m, 1, H8"), 1.75-
1.86 (m, 1, H8'), 2.00-2.11 (m, 2, H7',7"), 3.71 (s, 3, OMe), 4.27 ("q", J= 6.7 Hz, 1, H9'),
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4.67 (dd, J= 6.8, 3.1 Hz, 1, H4'), 4.95 (dd, J= 6.2, 3.5 Hz, 1, H3'), 5.11 (br d, J= 8.4 Hz,
1, NH), 5.50 (dd, J= 6.4, 2.0 Hz, 1, H2'), 5.54 (dd, J= 15.3, 7.2 Hz, 1, H5'), 5.68 (dt, J=
15.0, 6.4 Hz, 1, H6'), 6.15 (d, J= 1.9 Hz, 1, Hi'), 7.35 (t, J= 7.9 Hz, 4, Ph), 7.48 (t, J=
7.4 Hz, 2, Ph), 7.85 (d, J= 7.1 Hz, 4, Ph), 8.17 (s, 1, H2), 8.69 (s, 1, H8); 13C NMR 6
25.3 (CH 3), 27.1 (CH3 ), 27.9 (C7'), 28.3 (Boc), 31.7 (C8'), 52.3 (OMe), 52.9 (C9'), 79.9
(Boc), 84.1 (C2'), 84.3 (C3'), 87.8 (C4'), 90.5 (Cl'), 114.7 (CMe 2), 127.5 (C5'), 128.0
(C5), 128.7 (Ph), 129.4 (Ph), 133.0 (Ph), 133.9 (Ph), 134.1 (C6'), 144.1 (C8), 152.0 (C4),
152.3 (C2), 152.4 (C6), 155.3 (Boc), 172.2 (CO), 172.9 (C10'); MS m/z 727 (100%,
MH+). HRMS caled for C38H42N609 (M + H*) 727.3092, found 727.3099.
Methyl 1,5,6,7,8,9-Hexadeoxy-9(S)-tert-butoxycarbonylamino-1-(adenin-9-
yl)-2,3-0- isopropylidene--D-ribo-dec-5(E)-enofuranuronate (69-S). Procedure B:
Saturated (~0 °C) NH3/MeOH (3 mL) was added to a solution of 77-S (210 mg, 0.29
mmol) in MeOH (3 mL) at 5 °C, and the resulting mixture was stirred for 48 h at 0 *C.
Volatiles were evaporated and the residue was column chromatographed (50 -+ 95%
EtOAc/hexanes) to give 69-S (136 mg, 91%): 'H NMR 6 1.35 (s, 3, CH3), 1.37 (s, 9,
Boc), 1.55 (s, 3, CH 3), 1.52-1.60 (m, 1, H8"), 1.69-1.80 (m, 1, H8'), 1.90-2.00 (m, 2,
H7',7"), 3.65 (s, 3, OMe), 4.20 ("q", J= 7.0 Hz, 1, H9'), 4.56 (dd, J= 3.4, 7.1 Hz, 1, H4'),
4.89 (dd, J= 3.4, 6.1 Hz, 1, H3'), 5.05 (br d, J= 8.1 Hz, 1, NH), 5.44 (d, J= 6.0 Hz, 1,
H2'), 5.53 (dd, J= 7.2, 15.3 Hz, 1, H5'), 5.61 (dt, J= 15.3, 6.2 Hz, 1, H6'), 6.01 (d, J=
1.9 Hz, 1, Hi'), 6.35 (br s, 2, NH 2), 7.83 (s, 1, H2), 8.29 (s, 1, H8); 13C NMR 6 25.3
(CH 3), 27.1 (CH3), 27.9 (C7'), 28.3 (Boc), 31.7 (C8'), 52.3 (OMe), 52.9 (C9'), 79.9 (Boc),
84.2 (C2'), 84.5 (C3'), 87.8 (C4'), 90.4 (C1'), 114.5 (CMe2), 120.3 (C5), 127.8 (C5'),
133.7 (C6'), 140.0 (C8), 149.9 (C4), 152.5 (C2), 155.2 (Boc), 155.3 (C6), 173.1 (C10');
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MS m/z 519 (100%, MH+). HRMS caled for C24H34N60 7 (M + H*) 519.2567, found
519.2564.
Methyl 9(S)-Amino-1,5,6,7,8,9-hexadeoxy-1-(adenin-9-yl)-p-D-ribo-dec-5(E)-
enofuranuronate (71a-S). Procedure C: A solution of 69-S (130 mg, 0.25 mmol) in
CF 3CO 2H/H 20 (9:1, 3 mL) was stirred at 0 °C for 30 min. Volatiles were evaporated and
the residue was coevaporated (3 x toluene), and purified on RP-HPLC column
[CH 3CN/H 20 (10:90) for 15 min followed by gradient 10 -+ 25% CH 3CN/H 20 for 35
min at 2 mL/min] to give 71a-S (85 mg, 90%; tR 24 min): UV max 260 nm (E 14 700),
min 227 nm (c 3 250); 'H NMR (MeOH-d 4) 6 1.65-1.78 (m, 1, H8"), 1.79-1.89 (m, 1,
H8'), 2.07-2.18 (m, 2, H7',7"), 3.61 (t, J= 6.3 Hz, 1, H9'), 3.66 (s, 3, OMe), 4.13 (t, J=
5.1 Hz, 1, H3'), 4.32 (t, J= 5.3 Hz, 1, H4'), 4.64 (t, J= 4.6 Hz, 1, H2'), 5.70-5.73 (m, 2,
H5',6'), 5.89 (d, J= 4.4 Hz, 1, Hi'), 8.11 (s, 1, H2), 8.13 (s, 1, H8); 13C NMR (MeOH-d 4)
6 28.9 (C7'), 33.3 (C8'), 52.9 (OMe), 54.0 (C9'), 75.03 (C2'), 75.66 (C3'), 86.29 (C4'),
90.2 (C1'), 120.6 (C5), 130.4 (C5'), 134.1 (C6'), 141.3 (C8), 150.6 (C4), 153.9 (C2),
157.3 (C6), 174.7 (ClO'); MS m/z 379 (100%, MH+). HRMS calcd. for C16H22N60s (M +
H*) 379.1730, found 379.1724.
Methyl 9(R/S)-Amino-1,5,6,7,8,9-hexadeoxy-1-(adenin-9-yl)-P-D-ribo-dec-
5(E)-enofuranuronate (71a) and Ethyl 9(R/S)-Amino-1,5,6,7,8,9-hexadeoxy-1-
(adenin-9-yl)-p-D-ribo-dec-5(E)-enofuranuronate (71b). Step a (Debenzoylation):
Treatment of 68c-R/S (100 mg, 0.13 mmol) with NH 3/MeOH (3 mL) by procedure B
gave mixture of 69 and 70 (-3:2; 63 mg, ~92%, 9'R/S~ 1:1): MS m/z 519 (100%, MH+;
69), 533 (80%, MH+; 70); HRMS caled for 69 C24H34N60 7 (M + He), 519.2567, found
519.2562; caled for 70 C2 5H3 6N60 7 (M + H*) 533.2724, found 533.2718. Step b (Acid
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deprotection): Treatment of the above material 69/70 (63 mg) with CF 3CO 2H/H 20 (9:1, 4
mL) by procedure C gave 71a (23 mg, 47% from 68c; tR 23 min) and 71b (15 mg, 29%;
tR 25 min). 71a: 'H NMR (MeOH-d 4) S 1.65-1.95 (m, 2, H8',8"), 2.07-2.22 (m, 2, H7',7"),
3.59-3.65 (m, 1, H9'), 3.66 (s, 3, OMe), 4.13 (t, J= 5.1 Hz, 1, H3'), 4.30-4.39 (m, 1, H4'),
4.64 (t, J= 4.6 Hz, 1, H2'), 5.70-5.74 (m, 2, H5',6'), 5.89 (d, J= 4.4 Hz, 1, H1'), 8.11 (br
s, 1, H2), 8.13 (s, 1, H8); 13C NMR (MeOH-d 4) 6 28.9 (C7'), 33.3 (C8'), 52.9 (OMe), 54.0
(C9'), 75.03 & 75.10 (C2'), 75.66 & 75.68 (C3'), 86.29 & 86.35 (C4'), 90.2 (Cl'), 120.6
(C5), 130.4 (C5'), 134.1 (C6'), 141.3 (C8), 150.6 (C4), 153.9 (C2), 157.3 (C6), 174.7
(CIO'); HRMS caled. for C16H22N605 (M + H+) 379.1730, found 379.1724. Anal. Caled.
for C, 6H22.N605 (378.38): C, 50.79; H, 5.86; N, 22.21. Found: C, 51.11; H, 6.20; N,
21.85. 71b: UV max 260 nm (F 13 900), min 228 nm (s 3600); 1H NMR (MeOH-d 4) 6
1.22 (t, J= 7.2 Hz, 3, CH 3), 1.81-1.96 (m, 2, H8',H8"), 2.10-2.21 (m, 2, H7',7"), 3.88 (t, J
= 6.4 Hz, 1, H9'), 4.15-4.21 (m, 3, H3', CH 2), 4.33 ("t", J= 5.1 Hz, 1, H4'), 4.64-4.67 (m,
1, H2'), 5.68-5.76 (m, 2, H5',6'), 5.90 (d, J= 4.2 Hz, 1, H1'), 8.11 (s, 1, H2), 8.13 (br s, 1,
H8); 13C NMR (MeOH-d 4) 6 14.3 (CH 3), 28.5 (C7'), 31.2 (C8'), 53.4 (C9'), 63.5 (CH 2),
74.89 & 74.94 (C2'), 75.6 (C3'), 86.09 & 86.14 (C4'), 90.33 & 90.37 (C1'), 120.7 (C5),
130.98 & 131.00 (C5'), 133.09 & 133.25 (C6'), 141.4 (C8), 150.6 (C4), 153.9 (C2), 157.4
(C6), 170.8 (C10'). HRMS calc. for C17H24N60 5 (M + H*) 393.1886, found 393.1881.
Anal. Calcd. for C17H24-N605 (392.18): C, 52.03; H, 6.16; N, 21.42. Found: C, 52.32; H,
6.54; N, 20.99.
9(R/S)-Amino-1,5,6,7,8,9-hexadeoxy-1-(adenin-9-yl)-fl-D-ribo-dec-5(E)-
enofuranuronic acid (72). Procedure D. NaOH/H 20 (IM, 0.5 mL) was added to a
solution of 71b (25 mg, 0.06 mmol) in MeOH (4 mL) and stirring was continued at
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ambient temperature overnight. The resulting mixture was neutralized with AcOH to pH
-7. Volatiles were evaporated and the residue was purified by RP-HPLC [CH 3CN/H 20
(5:95), tR 15 min] to give 72 (17 mg, 80%): 'H NMR (MeOH-d 4) 8 1.87-1.95 (m, 1, H8'),
1.96-2.05 (m, 1, H8"), 2.22-2.30 (m, 2, H7',7"), 3.53 (dd, J= 2.4, 6.1 Hz, 0.5, H9'), 3.55
(dd, J= 2.4, 6.1 Hz, 0.5, H9'), 4.24 (t, J= 5.2, 0.5, H3'), 4.26 (t, J= 5.2, 0.5, H3'), 4.42 (t,
J= 5.9 Hz, 1, H4'), 4.74 (t, J= 4.6 Hz, 1, H2'), 5.85 (ddd, J= 1.8, 6.0, 15.7 Hz, 1, H6'),
5.81 (dd, J= 6.3, 15.7 Hz, 1, H5'), 6.02 (d, J= 4.3 Hz, 1, Hi'), 8.23 (s, 1, H2), 8.26 (s,
0.5, H8), 8.27 (s, 0.5, H8); MS m/z 365 (100%, MH+). HRMS caled. for C15H20N605 (M
+ H*) 365.1573 found 365.1568
Note: Treatment of 71a (15 mg, 0.04 mmol) with NaOH (iM, 0.4 mL) by
procedure D also gave 72 (11.8 mg, 82%).
9(R/S)-Amino-5-bromo-1,5,6,7,8,9-hexadeoxy-1-(adenin-9-yl)-fl-D-ribo-dec-
5(Z)-enofuranuronic acid (82). Procedure E: Step a (Bromination): Pyridinium
tribromide (40 mg, 0.12 mmol) was added to a solution of 68c-R/S (62 mg, 0.083 mmol)
in dioxane and the resulting mixture was stirred at ambient temperature for 8 h. Volatiles
were evaporated and the residue was partitioned (NaHCO 3//H 20/EtOAc). The organic
layer was washed (brine), dried (Na2SO 4) and evaporated to give crude 78 of sufficient
purity for direct use in next step: MS m/z 903 (55%, MH+[" Br 2]), 901 (100%,
MH+[81 79Br 2]), 899 (50%, MH+[79Br 2]). Step b (Dehydrobromination): DBU (0.3 mL)
was added to a solution of the crude 78 in dried THF (3 mL) and the resulting mixture
was stirred at room temperature overnight. Volatiles were evaporated and the residue was
partitioned (NaHCO 3//H20/EtOAc). The organic layer was washed (brine), dried
(Na2SO4), evaporated and chromatographed (30 -+ 90% EtOAc/Hexane) to give 79b {48
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mg, 70% from 68c; MS m/z 821 (100%, MH+[8 'Br], 819 (95%, MH+[79Br]} and the
corresponding N6 monobenzoylated product 79a {12 mg, 20% from 68c; MS m/z 717
(100%, MH+[8 'Br]), 715 (95%, MH+[79Br]}. Step c (Debenzoylation): Treatment of 79b
and the N6 monobenzoylated material 79a from step b with NH 3/MeOH at 0 0C by
procedure B (24 h) gave 80 as a ~1:1 mixture of methyl and ethyl esters of sufficient
purity for direct use in next step: MS m/z 599 (100%, MH+["1Br]), 597 (99%, MH+[79Br])
for 80 (R = Me) and 613 (97%, MH+[8 'Br]), 611 (95%, MH+[79Br]) for 80 (R = Et). Step
d (Acid deprotection): Treatment of 80 with CF 3CO 2H/H 2O (9:1, 3 mL) by procedure C
gave 81 (33 mg, tR 22 min) as -1:1 mixture of methyl and ethyl esters: MS m/z 459
(99%, MH+[8 'Br]), 457 (100%, MH+[79Br]) for 81 (R = Me) and 473 (86%, MH+[8'Br]),
471 (83%, MH+[79Br]) for 81 (R = Et). Step e (Saponification): Treatment of 81 (33 mg)
with NaOH (0.5 mL, iM) by procedure D gave 82 (20 mg, 54% overall yield from 68c;
tR 19 min): UV max 259 nm (E 14 100), min 227 nm (s 4 100); 'H NMR (MeOH-d 4 ) 6
1.86 -2.09 (m, 2, H8',8"), 2.39-2.49 (m, 2, H7',7"), 3.58-3.61 (m, 1, H9'), 4.52 ("q", J=
5.7 Hz, 1, H3'), 4.67-4.70 (m, 1, H2'), 4.98 (d, J= 6.7 Hz, 0.5, H4'), 5.01 (d, J= 6.4 Hz,
0.5, H4'), 6.11 (d, J= 2.9 Hz, 1, Hi'), 6.40 (t, J= 7.6 Hz, 1, H6'), 8.23 (s, 1, H2), 8.39 (s,
0.5, H8), 8.40 (s, 0.5, H8); 13C NMR (MeOH-d4) 8 26.7 & 26.9 (CT), 32.06 (C8'), 55.35
& 55.42 (C9'), 74.15 & 74.33 (C3'), 75.43 & 75.48 (C2'), 81.35 & 81.52 (C4'), 90.00 &
90.29 (C'), 120.1 (C5), 125.13 & 125.15 (C5'), 138.7 (C6'), 140.72 & 140.79 (C8),
150.57 & 150.63 (C4), 154.0 (C2), 157.4 (C6), 174.0 (C10'); MS m/z 445 (100%,
MH+[81Br]), 443 (98%, MH+[79Br]). HRMS calcd for C15H1979BrN605 (M + H*)
443.0678, found 443.0673.
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Diethyl fluoro(phenylsulfonyl)methylphosphonate. Step a: Oxidation. A
solution of oxone (20.11 g, 32.7 mmol, 50% reagent) in deionized-H 20 (150 mL) was
added slowly to a diethyl (phenylthiomethyl)phosphonate (2.00 g, 7.9 mmol) dissolved in
MeOH (40 mL) at 0 OC. A white precipitate was formed immediately and the
heterogeneous reaction was left stirring at ambient temperature for 4 h. The volatiles
were evaporated and the residue was partitioned between H20/CHCl 3 to give diethyl
(phenylsulfonyl)methylphosphonate (2.10 g, 92%). Step b: Fluorination. LHMDS (1M,
9.16 mL, 9.16 mmol) was added dropwise to a stirred solution of diethyl
(phenylsulfonyl)methylphosphonate (2.10 g, 7.32 mmol) in dried THF (25 mL) under N2
at - 78 OC. After 30 min Selectfluor (3.90 g, 11.0 mmol) was added and the
heterogeneous reaction mixture was stirred for 5 min. DMF (15 mL) was added and the
resulting yellow solution was allowed to warm to 0 OC and stirring was continued for 3.0
h. CHC13 (10 mL) and saturated NH4Cl/H 20 (10 mL) were added and the volatiles were
evaporated. The residue was partitioned (NaHCO 3/H20//CHCl 3) and the organic layer
was washed (brine), dried (Na2SO 4), evaporated and chromatographed (90:10
EtOAc/hexanes) to give diethyl fluoro(phenylsulfonyl)methyl phosphonate 30 ( 1.9 g,
85%).
(E/Z)-1-Fluoro-2-phenyl-1-(phenylsulfonyl)ethene (84a). Procedure F.
LHMDS (1.0 M/THF, 2.0 mL, 2.0 mmol) was added dropwise to a stirred solution of
diethyl fluoro(phenylsulfonyl)methylphosphonate (0.5 g, 1.61 mmol) in dried THF (8
mL) under N2 at -78 OC. After 30 min, 83a (0.18 mL, 0.19 g, 1.77 mmol) was added and
the resulting yellow solution was allowed to warm to -30 0C over 1.5 h. Saturated
NH4Cl/H20 (- 1 mL) was added, volatiles were evaporated and the residue was
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partitioned (NaHCO 3/H20//CHCl 3). The organic layer was washed (brine), dried
(Na2SO 4), evaporated and chromatographed (CHCl3) to give 84a 1 (E/Z, 95:5; 0.36 g,
85%). Crystallization of the crude product (without chromatography) from MeOH also
afforded 84a (E/Z, 95:5).
(E/Z)-1-Fluoro-4-(phenylsulfonyl)-1-butene (84b). Subjection of 83b (0.23 mL,
0.24 g, 1.77 mmol) to procedure F gave 84b13 2 (E/Z, 71:29; 0.42 g, 90%).
(E/Z)-1-Fluoro-3-benzyloxy-1-(phenylsulfonyl)-1-propene (84c). Subjection of
83c (0.1 mL, 0.10 g, 0.71 mmol) to procedure F, gave 84c (E/Z, 63:37; 0.18 g, 92%): IH
NMR 6 4.24 (m, 2, H3, E), 4.54 (s, 2, Bz) (E), 4.60 (s, 2, Bz) (Z), 4.68 (m, 2, H3), (Z),
6.03 (dt, J= 21.9, 4.9 Hz, 1, H2) (Z), 6.40 ( dt, J= 32.7, 5.0 Hz, 1, H2) (E), 7.30- 7.45
(m, 5, Ph), 7.58 (t, J= 5.7 Hz, 2, Ph), 7.70-7.76 (m, 1, Ph), 7.95 (t, J= 7.8 Hz, 2, Ph); 3C
NMR 6: 62.78 (d, JC-F = 3.1 Hz, CH 2, C3, Z), 63.39 (d, JC-F = 6.1 Hz, CH 2, C3, E),
128.31 (CH, Ph, E), 128.40 (CH, Ph), 128.47 (CH, Ph), 128.78 (CH, Ph), 128.87 (CH,
Ph), 128.97 (CH, Ph), 129.17 (CH, Ph), 129.986 (CH, Ph), 135.11 (CH, Ph), 135.25 (CH,
Ph), 137.45 (CH, Ph), 137.66 (CH, Ph), 137.97 (CH, Ph), 138.08 (CH, Ph), 151.57 (d, JC-
F = 292.7 Hz, CF, C1, Z), 153.93 (d, J C-F = 299.7, CF, C1, E); 19F NMR 6 -114.91 (d, J=
22.6 Hz, 0.37F, Z), -123.42 (d, J = 33.9 Hz, 0.63F, E); GC-MS m/z 306 [2%, M+; tR
25.27 min (Z) and 25.86 min (E)]. HRMS(AP-ESI) Calcd for C16Hi 5F0 3S (M+H+):
307.0804; Found: 307.0801
(E/Z)-1-Fluoro-2-phenyl-1-(phenylsulfonyl)-1-propene (84d). Subjection of
83d (0.21 mL, 0.21 g, 1.77 mmol) to procedure F, gave 84d13 1 (E/Z, 42:58; 0.37 g, 90%).
Column chromatography (hexane/EtOAc, 85:15) gave fractions enriched in each isomers.
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(E/Z)-1-Fluoro-2-phenyl-1-(tributyltin)ethene (85a). Procedure G. Argon was
bubbled through a solution of 84a (E/Z, 95:5; 490 mg, 1.87 mmol) in anhydrous benzene
(10 mL) for 15 min. Bu 3SnH (0.5 mL, 544 mg, 1.87 mmol) and AIBN (76.7 mg, 0.46
mmol) were added and degassing of oxygen was continued for another 10 min. The
solution was then heated (85 °C, oil bath) for 2h [additional AIBN (38 mg, 0.23 mmol)
and Bu3SnH (1.87 mmol, 0.5 mL) in degassed benzene (2 mL) was injected through a
septum via a precision syringe pump or periodically by manual injection over the 2 h
period]. The volatiles were evaporated and the residue was chromatographed (hexane) to
give 85a'3 (E/Z, 95:5; 740 mg, 96%).
(E/Z)-1-Fluoro-4-phenyl-1-(tributyltin)-1-butene (85b). Treatment of 84b (E/Z,
71:29; 690 mg, 2.37 mmol) with Bu3SnH (0.636 mL, 689 mg, 2.37 mmol) and AIBN (97
mg, 0.59 mmol) by procedure G gave 85b13 2 (E/Z, 86:14; 976 mg, 93 %): 19F NMR 6 -
99.36 (d, J= 37.6 Hz, dd, Jn-F = 263 Hz, 0.14F, Z), -102.9 (d, J = 52.7 Hz, dd, JSn-F =
229 Hz, 0.86 Hz, E).
Note: Careful separation on column chromatography (hexane) gave partially
separated isomers of 85b(E) (450 mg, 43%) followed by 85b (E/Z, 15:85; 520 mg, 50%).
(E/Z)-1-Fluoro-3-benzyloxy-1-(tributyltin)-1-propene (85c). Treatment of 84c
(E/Z, 63:37; 252 mg, 0.87 mmol) with Bu3SnH (0.23 mL, 252 mg, 0.87 mmol) and AIBN
(71 mg, 0.43 mmol) by procedure G gave 85c (E/Z, 77:23; 352 mg, 92%): IH NMR 6
0.90-0.97 (m, 9H, Bu), 1.00-1.03 (m, 6H, Bu), 1.29 (q, J= 14.7 Hz, 6H, Bu), 1.50-1.61
(m, 6H, Bu), 3.91 (d, J= 7.47 Hz, 2, H3, Z), 4.20 (d, J= 6.61 Hz, 2, H3, E), 4.50 (s, 2,
CH 2, E/Z), 5.05 (dt, J = 6.8, 46.64 Hz, 1, H2, E), 6.05 (dt, J = 3.2, 39.5 Hz, 1, H2, Z),
7.30-7.40 (m, 10, Ph); '9F NMR 6 -92.71 (dd, Jsn-F = 240.9 Hz, 16%, Z), -93.03 (d, J=
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35.4 Hz, 84%, 0.23F, Z), -97.94 (dd, JSn-F = 233.4 Hz, 16%, E); -98.25 (d, J= 53.5 Hz,
84% 0.77F, E); GC-MS m/z 399 [18%, M+-Bu [20 Sn]; tR = 25.59 min (Z) and 26.18 min
(E)]. HRMS(AP-ESI) Caled for C22H37FO 2 0Sn (M+Na+ ):479.1748; Found:479.1747.
(E/Z)-1-Fluoro-2-phenyl-1-(tributyltin)-1-propene (85d). Treatment of 84d
(E/Z, 48:52; 380 mg, 1.38 mmol) with Bu3SnH (0.37 mL, 400 mg, 1.38 mmol) and AIBN
(56 mg, 0.34 mmol) by procedure G gave 85d13 1 (E/Z, 45:55; 555 mg, 95 %).
(E/Z)-1-Fluoro-1-iodo-2-phenylethene (86a). Procedure H. A solution of NIS
(273 mg, 1.22 mmol) in CH 2C12 (5 mL) was added to 85a (E/Z, 95:5; 400 mg, 0.97
mmol) dissolved in CH2Cl 2 (5 mL) at -20 0C. The reaction mixture was allowed to warm
to 0 OC over 30 min and NaHSO 3 (~0.5 mL) was added to decolorize the reaction
mixture. Volatiles were evaporated and the residue was partitioned
(NaHCO 3/H20//CH2Cl 2). The organic layer was washed (brine), dried (Na2SO 4),
evaporated and chromatographed (hexane -+ 15% EtOAc/hexane) to give 86a13 3 (E/Z,
95:5; 229 mg, 95%): 'F NMR S -60.02 (d, J= 18.4 Hz, 0.05F, Z), -62.90 (d, J= 36.9 Hz,
0.95F, E).
(E/Z)-1-Fluoro-1-iodo-4-phenyl-1-butene (86b). Treatment of 85b (E/Z, 86:14;
380 mg, 0.87 mmol) with NIS (0.25 g, 1.10 mmol) by procedure H gave 86b 3 3 (E/Z,
78:22; 221 mg, 94%): '9F NMR 6 -66.26 (d, J= 16.9 Hz, 0.22F, Z), -70.21 (d, J= 34.6
Hz, 0.78F, E).
Analogous treatment of 85b(E) (450 mg, 1.02 mmol) gave 86b(E) (252 mg, 91%).
Analogous treatment of 85b (E/Z, 15:85; 520 mg, 1.18 mmol) gave 86b (E/Z, 15:85;
295 mg, 92%).
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(E/Z)-3-Benzyloxy-1-fluoro-1-iodo-1-propene (86c). Treatment of 85c (E/Z,
77:23; 400 mg, 0.88 mmol) with NIS ( 246 mg, 1.09 mmol) by procedure H gave 86c
(E/Z, 67:33; 236 mg, 0.80 mmol, 92%). 1H NMR 6 3.91 (dd, J= 1.9, 7.1 Hz, 2, H3, Z),
4.01 (dd, J= 2.9, 7.1 Hz, 2, H3, E), 4.42 (s, 2, CH 2O, E), 4.43 (s, 2, CH 2O, Z), 5.44 (dt, J
= 7.1, 34.0 Hz, 1, H2, E), 5.67 (dt, J= 7.1, 16.1 Hz, 1, H2, Z), 7.21-7.30 (m, 5, Ph). 13C
NMR 6: 63.62 (d, JC-F = 4.8 Hz, CH 2, C3, Z), 68.80 (d, JC-F = 7.1 Hz, CH 2, C3, E), 72.29
(CH 2O, E/Z), 115.19 (d, JC-F = 12.4 Hz, C, C1, E/Z), 120.19 (d, JC-F 7.5 Hz, CH, C2,
E/Z), 127.83 (CH, Ph, E/Z), 128.45 (CH, Ph, E/Z), 137.71 (CH, Ph, E/Z). 19F NMR 6: -
59.92 (dt, J= 2.1, 16.3 Hz, Z), -65.18 (dt, J= 2.7, 33.9 Hz). GC-MS m/z 292 [2%, M+; tR
= 15.09 min (Z) and 15.48 min (E)]. Anal. Caled. for COH1OFIO (291.97): C, 41.12; H,
3.45; Found: C, 41.56; H, 3.87.
(E/Z)-1-Fluoro-1-iodo-2-phenyl-1-propene (86d). Treatment of 85d (E/Z,
45:55; 450 mg, 1.06 mmol) with NIS (300 mg, 1.32 mmol) by procedure H gave 86d
(E/Z, 49:51; 263 mg, 95%). 'H NMR 6: 2.18 (d, J = 3.7 Hz, 1, H3, E), 2.21 (d, J= 4.6
Hz, 1, H3, Z), 7.28 (m, 2H, Ph), 7.31 (m, 2H, Ph), 7.36-7.45 (m, 6H, Ph). 19F NMR 6 -
68.27 Hz (s, E), -68.81 (s, Z); GC-MS m/z 262 [100%, M+; tR = 10.96 min (Z) and 12.31
min (E)]. HRMS Caled. for C9 H8FI (M+): 261.9655; Found: 261.9662.
(E/Z)-1-Bromo-1-fluoro-2-phenylethene (87a). Treatment of 85a (E/Z, 95:5;
800 mg, 1.95 mmol) with NBS (430 mg, 2.43 mmol) by procedure H (using NBS instead
of NIS) gave 87a134 (E/Z, 93:7; 390 mg, 100 %): 'H NMR 6 6.00 (d, J= 32.9 Hz, 0.93,
H2, E), 6.70 (d, J= 15.1 Hz, 0.07, H2, Z), 7.20 (t, J= 7.3 Hz, 2, Ph), 7.30 (t, J= 7.8 Hz,
1, Ph), 7.45 (d, J= 7.4 Hz, 2, Ph); 19F NMR 6 -69.5 (d, J= 32.7 Hz; 0.93F, E), -65.5 (d, J
= 15.1 Hz, 0.07F, Z).
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(E/Z)-1-Fluoro-1-bromo-3-benzyloxy-1-propene (87c). Treatment of 85c (E/Z,
77:23; 250 mg, 0.55 mmol) with NBS (122 mg, 0.68 mmol) by procedure H (using NBS
instead of NIS) gave 87c (E/Z, 77:23; 125 mg, 93%): 'H NMR 6 3.97 (dd, J= 1.9, 7.1
Hz, 2, H3, Z), 4.00 (dd, J= 2.6, 7.3 Hz, 2, H3, E), 4.42 (s, CH 2O, 2, E), 4.43 (s, CH 2O, 2,
Z), 5.19 (dt, J = 7.3, 30.5 Hz, 1, H2, E), 5.64 (dt, J= 7.1, 12.2 Hz, 1, H2, Z), 7.23-7.28
(m, 5, Ph). '3C NMR 6: 63.17 (CH 2, C3, E), 63.20 (CH 2, C3, Z), 66.30 (CH 2, C3, Z),
72.28 (CH 2O, E/Z), 107.33 (C, C1, E), 107.49 (C, Cl, Z), 109.89 (CH, C2, Z), 110.00
(CH, C2, E), 127.83 (CH, Ph, E/Z), 128.46 (CH, Ph, E/Z), 129.69 (C, Ph, E/Z); '9F NMR
6 -66.05 (dd, J= 2.2, 13.5 Hz, Z), -70.41 (dt, J= 2.3, 30.9 Hz, E). GC-MS m/z 245 [2%,
M+; tR = 13.11 min (Z) and 13.43 min (E). HRMS(AP-ESI) Caled for CioH1o79BrFO
(M+H+): 244.9977; Found: 244.9970.
(E/Z)-1-Chloro-1-fluoro-2-phenylethene (88a). Compound 85a (E/Z, 95:5; 50
mg, 0.12 mmol) was dissolved in dried CH 2Cl 2 (5 mL) and the temperature was adjusted
to -50 °C. Chlorine gas was bubbled through the solution over 5 min. until a light yellow
solution was obtained and the reaction mixture was allowed to warm to 0 °C. Volatiles
were evaporated and the residue was chromatographed (hexane -+ 5% EtOAc/hexane) to
give 88a19 (E/Z, 93:7; 13 mg, 70%): 'H NMR 6 5.80 (d, J= 31.0 Hz, 1, H2, E), 6.30 (d, J
= 12.8 Hz, 1, H2, Z), 7.20 (t, J= 7.3 Hz, 2, Bz), 7.30 (t, J= 7.8 Hz, 1, Bz), 7.45 (d, J=
7.3 Hz, 2, Bz); 19F NMR 6 -74.0 (d, J= 30.5 Hz), -71.5 (d, J= 12.8 Hz).
Ethyl 5-Fluoro-6-phenyl-5(Z)-hexenoate (89a). Procedure I. 4-Ethoxy-4-
oxobutylzinc bromide (0.5 M, 0.60 mL, 0.30 mmol) was added via syringe to a stirring
solution of 86a (E/Z, 95:5; 50 mg, 0.20 mmol) in dried benzene (5 mL) containing
Pd(PPh 3)4 (23 mg, 0.02 mmol) under N 2 Additional Pd(PPh3)4 (10 mg, 0.009 mmol) and
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-ethoxy-4-oxobutylzinc bromide (0.270 mL, 0.135 mmol) were added to the reaction
mixture over the 8 h period. Volatiles were evaporated and the residue was partitioned
(NaHCO3/H20//EtOAc). The organic layer was washed (brine), dried (Na2SO 4),
evaporated and chromatographed (hexane --+ 15% EtOAc/hexane) to give 89a(Z) (33 mg,
70%; 73% based on E isomer only): 'H NMR 6 1.26 (t, J= 7.1 Hz, 3, OEt, 3H), 1.95
(quint, J= 7.3 Hz, 2, H3), 2.40 (m, 4, H2, H4), 4.10 (q, J= 7.1 Hz, 2, OEt), 5.50 (d, J=
39.4 Hz, 1, H6), 7.15 (t, J = 7.2 Hz, 1, Ph), 7.30 (t, J= 7.4 Hz, 2, Ph), 7.40 (d, J = 7.4 Hz,
Ph); '3C NMR 6 14.64 (Ot), 22.05 (C3), 32.34 (d, JC-F = 26.9 Hz, C4), 33.55 (C2),
60.82 (OEt), 106.92 (d, JC-F =8.5 Hz, C6), 127.21 (Ph), 128.74 (Ph), 128.88 (Ph), 133.98
(Ph), 158.93 (d, JC-F = 266.7 Hz, C5), 173.52 (CO); 19F NMR 6 -102.2 (dt, J= 18.8 Hz,
41.4 Hz); MS m/z 237 (100%, MH+). Anal. Caled. for C14H17FO 2 (236.12): C, 71.16; H,
7.25; Found: C, 70.80; H, 7.16.
Treatment (2 h) of 86a (E/Z, 95:5; 50 mg, 0.20 mmol) with PdCl2(dppb) (6.0 mg,
0.01 mmol) and 4-ethoxy-4-oxobutylzinc bromide (0.5 M, 0.74 mL, 0.37 mmol) as
described in procedure I gave 89a (Z) (44 mg, 93%, 97% based on E isomer).
Treatment of 87a (E/Z, 93:7; 50 mg, 0.25 mmol) with Pd(PPh3)4 (23 mg, 0.25
mmol) and 4-ethoxy-4-oxobutylzinc bromide (0.5 M, 0.74 mL, 0.37 mmol) as described
in procedure I gave 89a (Z) (41 mg, 70 %, 75% based on E isomer).
Treatment of 88a (E/Z, 93:7; 120 mg, 0.77 mmol) with Pd(PPh3)4 (77 mg, 0.06
mmol) and 4-ethoxy-4-oxobutylzinc bromide (0.5 M, 2.30 mL, 1.15 mmol) as described
in procedure I gave 89a (Z) (145 mg, 80%; 86% based on E isomer).
Ethyl 5-Fluoro-8-phenyl-5(Z)-octenoate (89b). Treatment of 86b (E/Z, 78:22;
50 mg, 0.18 mmol) with Pd(PPh 3)4 (20 mg, 0.018 mmol) and 4-ethoxy-4-oxobutylzinc
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bromide (0.5 M, 0.54 mL, 0.27 mmol) in dried benzene (5 mL) as described in procedure
I [ additional Pd(PPh3)4 (10 mg, 0.009 mmol) and 4-ethoxy-4-oxobutylzinc bromide
(0.270 mL, 0.135 mmol) were added to the reaction mixture over the 24 h period ] gave
89b(Z) (29 mg, 60%; 78% based on E isomer only): IHNMR 6 1.25 (t, J= 7.3 Hz, 3,
OEt), 1.79 (quint, J= 7.3 Hz, 2, H3), 2.15 (dt, J= 7.2, 18.2 Hz, 2, H4), 2.28 (t, J= 7.5
Hz, 2, H2), 2.41 (m, 2, H7), 2.65 (t, J= 7.8 Hz, 2, H8), 4.13 (q, J= 6.1 Hz, 2, OEt), 4.48
(dt, J= 7.3, 37.7 Hz, 1, H6), 7.20 (t, J= 7.3 Hz, 2, Ph), 7.30 (t, J= 7.9 Hz, 1, Ph), 7.45
(d, J= 7.4 Hz, 2, Ph); 13C NMR 6 14.63 (CH 3, OEt), 21.92 (CH 2, C3), 25.61 (d, JC-F 4.7
Hz, CH 2, C7), 31.50 (CH 2 C2), 33.50 (CH 2, C8), 36.09 (CH 2, C4), 60.69 (CH 2, Ot),
105.32 (d, JC-F = 15.5 Hz, CH, C6), 126.25 (CH, Ph), 128.67 (CH, Ph), 128.81 (CH, Ph),
142.07 (C, Ph), 157.93 (d, JC-F = 253.7 Hz, CF, C5), 173.60 (C1, CO); 9F NMR 6 -110.1
(dt, J= 37.6, 15.1 Hz), MS m/z 265 (100, MH+). HRMS (AP-ESI) Calcd for C16H21FO2
(M+Lit): 271.0938; Found: 271.0940.
Analogous treatment (12 h) of 86b (E) (15 mg, 0.054 mmol) produced only
89b(Z) (11.9 mg, 88%; 98% quantitative yield based on GC/MS).
Analogous treatment (24 h) of 86b (E/Z, 15:85; 15 mg, 0.054 mmol) showed
(GC/MS, 19F NMR) a conversion of the E isomer into 89b (Z) (~14%) and slowly
decomposition of 86b(Z) but formation of 89b(E) was not detected.
Analogous treatment (8 h) of 86b (E/Z, 84:16; 25 mg, 0.09 mmol) with
PdCl2(dppb) (5% molar) and 4-ethoxy-4-oxobutylzinc bromide (0.5 M, 0.28 mL, 0.14
mmol) gave 89b(Z) (19.5 mg, 82%; 98% based on E isomer).
Ethyl 5-Fluoro-6-phenyl-5(Z)-heptenoate (89d). Treatment of 86d (E/Z, 49:51;
55 mg, 0.21mmol) with Pd(PPh3)4 (24 mg, 0.02 mmol) and 4-ethoxy-4-oxobutylzinc
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bromide (0.5 M, 0.60 mL, 0.30 mmol) as described in procedure I (reaction was heated at
60 °C for 24 h) gave 89d(Z) (23 mg, 45%; 94% based on E isomer): 'H NMR 6 1.26 (t, J
= 7.1Hz, 3, OEt), 1.56 (s, 3, H7), 1.92-2.10 (m, 2, H3), 2.40 (dt, J= 7.1, 14.4 Hz, 2, H4),
2.49 (t, J= 7.2 Hz, 2, H2), 4.14 (q, J= 7.1 Hz, 2, OEt), 7.25-7.35 (m, 3, Ph), 7.36-7.45
(m, 2, Ph); 13C NMR 6 14.63 (CH 3, OEt), 17.59 (d, J = 4.5 Hz, CH 3 C7), 22.25 (CH 2,
C3), 28.84 (d, J= 29.11 Hz, CH 2, C4), 33.59 (CH 2, C2), 60.76 (CH 2, OEt), 113.50 (d, Jc.
F = 15.5 Hz, C, C6), 127.08 (CH, Ph), 128.39 (CH, Ph), 128.55 (CH, Ph), 138.80 (C, Ph),
154.5 (d, JC-F = 253.5 Hz, C, C5), 173.62 (CO, C1); 19F NMR 6 -108.19 (t, J= 22.6 Hz).
HRMS (AP-ESI) Calcd. for C15H19FO 2 (M+Na+): 273.1266; Found: 273.1293.
Analogous treatment (8 h) of 86d (E/Z, 49:51; 15 mg, 0.06 mmol) with
PdC12(dppb) (5% molar) and 4-ethoxy-4-oxobutylzinc bromide (0.5 M, 0.18 mL, 0.09
mmol) gave in addition to 89d(Z) a new product tentatively assigned as 89d(E): 19F NMR
6 -107.82 ("tq", J= 22.6, 2.1 Hz, 0.84F), -109.91 ("tq", J= 22.5, 3.4 Hz, 0.16F); GC-MS
m/z 250 [8%, M+; tR = 17.20 min (E) and 18.74 min (Z)].
(Z)-2-Fluoro-1-phenyl-1,6-heptadiene (90a). Treatment of 86a (E/Z, 95:5; 75
mg, 0.30 mmol) with Pd(PPh3)4 (17 mg, 0.015 mmol) and 4-pentenylzinc bromide (0.5
M, 0.9 mL, 0.45 mmol) as described in procedure I gave 90a(Z) (37 mg, 65%; 69% based
on E isomer): 'H NMR 6 1.70 (q, J= 7.5 Hz, 2, H4), 2.15 (quint, J= 6.8 Hz, 2, H5), 2.32
(dt, J= 7.7 Hz, 15.4 Hz, 2, H3), 5.03 (dd, J= 1.3, 10.2 Hz, 1, Ha7), 5.04 (dd, J= 1.7,
17.3 Hz, 1, Hb7), 5.45 (d, J= 39.5 Hz, 1, Hl), 5.81 (ddt, J= 7.1, 10.2, 17.0 Hz), 7.2 (t, J
= 7.78 Hz, 1, Ph), 7.32 (d, J= 7.3 Hz, 2, Ph), 7.5 (d, J= 8.15 Hz, 2, Ph); 13C NMR 6:
25.91 (CH 2, C4), 32.71 (CH 2, C5), 33.29 (CH 2, C3), 106.2 (d, JC-F = 28.6 Hz, CH, Cl),
115.69 (CH 2, C7), 127.08 (CH, Ph), 128.56 (CH, Ph), 129.74 (CH, Ph), 134.26 (C, Ph),
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138.40 (CH, C6), 159.93 (d, JC-F = 266.6 Hz, C2); 19F NMR 6 -101.45 (dt, J= 18.8, 41.3
Hz); GC-MS m/z 190 [25%, M+; tR = 13.97 min (Z)]. Anal. Caled. for C13H, 5F (190.26):
C, 82.07, H, 7.95. Found: C, 82.41, H, 8.15.
Also 2,3-difluoro-1,4-diphenyl-1,3-butadienem3 1 (6 mg, 8%) was isolated during
chromatography as a less polar compound: '9F NMR 6 -127.95 (dd, J = 14.6, 28.6 Hz);
GC-MS m/z 242 [100%, M+; tR = 21.46 min].
(Z)-6 -Fluoro-9-phenyl-1,6-nondiene (90b). Treatment of 86b (E/Z, 78:22; 70
mg, 0.26 mmol) with Pd(PPh 3)4 (15 mg, 0.013 mmol) and 4-pentenylzinc bromide (0.77
mL, 0.38 mmol) in dried benzene (5 mL) as described in procedure I [additional
Pd(PPh3)4 (8 mg, 0.007 mmol) and 4-pentenylzinc bromide (0.4 mL, 0.2 mmol) were
added to the reaction mixture] gave 90b(Z) (43 mg, 76%; 98% based on E isomer): 'H
NMR 6 1.55 (q, J= 7.7 Hz, 2, H4), 2.04-2.20 (m, 4, H3, H5), 2.38 (dt, J= 7.6, 15.0 Hz,
2, H8), 2.65 (t, J= 7.3 Hz, 2, H9), 4.45 (dt, J= 7.4, 37.9 Hz, 1, H7), 4.65 - 5.05( m, 1,
H1), 5.75-5.85 (m, 1, H2), 7.18-7.25 (m, 3, Ph), 7.30-7.35 (m, 2, Ph); 1C NMR 6 23.04
(CH 2 C4), 25.75 (CH 2, C8), 31.5 (CH 2, C3), 33.18 (CH 2, C9), 36.19 (CH 2, C5), 104.64
(d, JC-F = 15.6 Hz, CH, C7), 115.40 (CH 2, Cl), 126.24 (CH, Ph), 128.68 (CH, Ph), 128.85
(CH, Ph), 138.58 (C, Ph), 142.18 (CH, C2), 158.76 (d, JC-F = 253.7 Hz, CF C6); 19F NMR
6 -109.65 (dt, J= 15.0, 41.3 Hz). MS m/z 219 (100%, MH+). Anal. Caled. for C15H19F
(218.15): C, 82.53, H, 8.77. Found: C, 82.43, H, 8.80.
The 19F NMR of the crude reaction mixture in addition to 90bZ (0.73F) showed
the presence of the E-isomer of 90b [-104.71 ppm (dt, J = 22.6, 64.0 Hz, 0.12F)] in
addition to the by-product tentatively as (Z)-1-fluoro-4-phenyl- 1 -butene [19F NMR 6 -
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130.33 (dd, J= 41.4, 82.8 Hz, 0.03F) and (Z,Z)-4,5-difluoro-1,8-diphenyl-3,5-octadiene [
-132.34 ppm (dd, J= 13.2, 26.3 Hz, 0.1OF)].
(E/Z)- 6-Fluoro-8-benzyloxy-1,6-octadiene (90c). Treatment of 86c (E/Z, 67:33;
63 mg, 0.215 mmol) with PdCI2(dppb) ( 5% molar) and 4-pentenylzinc bromide (0.5 M,
0.86 mL, 0.43 mmol) as described in procedure I [550 C for 8 h] gave 90c ( E/Z, 80:20,
46 mg, 86%).'H NMR 6 1.55 (quint, J= 7.4 Hz, 2, H4, E/Z), 1.98-2.04 (m, 2, H5, E/Z),
2.08 -2.19 (m, 2, H3, E/Z), 3.87 (d, J= 7.8 Hz, 0.4, OCH 2, Z), 4.02 (d, J= 7.1 Hz, 1.6,
OCH 2, E), 4.41 (s, 2, CH 2O, E/Z), 4.66 (dt, J= 7.2, 36.7 Hz, 0.8, Hi, E), 4.88-4.97 (m, 2,
H7, E/Z), 5.17 (dt, J= 7.8, 20.52 Hz, 0.2, H1, Z), 5.65-5.75 (m, 1, H6, E/Z), 7.20-7.27 (m,
5, Ph, E/Z); '3C NMR 6 25.13 (CH 2, C4, E), 25.45 (CH 2, C4, Z), 31.13 (CH 2, C5, E),
31.40 (CH 2, C5, Z), 32.82 (CH 2, C3, E/Z), 62.70 (OCH 2, Z), 62.77 (OCH 2, E), 71.86
(CH 2O, Z), 72.06 (CH 2O, E), 102.31 (d,
JC-F = 13.79 Hz, CH, C1, Z), 102.82 (d, JC-F = 22.85 Hz, CH, Cl, E), 115.19 (CH 2, C7,
E/Z), 127.58 (CH, Ph, E/Z), 127.82 (CH, Ph, E/Z), 128.36 (CH, Ph, E/Z), 137.85 (C, Ph,
E/Z), 138.34 (CH, C6, EZ), 160.93 (d, JC-F = 259.1 Hz, CF, C2, E,), 162.62 (d, JC-F =
254.8 Hz, CF, C2, Z); 19F NMR 6 -98.05 (q, J= 22.8 Hz, 1, Z), -104.21 (dt, J= 17.31,
36.74 Hz, 5, E); GC-MS m/z 235 [1%, M+; tR 16.95 min (Z) and 17.57 min (E)]. HRMS
Calcd. for C15H19FO (M+H+) 235.1498; Found: 235.1490.
Treatment of 86c (E/Z, 75:25, 20 mg, 0.07 mmol) with Pd(PPh 3)4 (5% molar) and
4-pentenylzinc bromide (0.5 M, 0.28 mL, 0.14 mmol) as described in procedure I (48 h)
gave 90c (56%, 19F NMR 6: -104.56 (dt, J = 15.05, 37.6 Hz) in addition to unchanged
86c (43%, EZ, - 44: 56).
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Treatment of 87c (E/Z, 77/23, 45 mg, 0.18 mmol) with PdC12 (dppb) (5% molar)
and 4 -pentenylzinc bromide (0.5 M, 0.7 mL, 0.36 mmol) as described in procedure I gave
90c (E/Z, 80:20; 36 mg, 84%).
(Z)-6-Fluoro-7-phenyl-1,6-octadiene (90d).Treatment of 86d (E/Z, 49:51; 65
mg, 0.25 mmol) with Pd(PPh 3)4 (14.3 mg, 0.012 mmol) and 4-pentenylzinc bromide (0.5
M, 0.75 mL, 0.38 mmol) as described in procedure I [55 0C for 4 h] gave 90d(Z) (23 mg,
45%; 92% based on E isomer): 'H NMR 6 1.68 (quint, J= 7.9 Hz, 2, H4), 1.95 (s, 3, H8),
2.12-2.20 (m, 2, H3), 2.38 (dt, J= 7.1, 23.6 Hz, 2, H5), 4.98 (dd, J= 8.0, 10.2 Hz, 2, H1),
5.78-5.90 (m, 1, H2), 7.15-7.38(m, 5, Ph); 3C NMR 6 17.72 (CH 3, C8), 26.16 (CH 2, C4),
31.38 (CH 2, C5), 33.41 (CH 2, C3), 110.08 (C, C7), 115.51 (CH 2, Cl) 126.99 (CH, Ph),
128.40 (CH, Ph), 128.54 (CH, Ph), 138.61 (C, Ph), 139.02 (CH, C2), 154.82 (d, JC-F =
255.6 Hz, CF, C6); '9F NMR 6 -108.10 (t, J= 23.1 Hz); GC-MS m/z 204 [5%, M+; tR=
14.59 min, Z]. Anal. Calcd. for C14H17FO 2 (204.28): C, 82.31; H, 8.39. Found: C, 82.56;
H, 8.78.
Assesment of the reaction progress by GC-MS and 19F NMR showed the gradual
conversion of the 86d(E) isomer into 90d(Z) [2 h (6%), 8 h (35%), 16 h (60%), 24 h
(92%)] while 86d(Z) isomer remained unchanged.
2-Fluoro-1-phenyl-4-[2-(1,3-dioxolanyl)]-1(Z)-butene (91a). Treatment of 86a
(E/Z, 95:5; 25 mg, 0.10 mmol) with Pd(PPh 3)4 (10 mg, 0.01 mL) and 2-[2-(1,3-
dioxolanyl]ethylzinc bromide (0.5 M, 0.4 mL, 0.2 mmol) as described in procedure I
[additional Pd(PPh3)4 (20 mg, 0.02 mmol) and 2-[2-(1,3- dioxolanyl]ethylzinc bromide
(0.8 mL, 0.4 mmol) were added to the reaction mixture over the 24 h period] gave 91a
(Z) (20 mg, 90%; 94% based on E isomer): 'H NMR 6 1.96 (dt, J= 4.6, 11.1 Hz, 2, H4),
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2.45 (dt, J= 7.6, 17.8 Hz, 2, H3), 3.85 (t, J= 5.4 Hz, 2, CH 2 dioxolanyl) 3.92 (t, J= 5.0
Hz, 2, CH 2 dioxolanyl), 4.95 (t, J= 4.5 Hz, 1, H5), 5.50 (d, J= 39.3 Hz, 1, Hi), 7.20 (t, J
= 7.4 Hz, 2, Ph), 7.30 (t, J= 7.8 Hz, 1, Ph), 7.45 (d, J= 7.3 Hz, 2, Ph); 3C NMR 6 27.82
(d, JC-F = 27.8 Hz, CH2, C3), 31.03 (CH 2, C4), 65.45 (CH 2, 2 x CH 2 from dioxolanyl),
103.74 (CH, Cl), 106.37 (CH, C5), 127.16 (CH, Ph), 128.66 (CH, Ph), 128.81 (CH, Ph),
134.08 (C, Ph), 159.25 (d, JC-F = 266.2 Hz, CF, C2); GC-MS m/z 222 [10%, M+; tR
18.19 min, Z]. HRMS (AP-ESI) Caled for C13H15F0 2 (M+Li+): 229.1216. Found:
229.1207.
Effect of the Pd catalysts on the efficiency of coupling: Progress of the reactions
was monitored by 19F NMR GC-MS and yields are based on 19F NMR and GC-MS of the
crude reaction mixtures.
Treatment of 86a (E/Z, 95:5, 25 mg, 0.10 mmol) with Pd(Ph3P)4 (5% molar) and
2-[2-(1,3- dioxolanyl]ethylzine bromide (0.5 M, 0.4 mL, 0.2 mmol) as described in
procedure I [2h, 50 0C] gave 91a (11%) and unchanged 86a (E/Z, 95:5, 85%).
Treatment of 86a (E/Z, 95:5, 25 mg, 0.10 mmol) with PdCl2(dppf) (5% molar)
and 2-[2-(1,3-dioxolanyl]ethylzinc bromide (0.5 M, 0.4 mL, 0.2 mmol) as described in
procedure I [2h, 50 0C] gave 91a (8%), unchanged 86a (E/Z, 95:5, 85%) and reduction
product (6%).
Treatment of 86a (E/Z, 95:5, 25 mg, 0.10 mmol) with Pd(OAc) 2 (5% molar) and
2-[2-(1,3- dioxolanyl]ethylzinc bromide (0.5 M, 0.4 mL, 0.2 mmol) as described in
procedure I [3.5h, 50 0C] gave 91a (95%).
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Treatment of 86a (E/Z, 95:5, 25 mg, 0.10 mmol) with Pd(dba)3 (5% molar) and 2-
[2-(1,3- dioxolanyl]ethylzinc bromide (0.5 M, 0.4 mL, 0.2 mmol) as described in
procedure I [2h, 50 0C] gave 91a (93%).
Treatment of 86a (E/Z, 95:5, 25 mg, 0.10 mmol) with PdCl 2(dppb) (5% molar)
and 2-[2-(1,3- dioxolanyl]ethylzinc bromide (0.5 M, 0.4 mL, 0.2 mmol) as described in
procedure I [2h, 50 0C] gave 91a (95%).
4-Fluoro-1-phenyl-6-[2-(1,3-dioxolanyl)]-3(Z)-hexene (91b). Treatment of 86b
(E/Z, 78:22; 30 mg, 0.11 mmol) with Pd(PPh3)4 (7 mg, 0.005 mmol) and 2-[2-(1,3-
dioxolanyl)]ethylzinc bromide (0.5 M, 0.44 mL, 0.22 mmol) in dried benzene (5 mL) as
described in procedure I [additional Pd(PPh 3)4 (4 mg, 0.0028 mmol) and 2-[2-(1,3-
dioxolanyl)]ethylzinc bromide (0.5 M, 0.2 mL, 0.1 mmol) were added] gave 91b(Z) (20
mg, 74%; 94% based on E isomer): 'H NMR 6 1.80-1.91 (m, 2, H6), 2.22 (dt, J= 5.0,
17.3 Hz, 2, H5), 2.40 (q, J= 7.5 Hz, 2, H2), 2.63 (t, J= 7.9 Hz, 2, H1), 3.86 - 3.90 (m, 2,
CH 2 dioxolanyl), 3.96-4.02 (m, 2, CH 2 dioxolanyl), 4.50 (dt, J= 7.4, 37.6 Hz, 1, H3),
4.86 (t, J= 4.6 Hz, 1, H7), 7.18-7.25 (m, 3, Ph), 7.28-7.35 (m, 2, Ph); 13C NMR 6: 25.60
(d, JC-F = 4.9 Hz, CH 2 C2), 26.76 (d, JC-F = 28.8 Hz, CH 2, C5) 31.02 (CH 2, C6), 36.08
(CH 2, C1), 65.26 (CH 2, 2x CH 2 dioxolanyl), 103.87 (CH, C7), 104.68 (d, JC-F =15.49 Hz,
CH, C3), 126.23 (CH, Ph), 128.66 (CH, Ph), 128.93 (CH, Ph), 142.11 (C, Ph), 158.24 (d,
JC-F = 253.2 Hz, CF, C4); 19F NMR 6 -109.37 (dt, J= 15.04, 37.6 Hz); GC-MS m/z 250
[1%, M+; tR = 17.74 min, Z]. FAB-HRMS: Calcd for C15H19F02 (MH+): 251.1448;
Found: 251.1455.
Analogous treatment of 86b (E) (15 mg, 0.054 mmol) produced only 91b(Z)
(89%, -98% based on GC/MS).
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Analogous treatment of 86b (E/Z, 15:85; 15 mg, 0.055 mmol) showed a
conversion of the E isomer into 91b(Z) (~14%) and disappearance of 86b(Z), but no
formation of 9b(E) was detected (GC/MS, 19F NMR).
3-Fluoro-2-phenyl-5-[2-(1,3-dioxolanyl)]-2(Z)-pentene (91d). Treatment of 86d
(E/Z, 49:51; 30 mg, 0.11mmol) with Pd(PPh3)4 (6.5 mg, 0.0057 mmol) and 2-[2-(1,3-
dioxolanyl]ethylzinc bromide (0.45 mL, 0.23 mmol) as described in procedure I [600 C
for 24 h; additional Pd(PPh 3)4 (6 mg, 0.005mmol) and 2-[2-(1,3- dioxolanyl]ethylzinc
bromide (0.45 mL, 0.23 mmol) were added to the reaction mixture over a 24 h period)]
gave 91d(Z) (12 mg, 46%; 90% based on E isomer]): 'HNMR 6 1.30 (s, 3, Hi), 1.94-
2.03 (m, 2, H4), 2.5 (dt, J= 8.1, 23.1 Hz, 2, H5), 3.89-3.94 (m, 2, CH 2 dioxolanyl), 3.95-
4.05 (m, 2, CH 2 dioxolanyl), 4.95 (t, J= 4.5 Hz, 1, H6), 7.20-7.38 (m, 5, Ph); 3C NMR 6
17.57 (CH 3, C1), 24.25 (d, JC-F = 29.2 Hz, CH 2, C4), 30.12 (CH 2, C5), 65.42 (2x CH 2
dioxolanyl), 103.95 (C, C2), 112.8 (CH, C6), 127.04 (CH, Ph), 128.40 (CH, Ph), 128.56
(CH, Ph), 138.88 (C, Ph), 153.8 (d, JC-F = 255.8 Hz, C, CF); 19F NMR 8 -108.75 (t, J=
22.6 Hz). HRMS (ESI) Calcd for C14H 17FO 2 (M+ Li+): 243.1373; Found: 243.1361.
3,3-Dimethyl-2-Fluoro-1-phenyl-1-butene (93a). Treatment of 86a (E/Z, 95:5,
40 mg, 0.16 mmol) with PdCl2(dppb) (5% molar) and tert-butylzinc bromide (0.5 M, 0.6
mL, 0.32 mmol) as described in procedure I [3 h, 50 °C] gave 93a (23 mg, 80%, 95%
bsed on GC-MS and 19F NMR ): 1H NMR 6 1.15 (s, 9, t-Bu), 5.40 (d, J= 40.7 Hz, H1),
7.17-7.41 (m, 5, Ph); 19F NMR 6 -109.47 (d, J= 40.7 Hz); GC-MS m/z 178 [80%, M+; tR
= 10.78 min]. HRMS Calcd. for C12H15F (M+H+) 179.1237; Found: 179.1246.
Treatment of 86a (E/Z, 95:5, 32 mg, 0.12 mmol) with tert-butylzinc bromide (0.5 M, 0.48
mL, 0.24 mmol) in the presence of Pd(Ph 3P)4 (5% molar) as described in procedure I [24
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h, 65 0C] gave 93a (60%) and 94131 (20%, 40% consumption of 86a): 9F NMR 6 -109.47
(d, J= 40.7 Hz, 0.60F), -127.95 ("dd", J= 28.6, 14.6 Hz, 0.40F).
Treatment of 86a (E/Z, 95:5, 40 mg, 0.16 mmol) with tert-butylzine bromide (0.5
M, 0.6 mL, 0.32 mmol) in the presence of Pd 2(dba)3 (5 % molar) as described in
procedure I [12 h, 50 0C] gave 94131 (35 mg, 45%) based on 19F NMR.
Coupling with secondary alkylzinc bromides:
Treatment of 86a (E/Z, 95:5; 18 mg, 0.07 mmol) with Pd2(dba) (5% molar) and 1-
methylbutylzinc bromide (0.5 M, 0.29 mL, 0.14 mmol) as described in procedure I [3h,
50 0C] gave a mixture of 93b (50%) and 94 (12%) in addition to Z-P-fluorostyrene 36
(26%): 19F NMR 6 -109.34 (dd, J= 40.2, 22.9 Hz, 0.50F, 93b), -122.49 (dd, J = 82.5,
44.6 Hz, 0.26F, Z-P-fluorostyrene), -127.95 ("dd", J= 28.6, 14.6 Hz, 0.24F, 94); GC-MS
for 93b/94 had m/z 192 (65%, M+; tR= 14.08 min; 93b), 242 (100%, M+; tR = 21.46 min;
94)
Treatment (18 h, 65 °C) of 86a (E/Z, 95:5; 22 mg, 0.088 mmol) with 1-
methylbutylzinc bromide (0.5 M, 0.35 mL, 0.17 mmol) in the presence of Pd(Ph 3P)4 (5%
molar) gave 93d [37%; 19F NMR 6 -101.01 (dt, J= 18.8, 40.3 Hz)], 94 (19%) and Z-3-
fluorostyrene (4%) as estimated based on the 19F NMR and GC-MS of the crude reaction
mixture.
Treatment of 86a (E/Z, 95:5, 50 mg, 0.20 mmol) and 3-pentylzine bromide (0.5
M, 0.60 mL, 0.30 mmol) in the presence of Pd(Ph 3P)4 (5% molar) as described in
procedure I gave inseparable mixture of 93c and 93d (30/70): GC-MS m/z 192 (85%, M+;
tR = 11.67 min, 93c), 192 (60%, M+; tR = 12.55; 93d). HRMS (AP-ESI) Calcd. for
C13H 17 F (M+Li+): 199.1474; Found: 199.1478.
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(Z)-Ethyl 5-Chloro-6-phenyl-5-hexenoate (98a). Procedure . 4-ethoxy-4-
oxobutylzine bromide (0.5 M, 1.45 mL, 0.722 mmol) was added via syringe to a stirring
solution of 96a125 (50 mg, 0.29 mmol) in dried THF (3 mL) containing PdCl2(ddpf) (24
mg, 0.029 mmol) under N 2 . The resulting mixture was heated at 65 0C overnight.
Volatiles were evaporated and the residue was partitioned (NaHCO 3/H 20/EtOAc).The
organic layer was washed (brine), dried (Na 2SO 4), evaporated, and chromatographed
(hexane -+ 10% EtOAc/hexane) to give 98a (47 mg, 65%) and 101a13 7 (14 mg, 22%).
Compound 98a had: 'H NMR 6 1.16 (t, J= 7.1 Hz, 3, OEt), 1.89 (quint, J= 7.1 Hz, 2,
H3), 2.27 (t, J= 7.4 Hz, 2, H4), 2.45 (t, J= 7.1 Hz, 2, H2), 4.04 (q, J = 7.1 Hz, 2, OEt),
6.40 (s, 1, H6), 7.15 (t, J= 7.3 Hz, 2, Ph), 7.25 (t, J= 7.9 Hz, 1, Ph), 7.45 (d, J = 7.4 Hz,
2, Ph). 13C NMR 6: 14.05 (CH3 , OEt), 22.61 (CH2, C3), 31.56 (CH2, C2), 40.28 (CH2,
C4), 60.34 (OEt, CH2), 125.25 (CH, C6), 127.55 (CH, Ph), 128.13 (CH, Ph), 128.98
(CH, Ph), 133.63 (C, C5), 134.97 (C, Ph), 174.10 (CO, Cl). GC-MS m/z 252 (30%, M+
[35C1]; tR = 20.00 min). HRMS (AP-ESI) Caled for C14H17C0 2 (M+H+): 253.0995;
Found: 253.0989.
Analogous treatment (65 °C, 2h) of 96a (50 mg, 0.29 mmol) with 4-ethoxy-4-
oxobutylzinc bromide (0.5 M, 1.45 mL, 0.722 mmol) in dried THE (5 mL) in the
presence of PdC12(dppb) (5% molar) gave 98a (39 mg, 53 %), 100a (26 mg, 27%),
101a 3 7 (10 mg, 15%).
Analogous treatment (65 °C, 2h) of 96a (50 mg, 0.29 mmol) with 4-ethoxy-4-
oxobutylzine bromide (0.5 M, 1.45 mL, 0.722 mmol) in dried THF (5 mL) in the
presence of Pd(PPh3)4 (5% molar) gave only the dialkylated byproduct 100a (68%) and
101a 37 (28%).
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(Z)-Ethyl 5-Chloro-6-(4-methoxyphenyl)-5-hexenoate (98b). Treatment (50 ®C
to 65 0C, overnight) of 96b (41 mg, 0.20 mmol) with 4-ethoxy-4-oxobutylzinc bromide
(0.5 M, 2 mL, 1.01 mmol) in the presence of PdCI2(dppf) (5% molar) and DPEPhos (3%
molar) in dried benzene (5 mL) as described in procedure J gave 98b(Z) (39.5 mg, 70 %)
and 100b (19 mg, 27 %). Compound 98b had: 'H NMR 6 1.26 (t, J= 7.1 Hz, 3, OEt),
2.01 (quint, J= 7.3 Hz, 2, H3), 2.36 (t, J= 7.4 Hz, 2, H4), 2.52 (t, J= 7.2 Hz, 2, H2),
3.82 (s, 3, OMe), 4.13 (q, J= 7.1 Hz, 2, OEt), 6.43 (s, 1, H6), 6.88 (d, J= 8.8 Hz, 2, Ph),
7.57 (d, J= 8.7 Hz, 2, Ph). 3 C NMR 6: 14.25 (CH 3, OEt), 22.80 (CH 2, C3), 32.84 (CH 2,
C2), 40.28 (CH 2, C4), 55.21 (OMe), 60.34 (OEt, CH 2), 113.56 (CH, Ph), 124.67 (CH,
C6), 127.55 (CH, Ph), 130.63 (CH, Ph), 131.63 (C5), 158.93 (Ph), 173.22 (CO, Cl). GC-
MS m/z 282 [25%, M+ [35C1]; tR = 23.50 min]
Analogous treatment of 96b (35 mg, 0.17 mmol) with 4-ethoxy-4-oxobutylzinc
bromide (0.5 M, 0.57 mL, 0.28 mmol) in dried benzene (5 mL) in the presence of
PdCl2(dppb) (5% molar) and DPEPhos (3 %) as described in procedure J gave 98b (30
mg, 63%), 100b (17 mg, 27%) and 101b (4 mg, 10%).
Analogous treatment of 96b (45 mg, 0.22 mmol) with 4-ethoxy-4-oxobutylzinc
bromide (0.5 M, 0.57 mL, 0.28 mmol) in dried benzene (5 mL) in the presence of
Pd(PPh3)4 (5% molar) and DPEPhos (3% molar) as described in procedure J gave 98b
(34 mg, 55%), 100b (28 mg, 35%) and 101b (5.5 mg, 10%).
Analogous treatment of 96c (45 mg, 0.24 mmol) with 4-ethoxy-4-oxobutylzinc
bromide (0.5 M, 0.57 mL, 0.28 mmol) in dried benzene (5 mL) in the presence of
PdCl 2(dppb) (5% molar) and DPEPhos (3% molar ) as described in procedure J gave
100c (75 mg, 90%) and 101c ( 5.5 mg, 10%).
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Treatment of 97a (50 mg, 0.19 mmol) with 4-ethoxy-4-oxobutylzinc bromide (0.5
M, 0.57 mL, 0.28 mmol) in dried THF (5 mL) in the presence of PdCl 2(dppf) (21 mg,
0.025 mmol) as described in procedure J gave 100a (29 mg, 69 %) and 101a (18mg,
28%).
Analogous treatment of 97a (50 mg, 0.19 mmol) with 4-ethoxy-4-oxobutylzinc
bromide (0.5 M, 0.57 mL, 0.28 mmol) in dried THE (5 mL) in the presence of
PdCl 2(dppb) (5% molar) as described in procedure J (65 0C, overnight) gave 100a (47
mg, 75 %) and 101a (10 mg, 24%).
Analogous treatment of 97a (50 mg, 0.19 mmol) with 4-ethoxy-4-oxobutylzinc
bromide (0.5 M, 0.57 mL, 0.28 mmol) in dried THE (5 mL) in the presence of Pd(Ph 3P)4
( 29 mg, 0.025 mmol) gave 100a (38 mg, 60%) and 101a (16 mg 38%).
(Z)-Ethyl 5-Bromo-6-(4-methoxyphenyl)-5-hexenoate (99b). Treatment of 97b
(40 mg, 0.13 mmol) with 4-ethoxy-4-oxobutylzinc bromide (0.5 M, 2 mL) in the
presence of PdCI 2(dppf) (5% molar) and DPEPhos (3% molar) in dried benzene (5 mL)
as described in procedure J gave 99b(Z) (20 mg, 47%) and 100b (13 mg, 27 %).
Compound 99b had: 'H NMR 6 1.17 (t, J= 7.1 Hz, 3, OEt), 1.92 (quint, J= 7.3 Hz, 2,
H3), 2.29 (t, J= 7.4 Hz, 2, H4), 2.57 (t, J= 7.4 Hz, 2, H2), 3.74 (s, 3, OMe), 4.06 (q, J=
7.1 Hz, 2, OEt), 6.61 (s, 1, H6), 6.80 (d, J= 8.8 Hz, 2, Ph), 7.47 (d, J= 8.7 Hz, 2, Ph).
13C NMR : 14.26 (CH 3, OEt), 23.49 (CH 2, C3), 32.72 (CH 2, C2), 42.34 (CH 2, C4),
55.26 (OMe), 60.39 (OEt, CH 2), 113.47 (CH, Ph), 124.54 (CH, C6), 127.83 (CH, Ph),
128.32 (C5), 131.63 (CH, Ph), 159.03 (Ph), 173.22 (CO, Cl). GC-MS m/z 326 [2%,
M+[79Br]; tR = 23.50 min].
105
Analogous treatment of 97b (45 mg, 0.15 mmol) with 4-ethoxy-4-oxobutylzinc
bromide (0.5 M, 0.57 mL, 0.28 mmol) in dried benzene (5 mL) in the presence of
PdCl 2(dppb) (5% molar) and DPEPhos (3%) as described in procedure J gave 100b (42
mg, 78%) and 101b (8 mg, 21%).
Analogous treatment of 97b (45 mg, 0.15 mmol) with 4-ethoxy-4-oxobutylzinc
bromide (0.5 M, 0.57 mL, 0.28 mmol) in dried benzene (5 mL) in the presence of
Pd(PPh3)4 (5% molar) and DPEPhos (3%) as described in procedure J gave 99b (20 mg,
40%), 100b (32 mg, 59%).
Treatment of 97b (45 mg, 0.15 mmol) with 4-ethoxy-4-oxobutylzinc bromide (0.5
M, 0.57 mL, 0.28 mmol) in dried benzene (5 mL) in the presence of Pd(PPh 3)4 (5%
molar) as described in procedure J gave only 100b (39 mg, 72%) and 101b (9.6 mg,
26%).
Treatment of 97c (50 mg, 0.18mmol) with 4-ethoxy-4-oxobutylzinc bromide (0.5
M, 0.57 mL, 0.28 mmol) in dried benzene (5 mL) in the presence of PdC12(dppb) (5%
molar) and DPEPhos (3%) as described in procedure J gave 100c (17 mg, 27%) and 101c
(4 mg, 10%).
Ethyl 6-phenyl-5-(3-ethoxycarbonylpropyl)hexenoate (100a). Compound 100a
had: 'H NMR 6 1.15 (t, J= 7.1 Hz, 3, OEt), 1.19 (t, J= 7.1 Hz, 3, OEt) 1.66-1.82 (m, 4,
H3), 2.10-2.22 (m, 4, H4), 2.27 (t, J= 7.4 Hz, 4, H2), 3.98-4.09 (m, 4, OEt), 6.25 (s, 1,
H6), 7.08-7.25 (m, 5, Ph); 13 C NMR 6 14.56 (CH 3, OEt), 14.62 (CH 3, OEt), 23.69 (CH 2,
C3), 23.77 (CH 2, C3'), 30.08 (CH 2, C4'), 34.18 ( CH 2, C2), 34.47 (CH 2, C2'), 36.50
(CH 2, C4), 60.60 (OEt, CH 2), 60.62 (OEt, CH 2), 126.51 (CH, C6), 127.07 ( CH, Ph),
128.98 (CH, Ph), 129.0 (CH, Ph), 138.47 (CH, Ph),141.45 (C, C5), 173.71 (CO),
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173.91(CO); GC-MS m/z 332 [35%, M+; tR = 25.36 min]. Anal. Calcd, for C2 0H2 8FO4
(332.20): C, 72.26; H, 8.49. Found: C, 71.92; H, 8.59.
Ethyl 6 -(4 -methoxyphenyl)-5-(3-ethoxycarbonylpropyl)hexenoate (100b).
Compound 100b had: 'H NMR 8: 1.20 (t, J = 7.1 Hz, 3, OEt), 1.26 (t, J= 7.1 Hz, 3,
OEt), 1.77-1.85 (m, 4, H3), 2.18-2.28 (m, 4, H4), 2.36 (t, J= 7.4 Hz, 4, H2), 3.82 (s, 3,
OMe), 4.08-4.18 (m, 4, OEt), 6.27 (s, 1, H6), 6.85 (d, J= 8.7 Hz, Ph), 7.12 (d, J= 8.4 Hz,
Ph); 13C NMR 6: 14.22 (CH 3, OEt), 14.26 (CH 3, OEt), 23.33 (CH 2, C3), 23.38 (CH 2,
C3'), 29.65 (CH 2, C4), 33.82 ( CH 2, C2), 34.13 (CH 2, C2'), 36.21 (CH 2, C4), 55.24
(OMe, CH 3) 60.28 (OEt, CH 2), 60.62 (OEt, CH 2), 113.56 (CH, Ph), 126.13 (CH, C6),
129.72 ( CH, Ph), 130.62 (Ph), 139.78 (C, C5), 157.91 (C, Ph) 173.45 (CO), 173.66
(CO); GC-MS m/z 362 [50%, M+; tR = 27.80 min].
Ethyl 6-phenyl-5-(3-ethoxycarbonylpropyl)heptenoate (100c). Compound
100c had: 'H NMR 6: 1.12 (t, J= 7.1 Hz, OEt), 1.19 (t, J= 7.1 Hz, OEt), 1.51-1.56 (m, 4,
H3), 1.51 (quint, J= 7.3 Hz, 2, H3), 1.71 (quint, J = 7.3 Hz, 2, H3'), 1.81 (t, J= 7.2 Hz,
2, H4), 1.87 (s, 3, CH 3), 2.00 (t, J= 7.1 Hz, 2, H4'), 2.12 (t, J= 7.1 Hz, 2, H2), 2.28 (t, J
= 7.1 Hz, 2, H2'), 3.96 (q, J= 7.2 Hz, 2, OEt), 4.08 (q, J= 7.2 Hz, 2, OEt), 6.98-7.24 (m,
5, Ph). 13C NMR 6: 14.19 (CH 3, OEt), 14.28 (CH 3, OEt), 21.13 (CH 3, C7), 23.67 (CH 2,
C3), 23.91 (CH 2, C3'), 30.19 (CH 2, C4), 31.95 (CH 2, C4'), 34.11 (CH 2, C2), 34.14 (CH 2,
C2), 60.15 (CH 2, OEt), 60.31 (CH 2, OEt), 125.95 (C, C6), 128.06 (CH, Ph), 128.13 (CH,
Ph), 133.33 (C, C5), 133.68 (CH, Ph), 145.05 (C, Ph), 173.55 (C1, CO), 173.64 (C1,
CO). GC-MS m/z 346 [50%, M+; tR = 25.15 min].
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5. CONCLUSION
S-Adenosyl-L-homocysteine (AdoHcy) hydrolase is an intracellular enzyme
which is crucial for the maintenance of biomethylation processes. The standard
mechanistic sequence involves the oxidation of AdoHcy at C3' ("oxidative activity")
followed by elimination of L-homocysteine, Michael type addition of water ("hydrolytic
activity") and reduction of the 3'-keto adenosine intermediate to yield adenosine. The 6'-
halo(homovinyl)adenosine analogues were found to be concentration and time dependent
inactivators of AdoHcy hydrolase. They underwent hydration of the 5',6' double bond by
the "hydrolytic activity" of the enzyme. To probe further "hydrolytic activity" of AdoHcy
hydrolase, analogues of AdoHcy with the carbon-5' and sulfur atoms replaced by a vinyl
or halovinyl unit were designed and synthesized. Also, L-adenosine, the enantiomer of
the natural substrate, was synthesized in order to examine the possibility of whether L-
adenosine can act as (un)likely substrate and/or inhibitor of AdoHcy hydrolase.
The first targets were L-adenosine and its 5'-aldehyde oxime. Their synthesis
started from L-xylose utilizing literature protocols. L-adenosine and its 5'-aldehyde
oxime were evaluated for their ability to inhibit the activity of recombinant human
placental AdoHcy hydrolase by incubating the enzyme with them at 200 pM for 20 min
at 37 °C. The AdoHcy hydrolase activity was determined by assaying the enzyme's
ability to catalyze the conversion of Ado and Hcy to AdoHcy. Under these conditions,
L-adenosine and its 5'-aledehyde oxime were found to be inactive as inhibitors of the
AdoHcy hydrolase. Docking calculations showed that binding of L-Ado is not as
specific as that of D-Ado for the AdoHcy hydrolase and that the binding energy of the
D-Ado/enzyme complex is lower than that of the L-Ado/enzyme complex. These results
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might explain why L-Ado and its analogues are inactive as inhibitors of AdoHcy
hydrolase.
The second targets were AdoHcy analogues in which the sulfur and C5' atoms
in the S-adenosyl-L-homocysteine were replaced by the vinyl or halovinyl unit. These
analogues should form a "stable" complex with the enzyme, which would interact with
the enzyme to identify the major binding groups of the active site of AdoHcy that
interact with Hcy moiety and participates in elimination and hydrolytic activity steps.
These targets were synthesized employing a metathesis approach to construct a new
C5'-C6' double bond and Negishi Pd-catalyzed cross-coupling to build a new C6'-C7'
single bond.
Cross-metathesis of the protected 5'-deoxy-5'-methyleneadenosine analogue
with racemic 2-amino-5-hexenoate (unnatural aminoacid) in the presence of Hoveyda-
Grubb's catalyst followed by standard deprotections afforded 5'E isomer of the
inseparable mixture of 9'R/S diastereomers. Metathesis of the chiral homoallylglycine
[(2S)-amino-5-hexenoate] with 6-N-dibenzoyl protected 5'-deoxy-5'-
methyleneadenosine precursor afforded the AdoHcy analogue with established
stereochemistry (5'E, 9'S). Contrary to products obtained from racemic
homoallylglycine, the 13C NMR spectra for products obtained from chiral
homoallylglycine showed only a single set of peaks. 'H NMR also showed some
spectral differences especially for H2 and H8 from the adenine base. The 5'-bromovinyl
analogue was synthesized using the bromination-dehydrobromination strategy with
pyridinium tribromide and DBU.
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Since literature reports on the Pd-catalyzed monoalkylation of dihaloalkenes
(Csp 2-Csp 3 coupling) were scarce, we undertook model studies on Pd-catalyzed cross-
coupling reactions between vinyl dihalides and alkyl organometallics. A series of 1-
fluoro- 1 -haloalkenes was chosen as precursors to study Pd-catalyzed Negishi coupling
with alkylzincs. It was found that 1-fluoro- 1 -haloalkenes underwent Pd-catalyzed
Negishi cross-couplings with primary alkylzinc bromides to give multisubstituted
fluoroalkenes. The alkylation was trans-selective giving pure Z-fluoroalkenes in most
cases. The highest yields were obtained with Pd2(dba)3 and PdCl2(dppb) catalysts but
the best stereochemical outcome was observed with less reactive Pd(PPh3)4. The tertiary
alkylzincs also produced desired fluoroalkenes. Coupling of 8,,8-dichlorostyrene and
pfl,-dibromostyrene with alkylzinc reagents afforded the monohalo substituted olefins,
but addition of DPEPhos ligands was found to be critical.
In summary, we have synthesized AdoHcy analogues in which the sulfur and
C5' atoms in the S-adenosyl-L-homocysteine were replaced by the vinyl or halovinyl
unit using a metathesis approach. We have also developed Pd-catalyzed Negishi cross-
coupling of 1-fluoro- 1 -(iodo, or bromo, or chloro)alkenes with alkylzincs, thus
providing stereoselective access to the internal fluoroalkenes.
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Figure 11. List of chemical structures for chemicals
MFSTA: N-Methyl-N-(trimethylsilyl)- DCC: dicyclohexylcarbodiimide
trifluoroacetamide
F3C /NC
C-NN
o SiMe3
BzCl: benzoyl chloride dppb: 1,4-bis(diphenylphosphino)butane
r .
(tBuO) 2CO: di-t-butylcarbonate dpephos:bis(o-diphenylphosphanyl)phenylether
o O
DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene dba: dibenzylideneacetone
N
0
NBS: N-bromosuccinimide
0
Br-N
O
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NIS: N-iodosuccinimide tBuPh 2SiCl: tert-butyichiorodiphenylsilane
o 9
I--N Si-CI
THF: tetrahydrofuran Ac 20: Acetic anhydride
oo 
O
DMSO: dimethyl sulfoxide triethyl orthoformate
/0
TMSOTf: trimethylsilyl trifluoromethane sulfonate p-toluenesulfonic acid
F F
/\S-OH
Imidazole
TFA: trifluoroacetic acid HN
F N
F
Pyr: pyridine
HO F
N
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